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Abstract 
Anaplasma marginale is a prevalent tick-transmitted intraerythrocytic riskettsial pathogen of 
cattle causing bovine Anaplasmosis. This disease is a major threat to global beef and cattle 
industry and causes huge economic losses each year, as there is no widely accepted 
vaccine against A. marginale available at present. Thus, development of novel sustained-
release subunit nanovaccines that can induce protective immunity against A. marginale with 
single administration is in great demand. However, current understandings of potential 
protective epitopes on the outer membrane of A. marginale are poor. In addition, the 
expression methods of these antigen candidates still await developing and their 
immunogenicity need to be evaluated.  
This thesis demonstrates a novel approach of combining bioengineering together with 
nanotechnology to address these problems. The major outcomes of the work presented in 
this thesis are as follows: (i) two immunogenic outer membrane proteins of A. marginale, 
VirB9-1 and VirB9-2 were chosen as antigen candidates and expression methods using 
Escherichia coli expressing systems were developed. (ii) purification methods for the 
expressed recombinant VirB9-1 and VirB9-2 were developed and high yield products were 
obtained; (iii) specially designed mesoporous silica nanoparticles were applied as both 
adjuvant and nanocarrier for VirB9-1 and VirB9-2 and the adsorption conditions were 
optimised; (iv) development of highly immunogenic nanovaccine formulation consisting of 
the two protein antigens combined with mesoporous silica nanoparticles, and the 
immunogenicity of the two antigens and the adjuvanting effect of the nanoparticle were 
investigated using murine models.  
This work introduces, to the best of our knowledge, the first high yield soluble expression of 
recombinant VirB9-1 in E. coli. Optimised purification methods are introduced and both 
purified and partially-purified VirB9-1 are demonstrated to adsorb to specially designed 
mesoporous silica nanoparticles at high loading capacity and induce high level immune 
responses in vivo. In addition, high yield insoluble expression of recombinant VirB9-2 in E. 
coli is also introduced in this thesis and a novel method that circumvents the protein refolding 
process by directly adsorbing VirB9-2 to mesoporous silica nanoparticles under denatured 
conditions is developed.  
This work contributes to better understandings of immunogenic outer membrane proteins of 
A marginale and the adjuvanting effect of mesoporous silica nanoparticles. These promising 
findings can serve as a solid foundation for further developments of novel nanovaccines 
against A. marginale, and therefore benefit worldwide beef and cattle industry. 
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Chapter 1 
Project overview 
1.1 Introduction 
Vaccination is one of the most efficacious and cost-effective ways to protect both human and 
domesticated animals from infectious diseases. At present, most vaccines require multiple injections 
over the course of several weeks to several months in order to develop a robust and protective immune 
response. This approach is inefficient for domesticated animals, which are not as compliant as human 
beings, especially for production animals such as cattle, which are dispersed over large areas most of 
the time, and are usually rounded up only before going to market. Multiple vaccine administrations 
will multiply the cost of vaccination, which is in conflict with the concept of cost-effectiveness. Thus, 
development of sustained-release vaccines to reduce the number of injections to a single 
administration is greatly needed in the market currently.  
In Queensland, cattle are the most important domesticated animal. Producing more than 12 million 
head of cattle per year, Queensland is Australia’s largest supplier of beef products. The beef industry 
is Queensland’s largest agricultural industry, providing about 83% of the total gross value of 
production of all of Queensland’s livestock industries and providing more than 32,000 beef-related 
jobs. Building on this strong position, Queensland’s beef industry intends to grow from $3.25 billion 
currently to $10 billion by year 2020. One of the major challenges for Queensland’s beef industry is 
cattle tick fever, which is mainly caused by Anaplasma marginale. A. marginale is the most prevalent 
tick-transmitted intraerythrocytic riskettsial pathogen of cattle causing anemia, abortions and death 
(Palmer and McElwain, 1995, Kocan et al., 2003). The disease results in significant morbidity and 
mortality in worldwide cattle populations, causing huge economic losses per year estimated to be 
approximately $146 million in Australia ($27 million in Queensland), over $300 million in the United 
States, and approximately $800 million in Latin America (Kocan et al., 2003). 
Currently, vaccines available are mainly live (blood-derived or attenuated) vaccines. However, they 
have a number of drawbacks, such as the requirements of multiple doses, a cold chain for storage, a 
short shelf life, the potential for the transmission of other pathogens, and for reversion to virulence, 
so they are considered neither safe nor efficacious (Kocan et al., 2003). Therefore, development of 
alternative safer and cost-effective vaccines using protein antigens in combination with the design of 
novel delivery systems having properties such as sustained release from a single application is 
urgently demanded. The convergence of nanotechnology and biomolecular engineering has shown 
considerable promise allowing for the development of novel nanoparticle vaccines, thus addressing 
the issues facing current animal vaccines, specifically A. marginale. 
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1.2 Anaplasma marginale 
Anaplasma marginale is a gram negative rickettsia in the order Rickettsiales and the family 
Anaplasmataceae. It was first discovered by Sir Arnold Theiler in 1910 as “marginal points” found 
in stained erythrocytes of sick cattle (Theiler, 1910). This pathogen primarily infects erythrocytes in 
cattle and causes Anaplasmosis, commonly known as “cattle tick fever”. This disease results in acute 
infections, causing anemia, weight loss, respiratory distress, lower milk production, abortions and 
death (Kocan et al., 2010). Animals that recover from acute infection remain persistently infected, 
becoming lifelong carriers and serve as reservoirs for transmission of the disease (Kocan et al., 2003). 
Transmission of A. marginale can be effected both biologically by ticks and mechanically by biting 
flies or blood-contaminated fomites (Kocan et al., 2003). Around 20 different species of ticks have 
been implicated as vectors for biological transmission (Kocan et al., 2010). The transmission occurs 
across the majority of the tropical and sub-tropical regions, including Queensland, causing huge 
economic losses each year. 
Vaccination has been an economical and effective way to control bovine anaplasmosis worldwide. 
Current vaccines against anaplasmosis caused by A. marginale can be divided into two major types: 
live and killed vaccines. Live vaccines involve the infection of cattle via inoculation with erythrocytes 
infected with less pathogenic isolates of A. marginale or Anaplasma centrale (Kocan et al., 2003). 
Although these vaccines can generate protective immunity that reduces or prevents clinical symptom, 
they do not prevent the infection of A. marginale in cattle. The infected cattle serve as a reservoir of 
infection for mechanical transmission or as a source of infection for ticks and further spread of the 
disease (Kocan et al., 2003). Other drawbacks such as the potential for the transmission of other 
pathogens and for reversion to virulence, lead to live vaccines being restricted in some areas around 
the world. Killed vaccines used A. marginale from haemolysed erythrocytes as an antigen that was 
lyophilized and combined with an oil-based adjuvant. However, disadvantages of these killed 
vaccines include the higher cost of purification of A. marginale from erythrocytes, the need for yearly 
boosters, and the lack of cross-protection among isolates from widely separated geographic areas 
(Kocan et al., 2003). In addition, the protective immunity afforded by killed vaccines is usually lower 
than that of live vaccines. Due to the limited protection and disadvantages of both types of vaccines 
against A. marginale, development of novel vaccines based on molecular bio-technologies is in great 
demand. 
1.3 Outer membrane proteins VirB9-1 and VirB9-2 
The cellular outer membrane of A. marginale has unique components as an immunogen, providing 
protective immunity against challenge in bovine hosts (Brown et al., 1998a). The majority of the outer 
membrane proteome is composed of a family of major surface proteins (MSP) including the well-
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characterized MSP1, MSP2, MSP3, MSP4, and MSP5. However, immunisation with several of these 
individual proteins, (MSP1, MSP2, and MSP3, and MSP4) has resulted in incomplete or no protection 
against infection (Brown et al., 1998b, Palmer and McElwain, 1995, Lopez et al., 2007). In recent 
studies, researchers have identified over 20 novel antigenic proteins in a complex A. marginale outer 
membrane immunogen by mass spectrometry and genomic mapping (Lopez et al., 2007). Among 
them, proteins VirB9-1, VirB9-2, and VirB10 of the type IV secretion system (T4SS) have shown to 
be the most promising. T4SS is a membrane protein complex comprising 12 proteins which have 
been found in many gram-negative bacteria (Fronzes et al., 2009, Low et al., 2014). The function of 
T4SS in A. marginale is transporting macromolecules, proteins, or DNA across the bacterial cell 
envelope into host cells, which is considered essential for virulence and intracellular survival (Fronzes 
et al., 2009, Low et al., 2014, Morse et al., 2012b, Lopez et al., 2007). Targeting and neutralizing 
T4SS proteins with antibodies may be devastating to bacterial survival and dissemination. Studies 
have shown that proteins VirB9-1, VirB9-2, and VirB10 are the most immunogenic of the T4SS 
proteins (Lopez et al., 2007, Morse et al., 2012b). They elicit significant CD4+ T-lymphocyte 
proliferation, IFN-γ secretion and IgG2 production in outer membrane-immunized cattle, all 
associated with protective immunity (Lopez et al., 2007, Morse et al., 2012b). These proteins that 
associate to form the outer cap of the T4SS complex are believed to be surface-exposed due to the 
lack of surface lipopolysaccharide in A. marginale, and are highly conserved among A. marginale 
strains (Fronzes et al., 2009, Lopez et al., 2007, Low et al., 2014, Morse et al., 2012a). Furthermore, 
VirB9-1 and VirB9-2 have shown linked recognition in VirB9-2 inducing helper T-cell response to 
help produce VirB9-1-specific IgG (Morse et al., 2012a, Morse et al., 2012b). VirB9-1 and VirB9-2 
may very likely to possess the key protective B-cell- and T-cell-epitopes. Vaccination using both 
these two proteins as antigen have great potential in inducing protective immunity in cattle. Thus, in 
this PhD project, VirB9-1 and VirB9-2 have been chosen to be the combined antigenic candidate. 
1.4 Silica nanoparticles 
As modern vaccine development moves on to subunit vaccines using non-infectious but less 
immunogenic antigens, the need for adjuvants and novel delivery systems that boost immunogenicity 
arises. Nanoparticles, for their similar size to cellular components, have the ability to enter living cells 
using the cellular endocytosis mechanism (Treuel et al., 2013, Zhao et al., 2014). This allows 
nanoparticles to improve antigen stability and immunogenicity by presenting antigens very efficiently 
to antigen presenting cells (Zhao et al., 2014). Compared to conventional adjuvants, such as 
aluminium salts, nanoparticle adjuvants have the advantage of being designed into various sizes, 
shapes, and surface properties suitable for targeted delivery and sustained release (Couvreur and 
Vauthier, 2006, Moghimi et al., 2005, Zhao et al., 2014). To date, a number of nanoparticles have 
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been approved for use in human vaccines and more are tested in clinical or pre-clinical trials (Roldão 
et al., 2010, Correia-Pinto et al., 2013, Kushnir et al., 2012, Plummer and Manchester, 2011). Among 
them, one of the most promising nanoparticles is silica, especially mesoporous silica nanoparticles 
(MSNs). MSNs are non-toxic and have excellent biocompatibility (Zhao et al., 2014). Their size and 
structure can be easily altered by controlling the sol-gel chemistry (Niu et al., 2012). The adjustable 
mesoporous structure provides high loading capacity and controlled release of biomolecules (Slowing 
et al., 2008). The abundant surface silanol groups of MSNs are beneficial for further modification to 
introduce additional functionality, such as adsorption of specific proteins and enhancement of cellular 
uptake (Xu et al., 2006, Yu et al., 2013, Xia et al., 2009). Due to these properties, MSNs show 
considerable potential as high-efficiency controlled-release nanocarriers in future vaccines (Slowing 
et al., 2008). This PhD project will focus on using VirB9-1 and VirB9-2 as antigens combined with 
specially designed MSNs to develop an effective nanovaccine formulation against A. marginale. 
1.5 Research objectives 
This PhD thesis aims to contribute to the development of A. marginale subunit vaccines based on 
VirB9-1 and VirB9-2 proteins with mesoporous silica nanoparticles. To achieve this aim, there are 
four specific objectives of this thesis as described below: 
1) To optimise expression of soluble VirB9-1 proteins in E. coli and develop a purification method. 
2) To optimise expression of VirB9-2 proteins in E. coli and develop a purification method. 
3) To adsorb VirB9-1 and VirB9-2 proteins to specially designed MSNs.  
4) To evaluate the immunogenicity of VirB9-1/9-2 adsorbed MSNs using murine models. 
The rationale behind each of these research objectives is explained further below. 
1.5.1 Expression of VirB9-1 and VirB9-2 proteins in E. coli. 
Cost-effectiveness is a key issue in veterinary vaccines. As mentioned in Section 1.1.3, the high cost 
of purification of A. marginale outer membrane is one of the barriers to marketing it as an efficient 
vaccine. Therefore, focus has shifted to using recombinant outer membrane protein VirB9-1 and 
VirB9-2 as antigens which is considered to be more economical. By far, the cheapest system to 
produce recombinant protein is the well-established E. coli expression system. If VirB9-1 and VirB9-
2 proteins can be expressed using E. coli, then the cost of preparing these antigens can be dramatically 
reduced. Furthermore, since the E. coli expression system is also commonly used for industrial and 
pharmaceutical protein production (Terpe, 2006, Schmidt, 2004), expression of target protein can be 
easily scaled-up and industrialised. 
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1.5.2 Adsorption of VirB9-1 and VirB9-2 proteins to MSNs 
VirB9-1 and VirB9-2 expressed from E. coli as recombinant proteins are by themselves not 
immunogenic enough. They need to be combined with adjuvant to enhance immunogenicity. The use 
of nanoparticles in vaccinology as novel adjuvants or carriers has been increasing exponentially in 
the past decade (Zhao et al., 2014). Compared to conventional adjuvants, nanoparticles can be 
designed into various composition, size, shape, and surface properties for further applications, such 
as selective targeting and controlled release. Among all nanoparticles, silica nanoparticles have the 
advantages of being non-toxic with excellent biocompatibility and cheap manufacturing. In 
particular, silica nanoparticles with mesoporous structure have high specific surface area, which can 
allow for a high adsorption capacity of antigen. Therefore, specially designed MSNs will be used as 
adjuvants to try to overcome the drawbacks of current A. marginale vaccines mentioned in Section 
1.1, such as the requirement for multiple doses. VirB9-1 and VirB9-2 need to be adsorbed onto MSNs 
to enhance their immunogenicity to an efficacious level. The adsorption conditions for VirB9-1 and 
VirB9-2 will be optimised and the adsorption capacity will be evaluated. 
1.5.3 Evaluate the immunogenicity of VirB9-1 and VirB9-2 using murine models 
To investigate the quality of our VirB9-1 and VirB9-2 antigens and the effect of the MSNs, in vivo 
immunogenicity tests using murine models is needed. Mice are small, easily housed and maintained, 
relatively inexpensive and can be tested in large quantities to obtain statistical results. Testing in 
murine models to assess immunogenicity is a standard gateway test prior to further testing in large 
animals.  
1.5.4 Thesis organisation 
This PhD thesis consists of 7 chapters in addition to this introductory chapter. 
Chapter 2 provides a literature review of key topics in this research. A review of the background and 
history of A. marginale, previous findings on the immunogenicity of VirB9-1 and VirB9-2, outer 
membrane proteins, adjuvants and the adjuvanting effect of silica nanoparticles is provided. 
Chapter 3 gives details on the methods and materials used across the breadth of this PhD research, 
including plasmids construction, transformation and expression in E. coli, lysis buffer screening, 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), Western blotting, protein 
purification and tobacco etch virus protease (TEVp) cleavage. 
Chapter 4 explains the reasons for choosing E. coli as the expression host and investigates the bio-
engineering process of preparing soluble VirB9-1 protein from E. coli. Including the design of the 
expression vector, optimisation of expression strains and conditions, screening of suitable lysis buffer 
conditions to increase protein solubility and stability for downstream purification, development and 
optimisation of purification methods. 
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Chapter 5 investigates adsorption of purified VirB9-1 and VirB9-2 to MSNs and the immunogenicity 
of VirB9-1 and VirB9-2 proteins with MSNs as adjuvants in comparison with traditional adjuvants 
using murine models. 
Chapter 6 explores simplification of the purification process for VirB9-1 and evaluates the 
immunogenicity of the partially-purified VirB9-1 in comparison with the highly purified preparations 
using murine models. 
Chapter 7 discusses whether soluble expression of VirB9-2 is necessary or not and investigates the 
bio-engineering process of preparing and purifying VirB9-2 protein as inclusion bodies in E. coli. 
This chapter further investigates the adsorption of purified VirB9-2 to modified MSNs from the 
denatured state. 
Chapter 8 summarise the findings from the work accomplished in this thesis and discusses the future 
research directions. 
1.6 Novelty of this study 
Previous studies showed that VirB9-1 and 9-2 were the most immunogenic of T4SS proteins and 
could be devastating to the survival and dissemination of A. marginale if targeted by antibodies. 
However, as outermembrane proteins, whether VirB9-1 and 9-2 can be expressed at high yield and 
high solubility in E. coli to meet the requirements as antigens has not been reported. Furthermore, 
will the recombinant VirB9-1 and VirB-2 be immunogenic enough for vaccination use? Can their 
immunogenicity be boosted by adjuvants such as nanoparticles? Can they induce protective 
immunity against A. marginale? 
Thus, to answer these questions, this thesis demonstrated, for the first time, high yield soluble 
expression of recombinant VirB9-1 in E. coli. In addition, the immunogenicity of the VirB9-1 and 
VirB9-2 antigens was enhanced by adsorbing to specially designed MSNs and induced high levels 
of both humoral and cellular immune responses using murine models. A mixed formulation of 
VirB9-1 and 9-2 induced even higher immune responses, indicating that there was no interference 
between the two antigens and vaccines using both VirB9-1 and VirB9-2 as antigen was feasible, 
which has greater potential of inducing protective immunity. Moreover, the purification method of 
VirB9-1 was simplified to further reduce the overall cost and achieved a six-fold higher yield of 
partially-purified VirB9-1. In vivo immunogenicity results proved that these partially-purified 
VirB9-1 with a certain level of aggregation and endotoxin could induce higher humoral and cellular 
immune responses than the purified ones. As for VirB9-2, though soluble expression in E. coli was 
unsuccessful, a novel purification method for VirB9-2 inclusion bodies was developed. The 
insoluble recombinant VirB9-2 were demonstrated to directly adsorb to specially designed 
hydrophobically modified MSNs under denatured conditions. This innovation of combining 
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purification with nanoparticle adsorption not only improved the preparation of VirB9-2 antigens by 
avoiding the tricky protein refolding process, but also may open a pathway towards developing new 
strategies for processing T-cell epitopes from insoluble recombinant protein expressions. Further 
immunogenicity of these VirB9-2 with MSNs shall be investigated in the future. 
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Chapter 2 
Literature review 
2.1 Anaplasma marginale  
Anaplasma marginale is a gram-negative rickettsia in the order Rickettsiales and the family 
Anaplasmataceae. It was first discovered by Sir Arnold Theiler in 1910 when he observed “marginal 
points” located at the periphery of stained erythrocytes of sick cattle (Theiler, 1910). Using 
Romanovsky’s staining method, A. marginale in erythrocytes appear as a dense, homogeneous 
bluish-purple and round structure of 0.3-1.0 µm in diameter (Figure 2-1). With the acridine orange 
staining method, the A. marginale body contains several subunits instead of a single compact unit 
(Ristic, 2013). These subunits, which are known as initial bodies, are round or oval and are 300-400 
nm in diameter. The initial bodies are enclosed in a double membrane and are surrounded by an 
envelope-like structure.  
This pathogen infects cattle causing bovine anaplasmosis, commonly known as “cattle tick fever”.  
The clinical symptoms of this disease consist of anemia, causing fever, icterus, constipation, 
weakness, inappetence, depression, dehydration, abortion, and often death (Ristic, 1977). 
Erythrocytes are the only known site of infection of A. marginale in cattle. A. marginale enters host 
erythrocytes cells by an endocytotic process. After entry, the dense form of A. marginale settles 
within a vacuolar membrane and transforms into the vegetative or reticulated form that multiplies by 
binary fission, forming large colonies of rickettsia. The reticulated form of A. marginale subsequently 
transforms into the dense form that can survive extracellularly and is then released from the host cell 
by fusing the inclusion membrane with the host cell membrane (Blouin and Kocan, 1998). During 
acute infection, over 70% of the erythrocytes may become infected (Kocan et al., 2003). Animals that 
survive acute disease remain persistently infected. These persistently infected cattle have lifelong 
immunity and are resistant to clinical disease on challenge exposure (Kocan et al., 2003). However, 
they provide a reservoir of infective blood for transmission of A. marginale by both direct mechanical 
transmission and biological transmission by ticks (Palmer et al., 1999). 
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Figure 2-1. Bovine erythrocytes infected with A. marginale (arrowheads) in a stained 
blood film. Bar, 10 µm. Adapted from Kocan et al. (Kocan et al., 2003). 
 
2.1.1 Transmission of A. marginale 
The transmission of A. marginale is mainly through two routes, biologically by ticks and 
mechanically by biting flies or blood-contaminated fomites. Literature showed that biological 
transmission by ticks is more efficient than the mechanical route (Scoles et al., 2005). Approximately 
20 species of ticks have been identified as A. marginale transmission vectors worldwide (Kocan et 
al., 2003). However, some strains of A. marginale are not infective for, or transmissible by, ticks 
(Kocan et al., 2004).  
The developmental cycle of A. marginale in cattle and ticks is shown as in Figure 2-2. When ticks 
feed on the blood of A. marginale infected cattle, the infected erythrocytes are taken into ticks and 
infection first happens in the gut cells. The infection of A. marginale then further develops to other 
tick tissues including salivary gland cells. At each site of infection in ticks, A. marginale develops 
within membrane bound vacuoles as reticulated form that multiplies by binary fission, forming large 
colonies of rickettsia. Then the reticulated form of A. marginale subsequently transforms into the 
dense form, which is infective and can survive outside the host cells. When the ticks feed on cattle 
again, the dense form of A. marginale is transmitted via the salivary glands and the cattle became 
infected by A. marginale.  
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Figure 2-2. Schematic of the development cycle of A. marginale in cattle and ticks. 
Infected erythrocytes are ingested by ticks (Dermacentor spp., Rhipicephalus spp., or 
Boophilus spp.) with the blood meal and infect the gut cells in ticks. The infection of 
A. marginale then develops to other tick tissues including salivary gland cells. When 
the ticks feed a second time, the rickettsia is transmitted back to cattle. The 
development of A. marginale in tick starts as the reticulated form and later change to 
the dense form, which is the infective form that can survive extracellularly. Obtained 
from Kocan et al. (Kocan et al., 2003). 
 
The other route of transmission of A. marginale is mechanical transmission. This usually happens 
through blood-contaminated fomites, including needles, dehorning saws, nose tongs, tattooing 
instruments, ear tagging devices and castration instruments. Mechanical transmission also occurs via 
arthropods, such as biting flies and mosquitos. At least 12 species of biting flies and mosquitos have 
been shown experimentally to have the potential of mechanically transmitting A. marginale, 
including stable flies (Stomoxys calicitrans), eight species of tabanids and three species of midges 
(Potgieter, 1979, Hawkins et al., 1982, Foil, 1989). Mechanical transmission is believed to be the 
major route of dissemination for A. marginale in areas where tick vectors are absent, such as certain 
areas of the U.S.A., Central and South America and Africa (Kocan et al., 2010). 
2.1.2 Economic Impact of Bovine Anaplasmosis  
Bovine anaplasmosis caused by A. marginale commonly occurs in most tropical and sub-tropical 
areas of the world. The disease results in significant morbidity and mortality in cattle populations, 
causing huge economic losses per year worldwide. However, few controlled studies have been carried 
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out to determine the exact annual loss caused by anaplasmosis in a country. Most reports claim in 
general, the loss is high, tremendous, or enormous. It has been estimated that the annual losses in 
cattle caused by A. marginale is over $300 million in the United States, around $800 million in Latin 
America, and over $160 million in Australia (Kocan et al., 2003, Lane et al., 2015). 
In Queensland, cattle are the most important domesticated animal. The beef industry is Queensland’s 
largest agricultural industry, providing about 83% of the total gross value of production of all 
Queensland’s livestock industries and providing more than 32,000 beef-related jobs. Producing more 
than 12 million head of cattle per year, Queensland produces almost half of Australia’s beef and veal 
(Figure 2-3). Queensland’s beef industry intends to grow from $3.25 billion currently to $10 billion 
by year 2020. However, one of the major challenges to Queensland’s beef industry is the cattle tick 
fever caused by A. marginale. 
 
 
Figure 2-3. Australian beef and veal production of each state in year 2015-16. Total: 
2.3 million tonnes cwt. Adapted from Meat & Livestock Australia (MLA). 
 
2.1.3 Control measures for Bovine Anaplasmosis  
Control measures for anaplasmosis caused by A. marginale have not changed for many years. There 
are three ways of control: 
1. Arthropod control by application of acaricides and pyrethroids. 
2. Chemotherapy by administration of oxytetracycline, imidocarb, or tetracyclines drugs. 
3. Vaccination.  
Arthropod control is labour-intensive and expensive. Excessive use of acaricides and pyrethroids also 
causes environmental problems and has risk of developing drug resistant tick and fly populations. 
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Nonetheless, arthropod control alone is not a solution to the control of anaplasmosis. It can only 
partially protect against A. marginale transmission, as mechanical transmission of A. marginale often 
occurs via blood-contaminated fomites. Furthermore, arthropod control is not practical in many areas. 
Chemotherapy can only prevent clinical disease in animals that become infected by A. marginale 
(Kocan et al., 2010). Current drugs available cannot clear A. marginale infection nor prevent cattle 
being infected (De Waal, 2000, Kocan et al., 2000). In addition, chemotherapy is expensive and often 
not applicable to range cattle.  Moreover, the intensive use of antibiotics increases the risk of the 
emergence of resistant strains of microorganisms (Kocan et al., 2010).  
Vaccination has been an economical and effective way to control bovine anaplasmosis worldwide. 
The history of using vaccines to protect cattle against A. marginale can go back to early 1900s in 
South Africa (Theiler, 1912). There are two major types of vaccines against A. marginale: live 
vaccines and killed vaccines. Live vaccines are the most widely used for vaccination against A. 
marginale. By inoculation with erythrocytes infected with less pathogenic Anaplasma centrale or 
attenuated live A. marginale, live vaccines can prevent clinical disease caused by A. marginale but 
cannot prevent cattle being infected (Kocan et al., 2003). These vaccinated cattle may serve as a 
reservoir of A. marginale for biological or mechanical transmission. In addition, vaccination with A. 
centrale does not provide effective cross-protection in widely separated geographic areas. Vaccinated 
cattle develop persistent infections that induce lifelong protective immunity, therefore revaccination 
is usually not required (Kocan et al., 2010). For vaccine production, splenectomised calves 
maintained under quarantine conditions are experimentally inoculated with selected strains and then 
serve as a source of infective blood.  
Killed vaccine was first developed and marketed in the United States in the 1960s (Brock et al., 1965). 
Compared to live vaccines, killed vaccines have several advantages, such as they have lower risk of 
contamination with undesirable infectious agents, do not require cold storage and cause minimal post-
inoculation reactions. However, killed vaccines require yearly re-vaccination and are more expensive 
than live vaccines due to the high cost of purification of A. marginale from erythrocytes. Similar to 
live vaccines, killed vaccine can prevent clinical disease caused by A. marginale, but does not prevent 
infection in cattle (Kocan et al., 2003). In addition, the protective immunity afforded by killed 
vaccines is usually less than that of live vaccines. Therefore, killed vaccines were withdrawn from 
the marketplace in USA in 1999 and are currently not available. In summary, both live and killed 
vaccines have relied on A. marginale from infected bovine erythrocytes as the antigen source, which 
have major disadvantages because of difficulties to standardise and the risk of transmitting other 
bovine pathogens that are not apparent at the time of blood collection (Kocan et al., 2000, Rogers et 
al., 1988). Both types of vaccines induce protective immunity that mutes or prevents clinical disease, 
but neither type prevents cattle from becoming persistently infected with A. marginale. 
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2.1.4 Immunopathology of A. marginale 
Early studies showed that macrophage activation correlates with protection against acute rickettsemia 
and anemia (Buening, 1976). Further studies showed the correlation between protection and antibody 
directed specifically against A. marginale surface B-cell epitopes, while antibody alone was not 
sufficient for protection (Tebele et al., 1991, Palmer and McElwain, 1995). Therefore, researchers 
proposed that the clearance of A. marginale requires induction of high titres of IgG2 antibody against 
surface B-cell epitopes concurrent with CD4+ T-cell-mediated macrophage activation for enhanced 
phagocytosis and microbial killing (Palmer et al., 1999). Fundamental to this model of protective 
immunity against A. marginale is the CD4+ T cell expressing interferon γ (IFN-γ) (Figure 2-4). In 
cattle, IFN-γ is responsible for enhancing the synthesis of the predominant opsonizing bovine IgG2 
and activating macrophages to increase receptor expression, phagocytosis, phagolysomosal fusion 
and release of rickettsiacidal nitric oxide (Brown et al., 1998). Therefore, to induce protective 
immunity against A. marginale, a vaccine is essential to include both T-cell and B-cell epitopes.  
 
Figure 2-4. Schematic of the clearance of A. marginale by CD4+ T-cell-mediated 
macrophage associated with IgG2 against MSP surface epitopes. MSP-specific CD4+ 
T cells secreting IFN-γ coordinate macrophage activation and B-cell isotype switching 
to IgG2 production. IFN-γ, interferon γ; MSP, major surface protein; TNF-α, tumour 
necrosis factor α; Th0, T helper 0 cell. Obtained from Palmer et al. (Palmer et al., 
1999). 
 
Studies have shown immunisation with purified A. marginale outer membranes can induce complete 
protection against infection by homologous strains (Brown et al., 1998). However, a vaccine based 
on the purified outer membrane cannot be economically manufactured due to the high cost of 
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purification of A. marginale from erythrocytes and the complex method of purification. A promising 
way to overcome these problems is to identify the key protective T-cell and B-cell epitopes in A. 
marginale outer membrane and use recombinant protein technology to express them cost-efficiently 
as antigens. 
The small genome of A. marginale is circular. The sequence of the St. Maries strain of A. marginale 
genome was completed in 2005 and found to be 1,197,687 bp in length (Brayton et al., 2005) (Figure 
2-5). There are 949 annotated coding sequences in this A. marginale genome. Among them, 62 were 
predicted to be outer membrane proteins, and of these, 49 belong to the major surface proteins msp1 
and msp2 superfamilies (Brayton et al., 2005). However, although major surface proteins are 
immunodominant in A. marginale outer membrane, they do not associate with protective immunity 
(Abbott et al., 2005). This may be due to the rapid change of these genes creating antigenically 
variable that serve to evade the host immune response (Brayton et al., 2002). 
 
Figure 2-5. Genome map of A. marginale St. Maries strain. The inner-most circle 
depicts the GC skew (G - C/G + C). The second and third circles show the position 
and orientation of rRNA (orange arrows) and tRNA (purple arrows) genes. The fourth 
and fifth circles show the positions of the predicted CDSs in the reverse (red) and 
forward (green) orientations. The sixth circle shows the positions of the BACs (full 
BACs in blue and pink; partial BACs in yellow) and gap-spanning PCR fragments 
(green) that were sequenced. The seventh circle shows the positions of the msp2 (blue) 
and msp1 (brown) superfamily genes. Obtained from Brayton et al. (Brayton et al., 
2005). 
 
Because immunodominant major surface proteins of A. margianle were not protective, researchers 
then focused on identifying other subdominant and conserved surface proteins that may possess key 
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T-cell and B-cell epitopes that lead to protective immunity in the outer membrane. Over 20 
subdominant antigenic proteins have been identified in a complex A. marginale outer membrane 
immunogen by mass spectrometry and genomic mapping (Lopez et al., 2005). Among them, several 
proteins from the type IV secretion system (T4SS) have been demonstrated to induce CD4+ T-cell 
responses, including IFN-γ production, and were recognized by IgG2 in cattle immunized with the 
outer membrane vaccine (Lopez et al., 2007, Lopez et al., 2008, Sutten et al., 2010). 
2.1.5 Type IV secretion system 
Type IV secretion system (T4SS) is a large membrane protein complex comprising 12 proteins 
(VirB1–VirB11 and VirD4) which have been found in many gram-negative bacteria (Chandran et al., 
2009, Fronzes et al., 2009) (Figure 2-6). The core complex of T4SS is assembled tightly of 14 copies 
of VirB7, VirB9 and VirB10 (Chandran et al., 2009), spanning through the two membranes of gram-
negative bacteria, forming a cylindrical structure of 185 Å in diameter and 185 Å in length containing 
two layers termed O (outer) and I (inner) (Fronzes et al., 2009). A channel goes through the core 
complex connecting the cytosol to the extracellular milieu, with a large opening of 55 Å in diameter 
to the cytoplasm and a small opening of 10-20 Å in diameter to the extracellular milieu (Fronzes et 
al., 2009).  
The function of T4SS is transporting macromolecules, proteins, or DNA across the bacterial cell 
envelope (Fronzes et al., 2009). This includes delivery of virulence factors into eukaryotic host cells 
to establish pathogen–host interaction, conjugative transfer of genetic material to increase genomic 
plasticity, and helping the pathogen to adapt to changes in its environment and to enhance intracellular 
survival (Chandran et al., 2009, Wallden et al., 2010). This has been widely documented for many 
gram-negative bacteria, such as Brucella suis (O'callaghan et al., 1999), Legionella pneumophila 
(Lammertyn and Anné, 2004), and Helicobacter pylori (Censini et al., 1996). Thus, bacterial T4SS 
proteins are logical targets for immunological intervention. Targeting and neutralizing T4SS proteins 
with antibodies may be devastating to bacterial survival and dissemination.  
Although the function of the T4SS in A. marginale has not been determined, the genome of this 
system is highly conserved in the Anaplasmataceae and Rickettsiaceae families (Gillespie et al., 
2010). Retention of these genes indicates their requirement for bacterial invasion and survival within 
bovine erythrocytes and/or tick cells (Morse et al., 2012). Several T4SS proteins may be surface 
exposed and could be targeted by neutralizing antibody, due to the fact that A. marginale lacks 
lipopolysaccharides (Brayton et al., 2005). Furthermore, T4SS proteins interact with each other 
within the bacterial membrane so that associated proteins could provide linked recognition for T-cell–
B-cell interactions (Morse et al., 2012).  
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Figure 2-6. Schematic model of T4SS of Agrobacterium tumefaciens and structures 
of T4SS components. A) The experimentally predicted locations of VirB/D4 
components of A. tumefaciens. Arrows indicate the sequential translocation steps 
identified during substrate secretion through the VirB/D4 system. B) Crystal structure 
of the TrwB hexamer, VirD4 homologue of the Escherichia coli conjugative plasmid 
R388. C) Single subunit of the TrwB hexamer with modelled plausible location of the 
N-terminal transmembrane domain. D) Crystal structure of the HP5025 hexamer, 
VirB11 homologue of Helicobacter pylori. E) Single subunit of the HP0525 hexamer. 
The N-terminal (NTD) and C-terminal (CTD) domains are indicated. F) Cryo-electron 
microscopy structure of the T4SS core complex of the E. coli conjugative plasmid 
pKM101, comprising the full-length TraN, TraO and TraF, which correspond to the 
VirB7, VirB9 and VirB10 homologues of A. tumefaciens respectively. G) Crystal 
structure of the outer membrane complex, comprising the O-layer. The inset shows 
the characteristic two-helix bundle of TraF that traverses the outer membrane. TraN, 
TraO and TraF are coloured red, blue and green respectively. H) Crystal structures of 
TraC, the VirB5 homologue encoded by pKM101. I) the periplasmic C-terminal 
domain of VirB8 from Brucella suis. OM, outer membrane; IM, inner membrane; 
TMS, transmembrane segment; Cyt., cytosol. Obtained from Wallden et al. (Wallden 
et al., 2010). 
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Among all the T4SS proteins of A. marginale, VirB9-1, VirB9-2, and VirB10 were discovered to be 
the most immunogenic. These proteins were predicted to be localized on the exterior surface of A. 
marginale, components of the purified A. marginale outer membrane vaccine that induced protective 
immunity (Lopez et al., 2005, Morse et al., 2012). Studies have shown that they can elicit significant 
CD4+ T-lymphocyte proliferation, IFN-γ secretion and IgG2 production in outer membrane-
immunized cattle, all associated with protective immunity (Lopez et al., 2007). Furthermore, VirB9-
1 and VirB9-2 showed linked recognition. Studies showed that VirB9-2 induced T-cell responses 
helping to produce IgG against in cattle (Morse et al., 2012). Based on these studies, a vaccine 
combination of VirB9-1 as B-cell epitopes and VirB9-2 as T-cell epitopes may likely be protective 
against A. marginale. Moreover, because these two proteins are highly conserved, the immunity they 
induce may be protective across multiple strains. However, as newly identified antigen candidates, 
VirB9-1 and 9-2 have been rarely reported as antigens in vaccination. Furthermore, VirB9-1 and 9-2 
are outer membrane proteins, which are generally considered very difficult to express. Whether these 
two proteins can be expressed cost-efficiently as antigens to meet the need for animal vaccination 
still remains a challenge. 
2.2 Protein Expression 
Protein expression refers to processes that living cells or organisms synthesise, modify and regulate 
proteins. In protein research, protein expression can also refer to the use of laboratory techniques 
required for the manufacture of proteins. Recombinant protein expression is one of the most powerful 
techniques used in life sciences. The ability to produce and purify an abundance of a desired 
recombinant protein opens a wide range of applications throughout biological and biomedical science 
as well as many other scientific research fields which require functional proteins for their research. 
Recombinant protein expression is also widely used in industry. Manufacturers use recombinant 
protein expression for proteomics research, genomics research, development, and manufacturing of 
biologics and pharmaceutical products. The global protein expression market size was estimated at 
USD $1.2 billion in 2016, and is expected to rise in the near future (Figure 2-7).  
Typically, recombinant protein expression is achieved by the manipulation of gene expression in an 
organism such that it expresses large amounts of a recombinant gene and translates the recombinant 
DNA into polypeptide chains which are ultimately folded into recombinant proteins. Many organisms 
can be used for recombinant protein, which are called protein expression systems. Among them, the 
most widely used expression systems are Escherichia coli, yeast, insect cells and mammalian cells. 
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Figure 2-7. Predicted growth of U.S. protein expression market by expression systems 
from year 2014-2025 (USD million). Obtained from Protein Expression Market Size 
By Product, Industry Report, 2018-2025 (URL: 
https://www.grandviewresearch.com/industry-analysis/protein-expression-market). 
 
2.2.1 Expression systems 
One commonly confronted question in recombinant protein expression is: should the protein(s) be 
expressed in bacteria, in yeast, in insect cells or in mammalian cells? Because every protein is 
different, there can be no “right” answer to this question (Gräslund et al., 2008). Nevertheless, 
choosing the appropriate expression system is critical for recombinant protein expression, as each 
protein expression system is different and has its own advantages and disadvantages (Table 2-1). 
Table 2-1. Brief comparison among expression systems. 
 E. coli Yeast Insect cells Mammalian cells 
Speed Very fast Fast Moderate Slow 
Yield Very high High Moderate Low 
Cost Very low Low High High 
PTM - Moderate Good Very good 
PTM: Post-translational modifications 
 
2.2.1.1 Mammalian cell expression system 
Mammalian cell expression systems can be used to produce recombinant proteins transiently or 
through stable cell lines, where the expression construct is integrated into the host genome by plasmid 
transfection or viral vector infection (Fuerst et al., 1986, Liljeström and Garoff, 1991). This system 
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is currently the dominant expression system for the production of therapeutic use proteins. Over 60% 
of the biopharmaceutical recombinant protein products approved by the Food and Drug 
Administration (FDA) are produced using mammalian cell expression systems (Zhu, 2012). 
Compared with other expression systems, mammalian cells are the most advanced and are capable of 
handling complex post-translational modifications, folding and assembly of recombinant proteins and 
protein complexes (Wurm, 2004). Recombinant proteins expressed in mammalian cells are provided 
with the best protein folding and the most accurate post-translational modifications (Walsh and 
Jefferis, 2006), therefore the protein structure and function are the closest to their native state. 
However, the disadvantages of mammalian cell expression systems are obvious. (i) Expression is 
laborious and time consuming. The commonly used mammalian cell lines for protein production are 
the Chinese hamster ovary (CHO), Human embryonic kidney (HEK-293) and Mouse myeloma (NS0) 
cell lines. Establishing a new cell line usually takes months and requires careful maintenance as the 
cells are delicate. The process from cloning to large-scale production of recombinant proteins often 
takes over 12 months (Wurm, 2004). (ii) The growth rate of mammalian cells is slow and the yield is 
low. The highest specific productivity is 90 pg/cell/day and volumetric yield is about 5 g/L (Hacker 
et al., 2008), which is rather low compared to other expression systems. (iii) The culture media is 
complex and expensive (Griffiths, 1986, Walsh and Jefferis, 2006). (iv) Genetic manipulation of 
mammalian cells for protein expression is difficult and complex (Kantardjieff et al., 2010). (v) 
Mammalian cells might contain oncogenes or viral DNA and have a potential for product 
contamination by viruses (Demain and Vaishnav, 2009), so the recombinant protein products must 
be tested more extensively. In general, mammalian cell expression systems are complicated and 
highly expensive, thus being most suited to pharmaceutical production where the return is high, and 
where post-translational modification is often required for efficacy in humans. 
2.2.1.2 Baculovirus-infected insect cell expression system 
The baculovirus-infected insect cell expression system is a widely used eukaryotic expression system. 
It has similar post-translational modification processing functions as most higher eukaryotics, such 
as the formation of disulphide bonds, glycosylation, acylation and phosphorylation (Chambers et al., 
2018), making the recombinant protein more similar to the native protein in both structure and 
function. The insect cells used for expression are infected with recombinant baculovirus carrying a 
strong gene promoter of a polyhedrin protein that allows many eukaryotic genes to be expressed 
efficiently. The most common species of baculoviruses used for protein expression studies are 
Autographa californica multiple nuclear polyhedrosis virus (AcMNPV) and Bombyx mori nuclear 
polyhedrosis virus (BmNPV), and the most common insect cell lines are Sf9, Sf21 and High Five 
(van Oers et al., 2015). Provided by the strong polyhedrin promoter, the expression level of the target 
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protein can be as high as about 50% of the total cellular protein, and even large exogenous genes of 
over 200 kDa can be successfully expressed.  In many cases, the expressed recombinant proteins are 
soluble and can be easily recovered from infected host cells. Moreover, the baculovirus-infected 
insect cell expression system has the ability to express multiple exogenous genes simultaneously in 
the same infected insect cell (Kim et al., 2008). Furthermore, baculoviruses are essentially 
nonpathogenic to mammals and plants. They have a restricted host range, which often is limited to 
specific invertebrate (Miller, 1988). Thus, protein products expressed from the baculovirus-infected 
insect cell expression system are generally considered safe for bio-applications. 
However, compared with E. coli and yeast, the baculovirus-infected insect cell expression system is 
more expensive and the duration of recombinant protein expression is longer, which usually takes at 
least two weeks for the protein products to deliver. In addition, the post translational modifications 
are still slightly different from mammalian cells, such as different glycosylation patterns (Harrison 
and Jarvis, 2006). Therefore, the protein products may not always be fully functional.  
2.2.1.3 Yeast expression system 
Yeasts are eukaryotic, single-celled microorganisms. As expression systems, yeasts have been widely 
used in the field of genetic engineering and contain merits from both prokaryotic and eukaryotic 
expression system: (i) yeasts have the post-translational modifications needed for most eukaryotic 
proteins (Gerngross, 2004); (ii) growing yeast is both faster and less expensive in comparison with 
mammalian cells and large-scale cultures can be achieved by using fermentation (Cereghino et al., 
2002). Another advantage of yeast expression systems is that they are endotoxin free. The history of 
using yeast species Saccharomyces cerevisiae in brewing and baking by humans goes back for 
thousands of years and is considered as GRAS (generally recognized as safe) organisms by the FDA. 
Thus, the proteins expressed from yeast system are usually considered safe and do not need a lot of 
host safety experiments. However, the yield of recombinant protein expression in S. cerevisiae is low 
due to low secretion and difficulties in secretion of proteins larger than 30 kDa (Romanos et al., 
1992). Furthermore, certain proteins were hyperglycosylated when expressed in S. cerevisiae, which 
may cause problems to the biological activity or immunogenicity of the proteins (Buckholz and 
Gleeson, 1991). 
Nowadays, methanol yeast expression system is the most widely used yeast expression system, with 
Pichia pastoris as the most popular host organisms. P. pastoris contains the methanolic yeast oxidase 
gene-1 (AOX1), which could be activated when methanol is the sole carbon source (Ahmad et al., 
2014). Compared with S. cerevisiae, P. pastoris has higher secretion efficiency and translation is 
closer to mammalian cells and does not undergo hyperglycosylation (Cereghino et al., 2002). 
However, the glycosylation of P. pastoris is still different to higher eukaryotes such as mammalian 
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cells, which means certain eukaryotic proteins may be expressed with diminished activity. Another 
disadvantage is that the use of methanol as an inducer for P. pastoris is a safety (fire) hazard at scale-
up, especially in industry (Spohner et al., 2015, Potvin et al., 2012).  
2.2.1.4 E. coli expression system 
The gram-negative bacterium E. coli is by far the most widely used expression host for the production 
of recombinant proteins. There are many advantages using E. coli to express recombinant proteins. 
(i) Genetic background of E. coli is well known. As one of the most well-studied prokaryotic 
microorganisms, the first complete DNA sequence of an E. coli genome (strain K-12) was published 
in 1997 (Blattner et al., 1997). Today, several hundred complete genomic sequences of various strains 
of E. coli are available. (ii) E. coli has fast growth kinetics. The growth rate of E. coli is very fast with 
a doubling time of about 20 min in optimised glucose-salts media environmental conditions (Sezonov 
et al., 2007). (iii) High cell density cultures are easily achieved and recombinant proteins can be 
expressed at high yield (Studier, 2005, Huang et al., 2012). (iv) The cost of growing E. coli is low. E. 
coli can be easily grown in mild conditions and rich complex media can be made from readily 
available and inexpensive components. (v) Transformation with exogenous DNA is fast and easy. 
The technique of plasmid transformation in E. coli is well-established and transformation can be 
performed in as little as 5 min (Pope and Kent, 1996), and is routinely done in laboratories around 
the world, including by undergraduate and high-school students. 
However, the disadvantage of the E. coli expression system is that E. coli, as a prokaryotic organism, 
lacks enzymes for eukaryotic functions such as post-translational modification, post-transcriptional 
modification and mRNA processing. It is difficult for E. coli to form correct disulphide bond pairing 
and correct conformational space folding (Choi and Lee, 2004). Thus, many eukaryotic proteins 
expressed in E. coli are biologically inactive or are not fully functional. Furthermore, high level 
expression of recombinant protein in E. coli often results in dense misfolded inactive protein 
aggregates which are called inclusion bodies (Middelberg, 2002). Inclusion bodies need extensive 
processing involving isolation from cell, solubilisation, refolding and purification to produce the 
bioactive proteins. Notably, the refolding process is a major bottle neck to the final product yield, as 
a great deal of yield may be lost during this process and there is no universal refolding method 
available (Middelberg, 2002). Details on inclusion bodies and protein refolding will be further 
reviewed later on in this chapter. Another disadvantage of the E. coli expression system is that 
recombinant protein expressed comes along with endotoxin. Endotoxins are lipopolysaccharides, 
which are major component of the outer membrane of gram-negative bacteria. They can elicit a 
variety of inflammatory responses in humans and animals, leading to multiple pathophysiological 
effects, such as endotoxin shock, tissue injury, and death (Magalhães et al., 2007). Therefore, 
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endotoxin usually needs to be removed from the protein products expressed in E. coli prior to 
application.  
Considering the pros and cons, this PhD study will focus on E. coli expression systems, primarily 
because of the cost advantages in a cost-sensitive industry (cattle production) and the tolerance of 
animal vaccine products to endotoxin levels. 
2.2.2 E. coli strains 
As the one of the most well-established expression systems, there are many different strains of E. coli 
available for recombinant protein expression. Most of these strains use the T7 promoter system for 
producing proteins. In this system, an expression vector containing a gene of interest cloned 
downstream of the T7 promoter is introduced into a host carrying a copy of the phage T7 RNA 
polymerase gene. The T7 RNA polymerase gene is usually controlled by a lac promoter (Rosano and 
Ceccarelli, 2014). When the inducer is added, T7 RNA polymerase is expressed and becomes 
dedicated to transcription of the gene of interest. This polymerase is highly active and has an 
extremely high rate of transcription (Mertens et al., 1995), therefore providing high yield expressions 
of recombinant proteins. Several commonly used E. coli strains are briefly introduced as followed. 
Strain BL21 (DE3) 
BL21 (DE3) is by far the most used E. coli strain for protein expression. It was derived from E. coli 
B and is deficient of lon and OmpT proteases (Daegelen et al., 2009). BL21 (DE3) contains the DE3 
lysogen that carries the gene for T7 RNA polymerase under control of the lacUV5 promoter, which 
is induced by IPTG for expression of the T7 RNA polymerase in order to express recombinant genes 
cloned downstream (Rosano and Ceccarelli, 2014).  
Strain BL21 (DE3) pLysS 
Compared with BL21 (DE3), BL21 (DE3) pLysS contains the pLysS plasmid that produces T7 
lysozyme to reduce basal level expression of the gene of interest by inhibiting T7 RNA polymerase 
(Terpe, 2006). This provides tight control of T7 RNA polymerase. Thus, this strain is suitable for 
expression of toxic genes. 
Strain Rosetta (DE3) 
Rosetta (DE3) host strains are BL21 (DE3) derivatives designed to enhance the expression of 
eukaryotic proteins that contain codons rarely used in E. coli. These strains supply tRNAs for the 
codons AUA, AGG, AGA, CUA, CCC, and GGA on a compatible chloramphenicol-resistant 
plasmid, pRARE. By supplying these rare codons, the Rosetta strains circumvent the need to 
synthesize codon optimised genes, and enable rapid evaluation of codon usage as a possible strategy 
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to enhance target protein expression (Novy et al., 2001). Thus, providing an “universal” translation 
that is not limited by the codon usage of E. coli.  
Strain Tuner 
Tuner strains are BL21 derivatives containing a mutation in the lac permease (lacZY) gene. The lac 
permease (lacY) mutation allows uniform entry of IPTG into all cells in the population, which 
produces a concentration-dependent, homogeneous level of induction (Khlebnikov and Keasling, 
2002). This enables adjustable levels of protein expression throughout all cells in a culture. By 
adjusting the concentration of IPTG, expression can be regulated from very low levels up to the 
robust. Lower level expression may enhance the solubility and activity of difficult target proteins. 
Strain Origami 
Origami host strains are K-12 derivatives that have mutations in both the thioredoxin reductase (trxB) 
and glutathione reductase (gor) genes (Berrow et al., 2006), which greatly enhances disulphide bond 
formation in the cytoplasm. These strains are compatible with ampicillin resistant plasmids and are 
ideal for use with some thioredoxin fusion-tag-containing vectors since thioredoxin further enhances 
the formation of disulphide bonds in the cytoplasm. 
2.2.3 Fusion Tags 
Fusion tags are small proteins or peptides genetically fused onto a recombinant protein. They are 
popular and powerful tools used in recombinant protein expression and purification. Fusion tags can 
improve the downstream purification process of the target recombinant protein by providing one-step 
affinity purification from crude extracts under mild elution conditions without prior steps, such as 
removing nucleic acid or other cellular material (Terpe, 2003). In addition, fusion tags can improve 
protein solubility, stability, expression and resistance to proteolytic degradation (Rosano and 
Ceccarelli, 2014). A wide range of fusion tags are available from small peptides to relatively large 
proteins, each with its own unique characteristics (Table 2-2). Due to their purposes, fusion tags are 
mainly divided into two categories: affinity tags and solubility tags (Malhotra, 2009). Affinity tags 
are usually small peptides of several amino acids, such as poly-Arg-, FLAG-, poly-His-, c-Myc-, S-, 
and Strep II-tags (Terpe, 2003). They can provide strong affinity interactions allowing the fused 
protein to be captured by corresponding matrices. Solubility tags include glutathione S-transferase 
(GST), maltose-binding protein (MBP), NusA, thioredoxin and small ubiquitin-like modifier 
(SUMO) tags (Rosano and Ceccarelli, 2014). They are small proteins that can enhance the solubility, 
stability and expression of the fused protein. Certain tags have a dual role and can serve as both 
solubility and affinity tag. For example, GST- and MBP-tags not only can enhance the solubility of 
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fusion proteins, but also provide one-step affinity-chromatography purification methods using 
glutathione and amylose resin, respectively (Smith and Johnson, 1988, di Guana et al., 1988). 
Table 2-2. Characteristics of common affinity tags used for recombinant protein expression. 
Tag Residues Size (kDa) Matrix Elution 
Poly-Arg 5-6 (usually 5) 0.80 Cation exchange 
resin 
High pH salt 
gradient 
Poly-His 2-10 (usually 6) 0.84 Immobilized metal 
ions (Ni2+, Co2+)   
Low pH or 
imidazole 
FLAG 8 1.01 mAb Low pH, EDTA, or 
FLAG peptide 
Strep-tag II 8 1.06 Strep-Tactin Biotin or 
desthiobiotin 
Human influenza 
hemagglutinin A (HA) 
9 1.10 mAb Low pH or HA 
peptide 
Bacteriophage T7 
epitope (T7-tag) 
11 1.09 mAb Low pH 
c-myc 11 1.20 Monoclonal 
antibody 
Low pH 
S-tag 15 1.75 S-fragment of 
RNase A 
Low pH 
Histidine affinity tag 
(HAT) 
19 2.31 Immobilized metal 
ions (Ni2+, Co2+)  
Low pH or  
imidazole 
Calmodulin-binding 
peptide (CBP) 
26 2.96 Calmodulin EGTA or EGTA 
and high salt 
Cellulose-binding 
domain (CBD) 
27-189 3-20 Cellulose Denaturation or 
ethylene glycol 
Streptavadin-binding 
peptide (SBP) 
38 4.03 Strep-Tactin Biotin 
Chitin-binding domain 
(CBD) 
51 5.59 Chitin  Thiol-containing 
reducing agent 
SUMO 100 12 Immobilized metal 
ions (Ni2+, Co2+)  
SUMO protease 
Thioredoxin 109 12 Phenylarsine oxide  β-mercaptoethanol 
Glutathione S-
transferase (GST) 
211 26 Glutathione Reduced 
glutathione 
Chloramphenicol acetyl 
transferase (CAT)  
218 24 Chloramphenicol Chloramphenicol 
Maltose-binding 
protein (MBP) 
396 42 Cross-linked 
amylose 
Maltose 
NusA 495 55 N/A N/A 
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Despite the benefits, all fusion tags, whether small or large, have the potential to interfere with the 
biological activity of a protein, impede its crystallization, or otherwise influence its behaviour 
(Malhotra, 2009, Costa et al., 2014). Thus, it is often necessary to remove the fusion tag from the 
final protein after expression or purification. Most fusion tag vectors are designed with specific 
enzymatic cleavage sites sequences downstream of the gene coding for the tag, allowing the tag be 
cleaved from the fusion protein (Arnau et al., 2006). Commonly used protease for tag cleavage 
include enterokinase, thrombin, factor Xa and the tobacco etch virus protease (TEVp) (Rosano and 
Ceccarelli, 2014). However, the removal of fusion tags is a critical point of the fusion approach and 
may cause several problems that could result in failure to recover active or structurally intact proteins. 
(i) Optimisation of cleavage condition: cleavage using proteases requires specific conditions which 
need to be optimised. (ii) Unspecific cleavage: unspecific cleavage may occur due to the recognition 
of a linear amino acid sequence (Costa et al., 2014). (iii) Cleavage efficiency: steric hindrance or the 
presence of unfavourable residues around the cleavage site may affect the cleavage efficiency of 
proteases (Waugh, 2011). (iv) Precipitation: the target protein may precipitate or aggregate when the 
fusion tag is removed (Waugh, 2011). (v) Re-purification: a re-purification step often is required after 
cleavage to separate the target protein from the tag and the added protease (Costa et al., 2014). In 
addition, the high cost of proteases may be a limitation for industrial and commercial applications. 
2.2.4 Inclusion bodies 
High level expression of recombinant proteins in E. coli often results in insoluble aggregations of 
dense misfolded polypeptides, which are known as inclusion bodies (Middelberg, 2002). The use of 
high expression temperature, high inducer concentration and strong promoter systems generally 
causes the recombinant protein to be expressed at a high translation rate. The over-expression of 
recombinant genes trigger transcription of heat-shock genes and other stress responses (Villaverde 
and Carrió, 2003), causing the partially-folded and misfolded protein molecules to aggregate and 
form inclusion bodies. The reduced environment of bacterial cytosol, lack of eukaryotic chaperones 
and post-translational machinery also contribute to the formation of inclusion bodies (Singh et al., 
2015, Middelberg et al., 1991). This creates a major obstacle for the production and purification of 
biologically active recombinant proteins. Bioactive protein products from inclusion bodies usually 
require extensive processing in prior to delivery. The conventional strategy to purify proteins from 
inclusion bodies often involve isolation of inclusion bodies from cell, solubilisation, protein refolding 
and purification of the refolded proteins (Middelberg, 2002, Singh and Panda, 2005, Middelberg et 
al., 1991).  
After expression, the inclusion bodies are released from the harvest cells by disruption of the cells 
using sonication, homogenization or chemical methods. Then, isolation of inclusion bodies from 
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other cellular components can be easily achieved by centrifugation due to their high density 
(Upadhyay et al., 2012) or by filtration using cross-flow membranes (Venkiteshwaran et al., 2007). 
Inclusions bodies often contain contaminants of host membrane fragments, proteins and DNA, which 
can be further removed by several washing steps using low concentrations of detergents or 
denaturants such as urea, deoxycholic acid and Trition X-100. These contaminants can significantly 
reduce refolding yield if not removed (Middelberg, 2002). 
Once the inclusion bodies have been isolated the next step is solubilisation. Solubilisation of inclusion 
bodies is to disrupt of intermolecular interactions and completely unfold the proteins. It is usually 
performed by using high concentrations of denaturants and chaotropes like 6-10 M urea and 4-6 M 
guanidine hydrochloride. Guanidine hydrochloride is often preferred to urea as the presence of 
isocyanate in urea solutions can cause irreversible modifications of amino or thiol groups of the 
protein (Guise et al., 1996). Sometimes dithiothreitol (DTT) or β-mercaptoethanol are added to these 
solubilisation reagents to reduce the misformed disulphide bonds of proteins with multiple cysteine 
residues and improve solubilisation (Singh et al., 2015). The resulting solution containing the 
solubilised inclusion bodies is then centrifuged to remove any remaining insoluble material.  
After solubilisation, the proteins released from inclusion bodies are in a denatured state, therefore a 
refolding process is required to recover the native structure and restore bioactivity. Protein refolding 
is the most critical step and determines the whole efﬁciency and yield of the process, which is often 
considered as the “bottleneck” of the overall protein preparation process. In general, protein refolding 
is accomplished by the removal of excess denaturants and reducing agents, thus creating an 
appropriate environment where proteins can fold spontaneously (Middelberg, 2002). The simplest 
and most widely used method for reducing denaturant concentration is by dilution into an appropriate 
refolding buffer. As no universal refolding buffer can be identified, it should be necessary to screen 
a limited set of conditions for each protein. Nevertheless, the dilution method is time-consuming and 
easy to form aggregates of inactive proteins if not carefully controlled (Clark, 2001). Thus, the 
recovery rate is rather low. Other protein refolding methods include dialysis (Sørensen et al., 2003), 
diafiltration (Yoshii et al., 2000), gel-filtration (Werner et al., 1994) and liquid chromatography (Li 
et al., 2004, Geng and Wang, 2007). However, there is no universal method or best preferred method 
as each protein is unique and behaves quite differently during the refolding process. An optimised 
refolding method would require extensive testing and may involve expensive chemicals, yet still 
result in significant decrease of yield (Middelberg, 2002). 
2.3 Adjuvants 
Adjuvant, also known as immunomodulatory agent or immune enhancer, is often added to vaccine 
preparations to boost immune system response. The word adjuvant originates from the Latin 
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“adjuvare” and means auxiliary or enhanced (Petrovsky and Aguilar, 2004). As a kind of additives to 
vaccines, adjuvants can non-specifically alter or enhance the body's specific immune response to 
antigens (Hunter, 2002). The use of adjuvants can induce long-term, highly effective specific immune 
responses and reduce the amount of antigen needed, therefore, can reduce the cost of vaccination. In 
1925, Ramon et al. discovered that the addition of certain substances unrelated to the vaccine can 
specifically enhance the body's resistance to diphtheria and tetanus toxins (Ramon, 1925). Then in 
1926, Glenny et al. demonstrated the adjuvant activity of aluminium compounds with diphtheria 
toxoid absorbed to alum (Glenny et al., 1926). However, traditional vaccines have been highly 
immunogenic as they are mostly made of whole bacteria or whole viruses. These vaccines contain a 
large amount of non-immunogenic substances, which could be toxic but also have adjuvanting effects. 
Thus, traditional vaccines do not require adjuvants to enhance immunogenicity. As a result, the study 
and use of adjuvants did not arouse people's extensive attention for a long time. Nowadays, with the 
rapid development of modern biotechnology and genetic engineering, a variety of novel subunit 
vaccines have been developed for many different diseases (Zhao et al., 2014). However, these 
vaccines, due to their small antigen sizes, often have disadvantages such as weak immunogenicity 
and difficult to induce effective immune responses. Therefore, there is a great demand for adjuvants 
to enhance their immunogenicity and induce protective immunity. The study of adjuvants, especially 
the development of new adjuvants, is very urgent. In recent years, in order to meet the needs of new 
vaccines, adjuvants have been evolving rapidly from traditional forms to novel and diversified forms 
with the aid of modern nanotechnology.  
The use of adjuvants can (i) increase the immunogenicity of a vaccine, especially for highly purified 
or recombinant antigens (Petrovsky and Aguilar, 2004); (ii) improve the immune efficacy of vaccines 
in populations with reduced immune responsiveness, such as infants and the elderly (Podda, 2001); 
(iii) facilitate the use of smaller doses of antigen or fewer doses of vaccination (Schwarz et al., 2009, 
Banzhoff et al., 2009). However, the molecular mechanisms underlying the effect of adjuvants are 
only partially understood. Studies over the years show that many adjuvants effects seem to be on 
antigen-presenting cells, such as dendritic cells (DCs), by affecting the migration, maturation, antigen 
presentation, and expression of costimulatory molecules by DCs, and these events in turn improve 
the responses to antigen of T and B cells (McKee et al., 2007). Adjuvants may also act directly on T 
or B cells, affecting the nature of CD4+ T helper (Th), CD8+ T cell, and B cell responses, improving 
their proliferation and/or conversion into memory cells that are essential for the success of vaccines 
(Lambrecht et al., 2009). Increasing understanding of how adjuvants work to stimulate particular 
immune responses will play an important role in the development of new and improved vaccines.  
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2.3.1 Aluminium salts 
Aluminium salts are the first classical adjuvant approved by the FDA for use in humans and have 
been used clinically for more than 80 years (Lindblad, 2004). Many vaccines contain aluminium salts, 
such as the DPT vaccine, haemophilus influenza vaccines and hepatitis A and hepatitis B virus 
vaccines. According to different preparation processes, vaccines based on aluminium salts can be 
divided into two types: aluminium adsorption vaccines and aluminium precipitation vaccines (Gupta, 
1998). Al-adsorption vaccines are prepared by adding antigens to aluminium salt solutions; Al-
precipitation vaccines are prepared by adding aluminium-based compounds into antigen solutions. 
Aluminium hydroxide or aluminium phosphate are commonly used aluminium-based adjuvants. 
Studies have found that aluminium salt adjuvant vaccines can reduce the amount of antigens used and 
enhance immune responses (HogenEsch, 2013). The mechanism of aluminium salts has not been fully 
understood so far. It is generally believed that the adsorption of aluminium-based particles by antigens 
forms a gel state (Brewer, 2006), which can increase the size and surface area of antigens, acts as an 
antigen storage reservoir. In addition, aluminium salt adjuvants may induce the formation of 
macrophage-rich granulomas at the injection site, delaying the absorption and clearance of antigens, 
thereby prolonging the stimulation time of the antigen from several days to several weeks 
(Vogelbruch et al., 2000). Studies have shown that aluminium hydroxide as an adjuvant can also 
activate Th2 cells to secrete IL-4, induce the expression of CD83, CD86 and MHC-II molecules, and 
then produce a Th2-type humoral immune response (HogenEsch, 2013, Marrack et al., 2009). 
Aluminium salts have many advantages as vaccine adjuvants, but there are also disadvantages. 
Although it can effectively induce humoral immune responses, it has no effect on cellular immunity 
and cannot induce a cellular immune response (HogenEsch, 2002, Marrack et al., 2009). Furthermore, 
aluminium-based adjuvants have potential toxicity, especially neurotoxicity, and may lead to 
neurological diseases such as Alzheimer’s (Shaw and Tomljenovic, 2013). 
2.3.2 Nanoparticles  
Nanoparticles have been regarded as the rising star of adjuvants, which contain a large category of 
different particles and materials. The author previously published a review on the use of nanoparticles 
as adjuvants for vaccines. The literature review of this section consists of the peer-reviewed paper 
published as: 
 
Liang Zhao, Arjun Seth, Nani Wibowo, Chun-Xia Zhao, Neena Mitter, Chengzhong Yu, 
Anton P. J. Middelberg. 2014. Nanoparticle vaccines. Vaccine, 32(3), 327-37.  
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Abstract 
Nanotechnology increasingly plays a significant role in vaccine development. As vaccine 
development orientates toward less immunogenic “minimalist” compositions, formulations that boost 
antigen effectiveness are increasingly needed. The use of nanoparticles in vaccine formulations 
allows not only improved antigen stability and immunogenicity, but also targeted delivery and slow 
release. A number of nanoparticle vaccines varying in composition, size, shape, and surface properties 
have been approved for human use and the number of candidates is increasing. However, challenges 
remain due to a lack of fundamental understanding regarding the in vivo behavior of nanoparticles, 
which can operate as either a delivery system to enhance antigen processing and/or as an 
immunostimulant adjuvant to activate or enhance immunity. This review provides a broad overview 
of recent advances in prophylactic nanovaccinology. Types of nanoparticles used are outlined and 
their interaction with immune cells and the biosystem are discussed. Increased knowledge and 
fundamental understanding of nanoparticle mechanism of action in both immunostimulatory and 
delivery modes, and better understanding of in vivo biodistribution and fate, are urgently required, 
and will accelerate the rational design of nanoparticle containing vaccines. 
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1. Introduction 
Vaccine development has a proud history as one of the most successful public health interventions to 
date. Vaccine development is historically based on Louis Pasteur’s “isolate, inactivate, inject” 
paradigm. As vaccine development moves increasingly to draw on modern concepts of rational 
design, the number of candidate vaccines is increasing (Oberg et al., 2011, Rappuoli et al., 2011). 
Most candidate vaccines rep-resent “minimalist” compositions (Mamo and Poland, 2012), which 
typically exhibit lower immunogenicity. Adjuvants and novel delivery systems that boost 
immunogenicity are increasingly needed as we move toward the era of modern vaccines. 
Nanotechnology offers the opportunity to design nanoparticles varying in composition, size, shape, 
and surface properties, for application in the field of medicine (Couvreur and Vauthier, 2006, 
Moghimi et al., 2005). Nanoparticles, because of their size similarity to cellular components, can 
enter living cells using the cellular endocytosis mechanism, in particular pinocytosis (Treuel et al., 
2013). These cutting-edge innovations underpinned a market worth US $6.8 billion in 2006 (Wagner 
et al., 2006) and predicted to reach US $160 billion by 2015 (Global Industry Analysts Inc., 2009). 
Indeed, nanoparticles are revolutionizing the diagnosis of diseases as well as the delivery of 
biologically-active compounds for disease prevention and treatment. The emergence of virus-like 
particles (VLPs) and the resurgence of nanoparticles, such as quantum dots and magnetic 
nanoparticles, marks a convergence of protein biotechnology with inorganic nanotechnology that 
promises an era of significant progress for nanomedicine (Tissot et al., 2008, Pankhurst et al., 2003). 
A number of approved nano-sized vaccine and drug delivery systems highlight the revolution in 
disease prevention and treatment that is occurring (Couvreur and Vauthier, 2006, Maurer et al., 2005, 
Dobrovolskaia and McNeil, 2016, Roldao et al., 2010). 
The use of nanotechnology in vaccinology, in particular, has been increasing exponentially in the past 
decade (Figure 2-8), leading to the birth of “nanovaccinology” (Mamo and Poland, 2012). In both 
prophylactic and therapeutic approaches, nanoparticles are used as either a delivery system to enhance 
antigen processing and/or as an immunostimulant adjuvant to activate or enhance immunity. 
Therapeutic nanovaccinology is mostly applied for cancer treatment (Bolhassani et al., 2011, 
Krishnamachari et al., 2011, Hamdy et al., 2011), and is increasingly explored to treat other diseases 
or conditions, such as Alzheimer’s (Chackerian, 2010), hypertension (Tissot et al., 2008), and nicotine 
addiction (Maurer et al., 2005). Prophylactic nanovaccinology, on the other hand, has been applied 
for the prevention of different diseases. A number of prophylactic nanovaccines have been approved 
for human use and more are in clinical or pre-clinical trials (Roldao et al., 2010, Correia-Pinto et al., 
2013, Kushnir et al., 2012, Plummer and Manchester, 2011). 
In this review, we provide an overview of recent advances in the broad area of nanovaccinology, but 
limit our review only to prophylactic vaccines. We first survey advances in the types of nanoparticles, 
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which are defined as any particulate material with size 1–1000 nm (Food and Drug Administration 
US, 2011), used for prophylactic vaccine design (Figure 2-9). We then discuss the interaction of 
nanoparticles with the antigen of interest, differentiating the role of the nanoparticle as either delivery 
system and/or immunostimulant adjuvant. The interaction of nanoparticles with immune cells and the 
biosystem are also discussed to provide understanding of antigen and nanoparticle processing in vivo, 
as well as clearance. This latter aspect is of particular timeliness considering that there is limited 
history of safe use for non-VLP nanoparticles in humans. We then conclude with remarks about the 
further potential and future prospects for prophylactic nanovaccinology. 
 
Figure 2-8. Number of publications returned using the search terms “nanoparticle*and 
vaccine*” from Web of Science (http://apps.webofknowledge.com/; results fora 
search conducted on 29 July 2013). 
 
 
Figure 2-9. The size range of nanoparticles used in nanovaccinology. 
 
2. Types of nanoparticles 
2.1. Polymeric nanoparticles 
A great variety of synthetic polymers are used to prepare nanoparticles, such as poly(d,l-lactide-co-
glycolide) (PLG) (Thomas et al., 2011, Kim et al., 1999, Vila et al., 2004), poly(d,l-lactic-coglycolic 
acid) (PLGA) (Thomas et al., 2011, Lü et al., 2009, Demento et al., 2012, Diwan et al., 2002, Silva 
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et al., 2013, Manish et al., 2013, Lutsiak et al., 2006), poly(g-glutamicacid) (g-PGA) (Akagi et al., 
2011, Akagi et al., 2005), poly(ethylene glycol) (PEG) (Vila et al., 2004), and polystyrene (Kalkanidis 
et al., 2006, Minigo et al., 2007). PLG and PLGA nanoparticles have been the most extensively 
investigated due to their excellent biocompatibility and biodegradability (Peek et al., 2008, Danhier 
et al., 2012). These polymeric nanoparticles entrap antigen for delivery to certain cells or sustain 
antigen release by virtue of their slow biodegradation rate (Diwan et al., 2002, Silva et al., 2013, 
Manish et al., 2013, Akagi et al., 2011, Danhier et al., 2012). PLGA has been used to carry antigen 
derived from various pathogens including Plasmodium vivax with mono-phosphoryl lipid A as 
adjuvant (Moon et al., 2012b), hepatitis B virus (HBV) (Thomas et al., 2011), Bacillus anthracis 
(Manish et al., 2013), and model antigens such as ovalbumin and tetanus toxoid (Demento et al., 
2012, Diwan et al., 2002). g-PGA nanoparticles are comprised of amphiphilic poly(amino acid)s, 
which self-assemble into nano-micelles with a hydrophilic outer shell and a hydrophobic inner core 
(Akagi et al., 2011, Akagi et al., 2005). g-PGA nanoparticles are generally used to encapsulate 
hydrophobic antigen (Akagi et al., 2011, Akagi et al., 2005). Polystyrene nanoparticles can conjugate 
to a variety of antigens as they can be surface-modified with various functional groups (Kalkanidis 
et al., 2006, Scheerlinck et al., 2006). 
Natural polymers based on polysaccharide have also been used to prepare nanoparticle adjuvants, 
such as pullulan (Uenaka et al., 2007, Hasegawa et al., 2006), alginate (Li et al., 2013), inulin (Honda-
Okubo et al., 2012, Saade et al., 2013), and chitosan (Feng et al., 2013, Thomann-Harwood et al., 
2013, Zhao et al., 2013, Nanda et al., 2012, Zhao et al., 2012, Borges et al., 2008). In particular, 
chitosan-based nanoparticles have been widely studied due to their biocompatibility, 
biodegradability, nontoxic nature and their ability to be easily modified into desired shapes and sizes 
(Akagi et al., 2011, Chua et al., 2011, Arca et al., 2009). These nanoparticles have been used in the 
preparation of various vaccines including HBV vaccines (Borges et al., 2008), Newcastle disease 
vaccines (Zhao et al., 2012), and DNA vaccines (Feng et al., 2013, Zhao et al., 2013, Nanda et al., 
2012). Inulin, a well-known activator of complement via the alternative pathway (Goetze and 
Mueller-Eberhard, 1971), is also a potent adjuvant. Nanoparticle adjuvants derived from inulin, such 
as AdvaxTM, have shown enhancement of immune response in vaccines against various viruses 
including influenza (Honda-Okubo et al., 2012) and hepatitis B (Saade et al., 2013). 
Polymers, such as poly(L-lactic acid) (PLA), PLGA, PEG, and natural polymers such as 
polysaccharides (Li et al., 2013, Démoulins et al., 2013, Vinogradov et al., 1999, Ferreira et al., 2013), 
have also been used to synthesize hydrogel nanoparticles, which are a type of nano-sized hydrophilic 
three-dimensional polymer network. Nanogels have favorable properties including flexible mesh size, 
large surface area for multivalent conjugation, high water content, and high loading capacity for 
antigens (Ferreira et al., 2013, Raemdonck et al., 2009). Chitosan nanogels have been widely used in 
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antigen delivery, such as Clostridium botulinum type-A neurotoxin subunit antigen Hc for an 
adjuvant-free intranasal vaccine (Nochi et al., 2010), and recombinant NcPDI antigen for Neospora 
caninum vaccination (Debache et al., 2011). 
2.2. Inorganic nanoparticles 
Many inorganic nanoparticles have been studied for their use in vaccines. Although these 
nanoparticles are mostly non-biodegradable, the advantage of them lies in their rigid structure and 
controllable synthesis (Kalkanidis et al., 2006). Gold nanoparticles (AuNPs) are used in vaccine 
delivery (Peek et al., 2008), as they can be easily fabricated into different shapes (spherical, rod, 
cubic, etc.) (Niikura et al., 2013) with a size range of 2–150 nm (Gregory et al., 2013), and can be 
surface-modified with carbohydrates (Marradi et al., 2013). Gold nanorods have been used as a carrier 
for an antigen derived from respiratory syncytial virus by conjugating the antigen to the surface (Stone 
et al., 2013). Other types of gold nanoparticles have been used as carriers for antigens derived from 
other viruses such as influenza (Tao et al., 2014) and foot-and-mouth disease (Chen et al., 2010), or 
as a DNA vaccine adjuvant for human immunodeficiency virus (HIV) (Xu et al., 2012) . 
Carbon nanoparticles are another commonly-studied composition for drug and vaccine delivery 
(Gregory et al., 2013). They are known for their good biocompatibility and can be synthesized into a 
variety of nanotubes and mesoporous spheres (Bianco et al., 2005, Wang et al., 2011, Smart et al., 
2006). The diameter of carbon nanotubes (CNTs) used as carriers is generally 0.8–2 nm with a length 
of 100–1000 nm (Villa et al., 2011, Parra et al., 2013), while the size of mesoporous carbon spheres 
is around 500 nm (Wang et al., 2011). Multiple copies of protein and peptide antigens can be 
conjugated on to CNTs for delivery and have enhanced the level of IgG response (Wang et al., 2011, 
Villa et al., 2011, Parra et al., 2013, Pantarotto et al., 2003). Mesoporous carbon nanoparticles have 
been studied for application as an oral vaccine adjuvant (Wang et al., 2011). 
One of the most promising inorganic materials for nanovaccinology and delivery system design is 
silica. Silica-based nanoparticles (SiNPs) are biocompatible and have excellent properties as 
nanocarriers for various applications, such as selective tumor targeting (Ow et al., 2005), real-time 
multimodal imaging (Benezra et al., 2011), and vaccine delivery. The SiNPs can be prepared with 
tunable structural parameters. By controlling the sol–gel chemistry, the particle size and shape of 
SiNPs can be adjusted to selectively alter their inter-action with cells (Niu et al., 2012). The abundant 
surface silanol groups are beneficial for further modification to introduce additional functionality, 
such as cell recognition, absorption of specific biomolecules, improvement of interaction with cells, 
and enhancement of cellular uptake (Yu et al., 2013, Alshamsan et al., 2008, Xia et al., 2009, He et 
al., 2003). In addition, porous SiNPs such as mesoporous silica nanoparticles (MSNs) and hollow 
SiNPs can be prepared by templating methods, which can be applied as a multifunctional platform to 
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simultaneously deliver cargo molecules with various molecular weights (Niu et al., 2012). MSNs 
with sizes in the range of 50–200 nm have been studied as both nano-carriers and adjuvants for 
delivery of effective antigens (Mody et al., 2013, Carvalho et al., 2010, Mahony et al., 2013), such as 
those derived from porcine circovirus (Guo et al., 2012) and HIV (Cheng et al., 2011). MSNs can be 
used to control the release of antigens by controlling the shape, pore size and surface functionalization 
(Mody et al., 2013, Manzano et al., 2008). Compared to solid SiNPs, MSNs have higher loading 
capacity for their larger specific surface area, and better performance in delivery and controlled 
release due to the tunable hollow and mesoporous structure. In addition, MSNs can be degraded which 
can then be excreted in the urine (Zhai et al., 2012, Yamada et al., 2012, Chen et al., 2012). With 
these properties, MSNs show potential to become high-efficiency, controlled-release nano-carriers in 
future vaccine formulations. 
Calcium phosphate nanoparticles can be created by mixing calcium chloride, dibasic sodium 
phosphate and sodium citrate under specific conditions (He et al., 2000, He et al., 2002). They are 
non-toxic and can be formed into a size of 50–100 nm (Joyappa et al., 2009). These nanoparticles are 
useful adjuvants for DNA vaccines and mucosal immunity (Mody et al., 2013, He et al., 2000, He et 
al., 2002, Joyappa et al., 2009), and show excellent biocompatibility. 
2.3. Liposomes 
Liposomes are formed by biodegradable and nontoxic phospholipids. Liposomes can encapsulate 
antigen within the core for delivery (Giddam et al., 2012) and incorporate viral envelope 
glycoproteins to form virosomes (Sharma et al., 2009, Khatri et al., 2008) including for influenza 
(Glück et al., 2004). Combination of 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) modified 
cationic liposome and a cationic polymer (usually protamine) condensed DNA are called liposome-
polycation-DNA nanoparticles (LPD), a commonly used adjuvant delivery system in DNA vaccine 
studies (Li et al., 1998, Li and Huang, 1997). The components of LPD spontaneously rearrange into 
a nano-structure around 150 nm in size with condensed DNA located inside the liposome (Li and 
Huang, 1997). Liposomes modified with maleimide can be synthesized into interbilayer-crosslinked 
multi-lamellar vesicles (ICMVs) by cation driven fusion and crosslinking (Moon et al., 2011) 
enabling slowed release of entrapped antigen. A number of liposome systems have been established 
and approved for human use, such as Inflexal®V and Epaxal®, which have been discussed in other 
reviews (Giddam et al., 2012, Watson et al., 2012). 
2.4. Immunostimulating complex (ISCOM) 
ISCOMs are cage like particles about 40 nm large in size, made of the saponin adjuvant Quil A, 
cholesterol, phospholipids, and protein antigen (Peek et al., 2008, Sharma et al., 2009, Homhuan et 
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al., 2004, Aguilar and Rodriguez, 2007, Morein et al., 1984). These spherical particles can trap the 
antigen by apolar interactions (Peek et al., 2008). ISCOMATRIX comprises ISCOMs without antigen 
(Peek et al., 2008, Sharma et al., 2009, Aguilar and Rodriguez, 2007, Pearse and Drane, 2004). 
ISCOMATRIX can be mixed with antigen, enabling a more flexible application than is possible for 
ISCOMs, by removing the limitation of hydrophobic antigens (Peek et al., 2008). Various antigens 
have been used to form ISCOMs, including antigens derived from influenza (Sambhara et al., 1998, 
Coulter et al., 2003), herpes simplex virus (Mohamedi et al., 2000), HIV (Agrawal et al., 2003), and 
Newcastle disease (Homhuan et al., 2004). 
2.5. Virus-like particles 
Virus-like particles (VLP) are self-assembling nanoparticles, lacking infectious nucleic acid, formed 
by self-assembly of biocompatible capsid proteins (Noad and Roy, 2003, Grgacic and Anderson, 
2006). VLPs are the ideal nanovaccine system as they harness the power of evolved viral structure, 
which is naturally optimised for interaction with the immune system, but avoid the infectious 
components. VLPs take the good aspects of viruses and avoid the bad. The naturally-optimised 
nanoparticle size and repetitive structural order means that VLPs induce potent immune responses, 
even in the absence of adjuvant (Zhang et al., 2000). VLP based vaccines are the first nanoparticle 
class to reach market – the first VLP vaccine for hepatitis B virus was commercialized in 1986 (Andre, 
1990) – and have become widely administered in healthy populations. In nanovaccinology, VLP 
nanoparticles have the strongest evidence base for safe use in healthy humans. Newer VLP vaccines 
for human papillomavirus (Cutts et al., 2007) and hepatitis E (Park, 2012) have been approved for 
use in humans in 2006 and 2011, respectively. 
VLPs can be derived from a variety of viruses (Figure 2-10) (Noad and Roy, 2003), with sizes ranging 
from 20 nm to 800 nm (Roldao et al., 2010, Pushko et al., 2013), and can be manufactured with a 
variety of process technologies (Pattenden et al., 2005). The historical approach to VLP manufacture 
involves an in vivo route, where the assembly of capsid proteins into VLPs occurs inside the 
expression host. The assembled particle is then purified away from adherent and encapsulated 
contaminants. In some cases it becomes necessary to disassemble and then re-assemble the VLP to 
improve quality (Pattenden et al., 2005); recently-approved VLP vaccines typically include some 
aspect of extracellular assembly within the processing regime. An emerging approach for VLP 
assembly is through cell-free in vitro processing (Campbell and Vogt, 1997, Sánchez-Rodríguez et 
al., 2012, Zhang et al., 1998, Lu et al., 2013). This approach inverts the traditional assemble-then-
purify paradigm; large-scale purification of the VLP building blocks from contaminants occurs first, 
then these are assembled in vitro, avoiding the need to disassemble VLP structures after assembly in 
39 
 
a cell. Further review of VLP manufacturing approaches is available elsewhere (Roldao et al., 2010, 
Kushnir et al., 2012, Chuan et al., 2012a, Lua et al., 2014). 
 
Figure 2-10. Structure of virus-like particles. Virus-like particles can be derived from 
a variety of viruses. HEV, hepatitis E virus; HPV, human papillomavirus 16; SIV-
HIV, hybrid VLP between simian immunodeficiency virus gag and human 
immunodeficiency virus env; HCV, hepatitis C virus; BTV, bluetongue virus. 
Reprinted from Trends in Microbiology, Vol. 11, Issue 8, Rob Noad and Polly Roy, 
Virus-like particles as immunogens, Pages 438–444, Copyright (2003), with 
permission from Elsevier (Noad and Roy, 2003). 
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VLPs commercialized to date are based on self-assembly of proteins derived from the target virus. 
However, VLPs can also act as a delivery platform where a target antigen from a virus unrelated to 
the VLP used is modularized on the surface of a VLP (Plummer and Manchester, 2011, Tissot et al., 
2010, Middelberg et al., 2011, Neirynck et al., 1999, Ionescu et al., 2006). These modular VLPs 
exploit known benefits of VLPs (optimised particle size and molecular structure) to target disease in 
an engineered fashion. With many VLP vaccines currently in clinical or pre-clinical trials (Roldao et 
al., 2010, Kushnir et al., 2012), an increase in the number of approved VLP-based vaccines can be 
expected. 
2.6. Self-assembled proteins 
Recognizing the power of the VLP approach, self-assembling systems that attempt to drive higher 
levels of protein quaternary structuring have emerged for the preparation of nanoparticle-based 
vaccines. Ferritin is a protein that can self-assemble into nearly-spherical 10 nm structure (Kanekiyo 
et al., 2013). By genetically fusing influenza virus haemagglutinin (HA) to ferritin, the recombined 
protein spontaneously assembled into an octahedrally-symmetric particle and reformed 8 trimeric HA 
spikes (Kanekiyo et al., 2013) to give a higher immune response than trivalent inactivated influenza 
vaccine, which typically is processed to destroy rather than build viral structure. This example 
highlights the importance of driving higher-order molecular structure in modern vaccines. The major 
vault protein (MVP) is another kind of self-assembling protein. Ninety-six units of MVP can self-
assemble into a barrel-shaped vault nanoparticle, with a size of approximately 40 nm wide and70 nm 
long (Champion et al., 2009). Antigens that are genetically fused with a minimal interaction domain 
can be packaged inside vault nanoparticles by self-assembling process when mixed with MVPs 
(Champion et al., 2009). Vault nanoparticles have been used to encapsulate the major outer mem-
brane protein of Chlamydia muridarum for studies of mucosal immunity (Champion et al., 2009). 
2.7. Emulsions 
Another type of nanoparticles used as adjuvants in vaccines delivery is nano-sized emulsions (Aguilar 
and Rodriguez, 2007, Shah et al., 2010, Aucouturier et al., 2001). These nanoparticles can exist as 
oil-in-water or water-in-oil forms, where the droplet size can vary from 50 nm to 600 nm (Shah et al., 
2010). Emulsions can carry antigens inside their core for efficient vaccine delivery (Shah et al., 2010) 
or can also be simply mixed with the antigen. One commonly-used emulsion is MF59TM, an oil-in-
water emulsion which has been licensed as a safe and potent vaccine adjuvant in over 20 countries 
(Peek et al., 2008, O’Hagan, 2007). It has been widely studied for use in influenza vaccines (O’Hagan, 
2007, De Donato et al., 1999, Nicholson et al., 2001). Another is Montanide™, a large family of both 
oil-in-water and water-in-oil emulsions, including water and water-in-oil emulsions, including ISA 
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50 V, 51, 201, 206 and 720 (Peek et al., 2008, Aucouturier et al., 2002). Montanide ISA 51 and 720 
have been used in Malaria vaccines (Kumar et al., 2004, Oliveira et al., 2005), Montanide ISA 201 
and 206 have been used in foot-and-mouth disease vaccines (Dar et al., 2013). 
Recently, a tailorable nano-sized emulsion (TNE) platform technology has been developed using non-
covalent click self-assembly for antigen and drug delivery (Chuan et al., 2012b, Zeng et al., 2013). 
An oil-in-water nanoemulsion is formed using designed biosurfactant peptides and proteins. Using a 
self-assembling peptide-protein system, immune-evading PEG and a receptor-specific antibody can 
be arrayed in a selectively proportioned fashion on the aqueous interface of a nano-sized oil-in-water 
emulsion (Figure 2-11). Targeted delivery of protein antigen to dendritic cells was achieved (Zeng et 
al., 2013). This work demonstrates a new and simple way to make biocompatible designer 
nanoemulsions using non-covalent click self-assembly by sequential top-down reagent addition. 
3. Nanoparticle interaction with antigen 
Vaccine formulations comprising nanoparticles and antigens can be classified by nanoparticle action 
into those based on delivery system or immune potentiator approaches. As a delivery system, 
nanoparticles can deliver antigen to the cells of the immune system, i.e. the antigen and nanoparticle 
are co-ingested by the immune cell, or act as a transient delivery system, i.e. protect the antigen and 
then release it at the target location (Mody et al., 2013). For nanoparticles to function as a delivery 
system, association of antigen and nanoparticle is typically necessary. For immune potentiator 
approaches, nanoparticles activate certain immune pathways which might then enhance antigen 
processing and improve immunogenicity. 
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Figure 2-11. Schematic representation of PEG (white) chemically conjugated to 
DAMP4 protein (dark blue) being introduced to a solution containing pre-formed 
nanoemulsion oil core (light yellow) stabilized by AM1 peptide (red), in aqueous 
buffer (light blue background). DAMP4 protein, which is chemically similar to AM1 
peptide, is able to integrate into the oil-water interface formed between the core and 
the aqueous bulk. Prior conjugation of PEG to DAMP4 leads to its functional display 
at the interface through non-covalent molecular self-assembly. (For interpretation of 
the references to color in figure legend, the reader is referred to the web version of the 
article.) 
Reprinted from Small, http://dx.doi.org/10.1002/smll.201300078, B.J. Zeng, Y.P. 
Chuan, B. O’Sullivan, I. Caminschi, M.H. Lahoud, R. Thomas, A.P.J. Middelberg, 
Receptor-Specific Delivery of Protein Antigen to Dendritic Cells by a Nanoemulsion 
Formed Using Top-Down Non-Covalent Click Self-Assembly, Copyright (2003), 
with permission from John Wiley and Sons (Zeng et al., 2013). 
 
Hard material nanoparticles, such as those based on silica, gold, and calcium phosphate, have 
predominantly been examined for use as a delivery system (Oyewumi et al., 2010) and have thus been 
engineered to promote antigen attachment. Attachment of antigen has been achieved through simple 
physical adsorption or more complex methods, such as chemical conjugation or encapsulation (Figure 
2-12). Adsorption of antigen onto a nanoparticle is generally based simply on charge or hydrophobic 
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interaction (Mody et al., 2013, Wendorf et al., 2006, Stieneker et al., 1991). Therefore, the interaction 
between nanoparticle and antigen is relatively weak, which may lead to rapid disassociation of antigen 
and nanoparticle in vivo. Encapsulation and chemical conjugation provide for stronger interaction 
between nanoparticle and antigen. In encapsulation, antigens are mixed with nanoparticle precursors 
during synthesis, resulting in encapsulation of antigen when the precursors particulate into a 
nanoparticle (He et al., 2000). Antigen is released only when the nanoparticle has been decomposed 
in vivo or inside the cell. On the other hand, for chemical conjugation, antigen is chemically cross-
linked to the surface of a nanoparticle (Slütter et al., 2010). Antigen is taken up by the cell together 
with the nanoparticle and is then released inside the cell. In soft matter nanoparticle delivery system, 
such as those based on VLPs, ISCOM, ISCOMATRIXTM, or liposomes, attachment of antigen is 
achieved through chemical conjugation, adsorption, encapsulation, or fusion at DNA level (Giddam 
et al., 2012, Glück et al., 2004, Morein et al., 1984, Pearse and Drane, 2004, Middelberg et al., 2011, 
Neirynck et al., 1999, Ionescu et al., 2006). 
For nanoparticles to act as an immune potentiator, attachment or interaction between the nanoparticle 
and antigen is not necessary, and may be undesirable in cases where modification of antigenic 
structure occurs at the nanoparticle interface. Soft-matter nanoparticles, such as emulsion-based 
adjuvants MF59TM and AS03TM, have been shown to adjuvant a target antigen even when they are 
injected independently of, and before, the antigen (Morel et al., 2011, O'Hagan et al., 1997). Building 
on this idea, formulation of immune potentiator nanoparticles with a target antigen could be possible 
through simple mixing of nanoparticle and adjuvant, shortly prior to injection, with minimal 
association between nanoparticle and antigen needed. This approach has only recently been 
investigated for hard-material nanoparticle adjuvants, with results suggesting that nanoparticles may 
act as a size-dependent immune potentiator adjuvant even when not conjugated to the antigen 
(Wibowo, 2012). This new finding is consistent with a number of other studies that have demonstrated 
induction of inflammatory immune responses after injection of hard material nanoparticles alone and 
without antigen (Vallhov et al., 2012, Vallhov et al., 2007). Further studies into the use of 
nanoparticles as immune-potentiating adjuvants are clearly needed. As the interaction of 
nanoparticles with the immune system becomes more fully under-stood, we expect their impact to be 
broadened. 
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Figure 2-12. Interaction of nanoparticle with antigen of interest. Formulation of 
nanoparticle and antigen of interest can be through attachment (e.g. conjugation, 
encapsulation, or adsorption) or simple mixing. 
 
4. Nanoparticle interactions with antigen presenting cells 
Incorporating antigenic components into nanoparticles has attracted extensive interest with a focus 
on how to deliver antigen more efficiently to antigen presenting cells (APCs) and subsequently induce 
their maturation and cross presentation of antigen for activation of a potent immune response (Reddy 
et al., 2006, Jones, 2008, Babensee, 2008, Bachmann and Jennings, 2010, Scheerlinck and 
Greenwood, 2008). As specialized APCs which efficiently uptake and process antigen, dendritic cells 
(DCs) and macrophages are often targeted in vaccine design. Good understanding of DC and 
macrophage uptake mechanisms and interactions of NPs with these cells is therefore very important 
for developing efficacious nanoparticle vaccines (Zolnik et al., 2010, Dobrovolskaia et al., 2008, 
Kumari and Yadav, 2011). Studies have reported that size, charge and shape of nanoparticles play 
significant roles in antigen uptake. 
Generally, nanoparticles having a comparable size to pathogens can be easily recognized and are 
consequently taken up efficiently by APCs for induction of immune response (Xiang et al., 2006, 
Akagi et al., 2007, Uto et al., 2007, Copland et al., 2003, Elamanchili et al., 2004, Lutsiak et al., 2002, 
Lin et al., 2013). DCs preferentially uptake virus-sized particles (20–200 nm) while macrophages 
preferentially uptake larger particles (0.5–5 µm) (Xiang et al., 2006). In an in vitro study using 
polystyrene particles ranging from 0.04 µm to 15 µm, the optimum size for DC uptake was found to 
be smaller than 500 nm (Foged et al., 2005). Similarly, 300 nm sized PLGA particles also showed 
higher internalization and activation of DCs in com-parison to 17, 7 and 1 µm particles (Joshi et al., 
2013). Higher uptake of smaller PLA particles (200–600 nm) in comparison to larger ones (2–8 µm) 
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has also been reported for uptake by macrophages (Kanchan and Panda, 2007). Different studies 
however, show discrepancies in optimum nanoparticle vaccine size. Amphiphilic poly(amino acid) 
(PAA) nanoparticles of 30 nm were shown to have a lower DC uptake than that of 200 nm 
nanoparticles (Kim et al., 2010). Polyacrylamide hydrogel particles of 35 nm and 3.5 µm in size 
showed no difference in macrophages uptake (Cohen et al., 2008). These discrepancies may be related 
to the intrinsic differences in the material properties, with each material having an optimum size for 
induction of potent immune response (Yan et al., 2013). 
In addition to particle size, surface charge also plays a significant role in the activation of immune 
response. Cationic nanoparticles have been shown to induce higher APC uptake due to electrostatic 
interactions with anionic cell membranes (Foged et al., 2005). In vitro studies suggested that a 
cationic surface could significantly enhance the uptake of polystyrene particles of micron size (∼1 
µm) by macrophages and DCs in comparison with a neutral or negative surface (Foged et al., 2005, 
Thiele et al., 2003, Wischke et al., 2006), but not for the smaller nanoparticles (100 nm) (Foged et 
al., 2005). However, other in vivo studies revealed that either positively (Nakanishi et al., 1999) or 
negatively charged (Yotsumoto et al., 2004) liposomes could act as efficient adjuvants to induce cell-
mediated immune response. Furthermore, due to their electrostatic interaction with anionic cell 
membranes, cationic particles are more likely to induce hemolysis and platelet aggregation than 
neutral or anionic particles (Goodman et al., 2004). 
Particle shape plays an equally important role in the interaction between nanoparticles and APCs. For 
big particles (>1 µm), particle shape plays a dominant role in phagocytosis by macrophages as the 
uptake of particles is strongly dependent on the local shape at the interface between particles and 
APCs (Champion and Mitragotri, 2006). Worm-like particles with high aspect ratios (>20) exhibited 
negligible phagocytosis compared to spherical particles (Champion and Mitragotri, 2009). On the 
other hand, spherical gold nanoparticles (AuNPs) (40 nm) were more effective in inducing antibody 
response than other shapes (cube and rod) or the 20 nm-sized AuNPs, even though the rods (40 nm × 
10 nm) were more efficient in APC uptake than the spherical and cubic AuNPs (Niikura et al., 2013). 
A number of studies also reported the effect of hydrophobicity, showing higher immune response for 
hydrophobic particles than hydrophilic ones (Hillaireau and Couvreur, 2009, Raghuvanshi et al., 
2002). A number of other factors such as surface modification (pegylation, targeting ligands) and 
vaccine cargo (Thomann-Harwood et al., 2013) have been shown to affect the interaction between 
nanoparticles and APCs as well. 
5. Nanoparticle-biosystem interactions 
Designing safe and efficacious nanoparticle vaccines requires a thorough understanding of the 
interaction of nanoparticles with biological systems which then determines the fate of nanoparticles 
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in vivo. Physicochemical properties of nanoparticles including size, shape, surface charge, and 
hydrophobicity influence the interaction of nanoparticles with plasma proteins (Aggarwal et al., 2009, 
Nel et al., 2009) and immune cells (Hillaireau and Couvreur, 2009). These interactions as well as 
morphology of vascular endothelium play an important role in distribution of nanoparticles in various 
organs and tissues of the body. 
The lymph node (LN) is a target organ for vaccine delivery since cells of the immune system, in 
particular B and T cells, reside there. Ensuring delivery of antigen to LNs, by direct drainage (Moon 
et al., 2012a, Reddy et al., 2007) or by migration of well-armed peripheral APCs (Seubert et al., 
2008), for optimum induction of immune response is therefore an important aspect of nanoparticle 
vaccine design. Distribution of nanoparticles to the LN is mainly affected by size (Oussoren and 
Storm, 1997, Swartz, 2001). Nanoparticles with a size range of 10–100 nm can penetrate the 
extracellular matrix easily and travel to the LNs where they are taken up by resident DCs for 
activation of immune response (Swartz, 2001, Cubas et al., 2009, Dane et al., 2011, Fifis et al., 2004). 
Particles of larger size (>100 nm) linger at the administration point (Reddy et al., 2007, Dane et al., 
2011, De Temmerman et al., 2011) and are subsequently scavenged by local APCs (Reddy et al., 
2007, Fifis et al., 2004, Manolova et al., 2008), while smaller particles (<10 nm) drain to the blood 
capillaries (Swartz, 2001, Manolova et al., 2008). The route of administration and biological 
environment to which nanoparticles are exposed could also affect the draining of nanoparticles to the 
LN. It was reported that small PEG coated liposomes (80–90 nm) were significantly present in larger 
amounts in LNs after subcutaneous administration as compared to intravenous and intraperitoneal 
administration (Allen et al., 1993). 
In addition to targeting lymphatic organ for efficient activation of immune response, design of 
nanoparticle vaccines also needs to consider nanoparticle clearance from the body. Adverse effects 
may occur when nanoparticles are not degraded or excreted from the body and hence, accumulate in 
different organs and tissues. Clearance of nanoparticles could be achieved through degradation by the 
immune system or by renal or biliary clearance. 
Renal clearance through kidneys can excrete nanoparticles smaller than 8 nm (Longmire et al., 2008, 
Choi et al., 2007). Surface charge also plays an important role in determining renal clearance of 
nanoparticles. Few reports have suggested that for appropriate identically sized particles, based on 
surface charge, ease of renal clearance follows the order of positively-charged < neutral < negatively 
charged (Ohlson et al., 2001, Deen et al., 2001). This may be attributed to the presence of negatively-
charged membrane of glomerular capillary (Almeida et al., 2011). 
On the other hand, biliary clearance through liver allows excretion of nanoparticles larger than 200 
nm (Longmire et al., 2008, Arora et al., 2012). Surface charge also plays role in biliary clearance with 
increase in surface charges showing increased distribution of nanoparticles in the liver (He et al., 
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2010). Furthermore, a study reported shape dependent distribution of nanoparticles where short rod 
nanoparticles were predominantly found in liver, while long rods were found in spleen. Short rod 
nanoparticles were excreted at a faster rate than longer ones (Huang et al., 2011). 
In order to aid understanding of interaction of nanoparticles with immune cells and the biosystem, 
many different in vivo molecular imaging techniques including magnetic resonance imaging (MRI), 
positron emission tomography (PET), fluorescence imaging, single photon emission computed 
tomography (SPECT), X-ray computed tomography (CT) and ultrasound imaging could be 
employed. Owing to its excellent soft tissue contrast and non-invasive nature, MRI imaging is 
extensively used for obtaining three-dimensional images in vivo. Superparamagnetic iron oxide 
nanoparticles (SPION) have been extensively used as contrast agents for morphological imaging 
(Sulek et al., 2011, Lee et al., 2006). PET usually employs an imaging device (PET scanner) and a 
radiotracer that is usually intravenously injected into the bloodstream. Due to high sensitivity of this 
technique, it is used to study the biodistribution of particles of interest. The only disadvantage of this 
technique is relatively low spatial resolution as compared to other techniques. PET imaging of 64Cu 
radiolabelled shell-crosslinked nanoparticles has been demonstrated (Sun et al., 2007). Fluorescence 
imaging facilitates imaging of nanoparticles using fluorescent tags. Dye-doped silica nanoparticles 
as contrast imaging agents for in vivo fluorescence imaging in small animals have been reported 
(Wang et al., 2013). 
Nowadays, more attention is being paid to synergize two or more imaging techniques that 
complement each other and provide an opportunity to overcome shortcomings of individual 
techniques in terms of resolution or sensitivity. For instance, simultaneous PET-MRI imaging is a 
new emerging hybrid imaging system that combines the morphological imaging component of MRI 
with the functional imaging component of PET (Judenhofer et al., 2008). Multifunctionality of 
nanoparticles can be utilized for such hyphenated imaging. 
6. Concluding remark 
Nanoparticle-containing vaccines have attracted tremendous interest in recent years, and a wide 
variety of nanoparticles have been developed and employed as delivery vehicles or immune 
potentiators, allowing not only improvement of antigen stability and the enhancement of antigen 
processing and immunogenicity, but also the targeted delivery and slow release of antigens. In 
addition, nanoparticles have been increasingly used to deliver not only antigen of interest but also co-
adjuvant, such as poly(I:C), CpG and MPL (De Temmerman et al., 2011, Hafner et al., 2013). 
However, the application of nanoparticles in vac-cine delivery as well as in drug delivery is still at an 
early stage of development. A number of challenges remain, including difficulty in reproducibly 
synthesizing non-aggregated nanoparticles having consistent and desirable properties, a lack of 
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fundamental understanding of how the physical properties of nanoparticles affect their biodistribution 
and targeting, and how these proper-ties influence their interactions with the biological system at all 
levels from cell through tissue and to whole body. Therefore, rational design in combination with the 
reproducible production of nanoparticles with desirable properties, functionalities and efficacy 
becomes increasingly important, and it is anticipated that the adoption of new technologies, for 
example microfluidics, for the controlled synthesis of nanoparticles will accelerate the development 
of suitable nanoparticles for pharmaceutical applications (Zhao et al., 2011). Furthermore, by 
integrating some other attractive properties, such as slow release, targeting and alternative 
administration methods and delivery pathways, novel vaccine systems for unmet needs including 
single-dose and needle-free delivery will become practical in the near future. 
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Chapter 3  
General Methods and Materials 
3.1 Materials  
Ampicillin, chloramphenicol, 3-(N-Morpholino)propanesulfonic acid (MOPS) (titration grade), Tris-
base, urea (reagent grade), dithiothreitol (DTT) (TLC grade), glutathione (GSH), Tween-20 and 
Bromophenol blue (ACS grade) were all obtained from Sigma-Aldrich (St. Louis, Missouri, USA). 
Tryptone (bacteriological grade), agar (bacteriological grade), guanidinium chloride (technical grade) 
and sodium dodecyl sulphate (SDS) (reagent grade) were obtained from Amresco (Solon, Ohio, 
USA). Manganese (II) chloride tetrahydrate (AR grade), calcium chloride (AR grade), potassium 
chloride (AR grade), sodium chloride (AR grade), ammonium persulfate (AR grade) and acetic acid 
glacial (AR grade) were obtained from Ajax Finechem (Sydney, New South Wales, Australia). 
Potassium acetate (AR grade), rubidium chloride (AR grade) and yeast extract were obtained from 
Merck (Darmstadt, Hesse, Germany). Ethylenediaminetetraacetic acid disodium (EDTA-Na2) (AR 
grade), monopotassium phosphate (AR grade), dipotassium phosphate (AR grade), sodium hydrogen 
phosphate (AR grade), glycerol (AR grade) and Triton X-100 (LR grade) were obtained from Chem-
Supply (Gillman, South Australia, Australia). Isopropyl β-D-1-thiogalactopyranoside (IPTG) was 
obtained from Astral Scientific (Caringbah, New South Wales, Australia). 
Tetramethylethylenediamine (TEMED) and 40% polyacrylamide were obtained from Bio-Rad 
(Hercules, California, USA). Coomassie brilliant blue R was obtained from GE Healthcare 
(Amersham, England, UK). 
3.2 Plasmid construction 
The cloning work for all plasmid constructions was done by the Protein Expression Facility (PEF, 
The University of Queensland). Full length genes encoding VirB9-1 (Genome ID: AM097) and 
VirB9-2 (Genome ID: AM1315) were amplified by polymerase chain reaction (PCR) (Table 3-1). 
The amplified DNA fragments were inserted between the BamHI and XhoI sites of a pGEX-4T-1 
glutathione S-transferase (GST) tagged expression vector (GE Healthcare, Amersham, England, UK). 
The thrombin recognition site sequence of the vector was mutated into a tobacco etch virus protease 
(TEVp) recognition site sequence and GGGGS (G4S) linker sequence was added on both sides of the 
TEVp recognition site by site-directed mutagenesis before gene insertion (Figure 3-1). The vector 
confers ampicillin resistance up to 100µg/ml and a tac promoter inducible by IPTG. Purified plasmid 
DNA was sequenced using ABI BigDye Terminator v3.1 Sequencing was conducted by the 
75 
 
Australian Genome Research Facility (AGRF). Data analysis was performed using the software 
Sequencher™ 4.7 (Gene Codes Corporation). 
Table 3-1. Primer sequences used to amplify VirB9-1/9-2 genes. 
Gene  Primers 
VirB9-1 Forward 5'-
GAAAACTTGTACTTCCAAGGAAAACGGCGGCAGTAAGGCTT 
TCATGGTTTGTGCTG-3' 
 Reverse 5'-
CCCTTTAATAAGCACGTGGGATCAACGTCCCCTTCTGGATGT 
AGA-3' 
VirB9-2 Forward 5'-
GAAAACTTGTACTTCCAAGGAGGCGGCGGCAGTAAAAACTT 
GCTTGCGTGCTCGGC-3' 
 Reverse 5'-
CCCYYYAAYAAGCACGYGGGAYCAAAGCACCGYAYYCACY 
ACYYC-3' 
 
 
Figure 3-1. Vector map of VirB9-1 and VirB9-2 expression vector. The construct 
sequence for VirB9-1 and VirB9-2 is in Appendix B. Modified figure obtained from 
Zhang et al. (Zhang et al., 2009). 
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3.3 Competent cell preparation 
Escherichia coli strain Rosetta (DE3) pLysS can enhance the correct folding of disulphide-bonded 
recombinant proteins by supplying tRNAs for rare E. coli codons AUA, AGG, AGA, CUA, CCC and 
GGA. The pLysS plasmid produces T7 lysozyme to reduce basal level expression of the gene of 
interest and is suitable for expression of toxic genes. This strain was chosen as the host strain for 
plasmid expression. Competent Rosetta (DE3) pLysS cells were prepared using the calcium chloride-
mediated method as previously described (Sambrook and Russell, 2001, Chuan et al., 2008). Master 
Rosetta (DE3) pLysS cells were streaked on LB agar plate (10 g/L tryptone, 5 g/L yeast extract, 10 
g/L NaCl, 15 g/L agar, 34 µg/mL Chloramphenicol) and incubated at 37 °C. Single colony was 
selected and inoculated into 5 mL LB broth (10 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl, 34 µg 
/mL chloramphenicol) in a 15 mL Falcon tube, then incubated overnight at 180 rpm, 30 °C using a 
Ratek Orbital Shaking Incubator OM15 (Ratek Instruments, Boronia, Victoria, Australia). 50 mL LB 
broth was inoculated with 2.5 mL of the overnight culture and incubated at 180 rpm, 37 °C using a 
Ratek Orbital Shaking Incubator OM15 until OD600 reached 0.5-0.6. The culture was then transferred 
onto ice for 10 min, then centrifuged at 4000 g, 10 min, 4 °C. Pellets were collected and resuspended 
in 20 mL TB1 buffer (2.94 g/L potassium acetate, 12.1 g/L rubidium chloride, 10 g/L MnCl2·4H2O, 
10 mM calcium chloride, 15% (v/v) glycerol, pH 5.8) by pipetting up and down gently.  The cell 
suspension was incubated on ice for 30 min, followed by centrifugation at 4000 g, 10 min, 4 °C. 
Pellets were collected and resuspended in 2 mL TB2 buffer (2.1 g/L MOPS, 1.21 g/L rubidium 
chloride, 75 mM calcium chloride, 15% (v/v) glycerol, pH 6.5), then aliquoted into 1.5 mL Eppendorf 
tubes and snap frozen in liquid nitrogen before frozen storage until required. 
3.4 Plasmid transformation 
The VirB9-1 and VirB9-2 plasmids were individually transformed into E. coli Rosetta (DE3) pLysS 
competent cells. 1 µL of plasmid was mixed with 50 µL of competent cells and incubated on ice for 
20-30 min, then the mixture was heat shocked at 42 °C for 45 seconds, followed by incubation on ice 
for another 2 min. After incubation, cells were transferred into 950 µL LB broth (10 g/L tryptone, 5 
g/L yeast extract, 10 g/L NaCl, 50 µg /mL Ampicillin, 34 µg /mL Chloramphenicol) in a 15 mL 
round-bottom polypropylene tube and incubated at 220 rpm, 37 °C for 1 hour using a Ratek Orbital 
Shaking Incubator OM15. The culture was then plated on LB agar plate (10 g/L tryptone, 5 g/L yeast 
extract, 10 g/L NaCl, 15 g/L agar, 50 µg /mL Ampicillin, 34 µg /mL Chloramphenicol) and incubated 
overnight at 37 °C. The next day, a single colony from the overnight plate was selected and inoculated 
into 5 mL TB medium (12 g/L tryptone, 24 g/L yeast extract, 2.31 g/L KH2PO4, 12.54 g/L K2HPO4 
0.4% (v/v) glycerol, 50 µg /mL Ampicillin, 34 µg /mL Chloramphenicol) in a 15 mL Falcon tube and 
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then incubated overnight at 180 rpm, 30 °C using a Ratek Orbital Shaking Incubator OM15. Finally, 
the culture was aliquoted into 500 µL in 1.5 mL Eppendorf tubes and mixed with the same volume 
of sterile 60% v/v glycerol, then snap frozne in liquid nitrogen and stored in -80 °C. 
3.5 Protein expression 
The frozen glycerol stock of transformed cells was scraped with a sterile pipette tip and streaked onto 
an LB agar plate (10 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl, 15 g/L agar, 50 µg /mL 
Ampicillin, 34 µg /mL Chloramphenicol) and incubated overnight at 37 °C. Single colony from the 
plate was selected and inoculated into 5 mL TB medium (12 g/L tryptone, 24 g/L yeast extract, 2.31 
g/L KH2PO4, 12.54 g/L K2HPO4 0.4% (v/v) glycerol, 50 µg /mL Ampicillin, 34 µg/mL 
Chloramphenicol) in a 15 mL Falcon tube and incubated overnight at 180 rpm, 30 °C using a Ratek 
Orbital Shaking Incubator OM15.  A culture of 800 mL TB medium was inoculated with 800 µL of 
overnight culture in a 2.5 L baffled polypropylene flask and incubated in a shaking incubator (Bioline 
model BL 4720, Edwards Instrument Company, Narellan, New South Wales, Australia) at 180 rpm, 
37 °C, until OD600 reached 0.5–0.8. Then the culture was cooled to the selected expression 
temperature in a cold water bath prior to induction with 0.2 mM IPTG, followed by incubation in a 
shaking incubator (Multitron Standard, Infors HT, Bottmingen, Arlesheim, Switzerland) at 180 rpm 
for 17 h, at different expression temperatures. After incubation, the final OD600 reading was checked 
and noted, then the culture was split into two 400 mL aliquots and centrifuged at 6000 g, 20 min, 4 
°C. Most of the supernatant was discarded with only 30 mL of supernatant reserved for resuspending 
the cell pellets which were then transferred into 50 mL Falcon tubes, followed by centrifugation at 
4500 g, 20 min, 4 °C. The supernatant was discarded and the cell pellets were stored at –80 °C prior 
purification. 
3.6 Lysis buffer screening  
Expressed proteins need to be released from the cells for purification. While the proteins are stable 
inside the cells, they may become unstable once they are released from the cell cytoplasm into the in 
vitro environment. Therefore, a suitable lysis buffer is needed to create an environment that can keep 
the proteins stable, while also aiding breakage of the cell wall. However, each protein has its unique 
structure and behaves differently in buffer. So the composition of the lysis buffer needed to be 
screened and optimised for the particular expressed protein of interest.  
Expression cultures were harvested into 30 mL pellets by centrifugation at 4500 g, 20 min, 4 °C. The 
pellets were resuspended in 30 mL lysis buffers of different pH and salt concentrations and lysed by 
sonication using a Branson Sonifier 450 cell disruptor (Branson Ultrasonics Corporation, Danbury, 
Connecticut, USA) at output 30 for 4 cycles of 40 seconds. 1 mL samples were taken from the cell 
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lysates and centrifuged at 27,000 g, 4 °C for 5 min. The supernatant was transferred to a new tube, 
and pellets remaining were resuspended in 1 mL of lysis buffer. Both the supernatant and resuspended 
pellets were analysed by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). 
3.7 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) protocol 
SDS-PAGE is a common method for separating proteins based on their molecular weight by 
electrophoresis and uses a polyacrylamide gel as a support medium and sodium dodecyl sulphate 
(SDS) to denature the proteins. This method was first described in 1970 (Laemmli, 1970). 
 SDS is an anionic detergent that can denature the protein sample and coat the biomolecule with a 
uniform negative charge proportional to the molecular weight. Once the protein samples are coated 
by SDS, they became negatively charged and are strongly attracted toward the anode in an electric 
field. Coating with SDS gives them a fixed charge-to-mass ratio, allowing separation based on size. 
The polyacrylamide gel matrix restrains larger molecules from migrating as fast as smaller molecules, 
therefore separates the protein samples based on their molecular weight. The polyacrylamide gel is 
made of two layers. The lower layer (separating gel) of pH 8.8 buffered by Tris-HCl is responsible 
for actually separating the protein samples by size. While the upper layer (stacking gel) of 6.8 pH 
buffer by Tris-HCl is for focusing the protein samples into micrometre thin layers before they reach 
the separating gel.  
The effects of the two layers are achieved by the glycine in the running buffer used in SDS-PAGE. 
Glycine is a weak acid and it can exist in either of two states, an uncharged zwitterion, or a charged 
glycinate anion. When in the pH 6.8 environment of the stacking gel glycine is uncharged and 
migrates through the gel much slower than the protein samples. While the chloride ions in the stacking 
gel migrate much faster than the protein samples. The chloride ions create a narrow zone with a steep 
voltage gradient that pulls the glycine along behind it, resulting in two narrowly separated fronts of 
migrating ions. As the two fronts of ions sweep through the sample wells in the stacking gel, they 
trap the protein samples in between and compress them into a thin band. When the protein samples 
enter the separating gel, the pH 8.8 environment causes the glycine to be negatively charged and can 
migrate much faster than the protein samples. So the glycine quickly overtakes the protein samples, 
leaving them behind to be separated by size due to the gel matrix. 
After running the gel, protein samples in the gel need to be stained in order to be seen. Coomassie 
brilliant blue R is the commonly used dye. It can be dissolved in an acetic acid solution containing 
methanol and binds to proteins through ionic interactions between dye sulfonic acid groups and 
positive protein amine groups as well as through Van der Waals attractions. However, the 
polyacrylamide gel can also be stained by the Coomassie brilliant blue R dye. Therefore, a destaining 
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process using an acetic acid solution is needed to remove the dye from the gel background before 
imaging. 
3.7.1 SDS-PAGE gel preparation 
The gels used for SDS-PAGE analysis in this thesis were 10% polyacrylamide gels. The separating 
gel and stacking gel were prepared by mixing all the reagents listed in Table 3-2, respectively. Then 
the separating gel was cast into the pre-set gel cassette approximately 1.5 cm below the short plate 
top edge, followed by adding isopropanol on top of the separating gel to even the gel edge. The 
separating gel was left to polymerize for 15-20 min, before removing the isopropanol and washing 
with water. Stacking gel was then cast on top of the separating gel and the comb was placed to form 
the sample wells. The stacking gel was left to polymerize for another 15-20 min. 
Table 3-2. Recipe of polyacrylamide gel. 
Separating gel Stacking gel 
Gel percentage (%)  10 Gel percentage (%)  5 
40% polyacrylamide (mL) 2.5 40% polyacrylamide (mL) 0.625 
1.5 M Tris buffer pH 8.8 (mL) 2.5 1 M Tris buffer pH 6.8 (mL) 0.625 
10% Ammonium persulfate (mL) 0.1 10% Ammonium persulfate (mL) 0.05 
10% SDS (mL) 0.1 10% SDS (mL) 0.05 
TEMED (mL) 0.004 TEMED (mL) 0.005 
H2O (mL) 4.8 H2O (mL) 3.65 
Total volume (mL) 10 Total volume (mL) 5 
3.7.2 Protein sample preparation 
Protein samples for SDS-PAGE were mixed with 5x sample buffer (225 mM Tris-base, 250 mM 
DTT, 50 mg/mL SDS, 0.5 mg/mL bromophenol blue, 50% (v/v) glycerol) and heated on a heating 
block (Ratek dry block heater model DBH20D, Ratek Instruments, Boronia, Victoria, Austraila) at 
100 °C for 5 min to denature the protein sample. Bromophenol blue in the sample buffer served as a 
tracking dye. 
3.7.3 Running SDS-PAGE gels 
Protein samples were loaded to the gel with 6 µL of Novex® sharp pre-stained protein standard as 
marker ladder. Then the gel was run at 150 V for 1 hour in Tris-Glycine running buffer (24 mM Tris-
base, 192 mM glycine, 35 mM SDS, pH 8.3). 
80 
 
3.7.4 Staining and destaining of SDS-PAGE gels 
The gel was carefully removed from the gel cassette and stained with Coomassie brilliant blue R 
staining solution (Table 3-3) on a platform shaker (Ratek Instruments, Boronia, Victoria, Austraila) 
with gentle shaking for 1 h, followed by 2 h of destaining with destaining solution (Table 3). Then 
the gel was rinsed with milli-Q water and imaged by ChemiDocTM MP Imaging System (Bio-Rad, 
Hercules, California, USA). 
Table 3-3. Recipe of staining solution and destaining solution. 
Staining solution Destaining solution 
Acetic acid (mL) 50 Acetic acid (mL) 50 
Methanol (mL) 225 Methanol (mL) 225 
Milli-Q water (mL) 225 Milli-Q water (mL) 225 
Coomassie brilliant blue R (g) 1.0   
Total volume (mL) 500 Total volume (mL) 500 
3.8 Anti-GST Western blot protocol 
Western blotting is an important technique used in cell and molecular biology to identify specific 
proteins from a complex mixture of proteins extracted from cells. The protein sample is first separated 
by SDS-PAGE, then transferred or blotted onto a matrix, finally stained with antibodies specific to 
the target protein, for identification. The matrix for transfer is a membrane made of nitrocellulose. 
The protein sample can be transferred from the polyacrylamide gel to the nitrocellulose membrane 
under transverse electric field and binds to the membrane through hydrophobic interactions. After 
transferring, the membrane needs to be blocked to prevent nonspecific binding of antibodies during 
subsequent steps. Blocking solution is often made of 5% bovine serum albumin (BSA) or skim milk 
powder in phosphate buffered saline (PBS) with 0.1% Tween-20. Tween-20 can reduce nonspecific 
protein-protein bindings. After blocking, the membrane is incubated with primary antibody specific 
to target protein which binds to the target protein, followed by wash step to remove unbound 
antibodies. Then the membrane is incubated with enzyme conjugated secondary antibody that binds 
to the primary antibody. Finally, a chemical substrate is applied to the membrane which reacts with 
the enzyme conjugated to the secondary antibody. The substrate will luminesce and the level of the 
target protein on the membrane can be then analysed by chemiluminescent detection methods. 
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3.8.1 Transfer and blocking 
After running SDS-PAGE as described in Section 3.7.1-3.7.3, the gel was removed from the glass 
cassette and a piece of nitrocellulose membrane pre-soaked with transfer buffer (Table 3-4) was 
placed on top of the gel. Then, one piece of filter paper and three pieces of blotting pads were placed 
on top of the membrane, all pre-soaked with transfer buffer. Another piece of filter paper and three 
pieces of blotting pads were also placed beneath the gel, all pre-soaked with transfer buffer, and air 
bubbles in between all layers of the gel membrane sandwich were removed. The gel membrane 
sandwich was then positioned in the cathode core and slid into the buffer chamber of the XCell II 
Blot module (Invitrogen, Carlsbad, California, USA). The blot module was filled with transfer buffer 
and transferred at 30 V for 1 h. After transfer, the membrane was blocked with 5% skim milk powder 
(Coles, Australia) in PBST (1× PBS, 0.1% Tween-20) at 4 °C, overnight. 
Table 3-4. Recipe of transfer buffer. 
Transfer Buffer 
NuPAGE® Transfer Buffer (20X) (mL) 50 
NuPAGE® Antioxidant (mL) 1 
Methanol (mL) 100 
Deionized water (mL) 849 
Total volume (mL) 1,000 
 
3.8.2 Incubation with primary and secondary antibodies 
The membrane was removed from the blocking solution and then incubated with primary antibodies 
of mouse anti-GST antibody (Bio-Rad, Hercules, California, USA) at 1:500 dilutions in PBST with 
5% skim milk powder in room temperature for 1 hour. The membrane was then washed 6 times for 
10 min each in PBST. After washing, the membrane was incubated with secondary antibodies of 
horseradish peroxidase (HRP)-conjugated goat anti-mouse antibody (Bio-Rad, Hercules, California, 
USA) at 1: 10,000 dilutions in PBST with 5% skim milk powder in room temperature for 1 h. The 
membrane was then washed 3 times for 10 min each in PBST. After wash, the membrane was 
incubated with the Novex®ECL HPR chemiluminescent substrate reagent kit (Invitrogen, Carlsbad, 
California, USA) and then visualized via chemiluminescence by ChemiDoc® MP Imaging System 
(Bio-Rad, Hercules, California, USA). 
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3.9 Protein purification 
3.9.1 VirB9-1 protein purification  
The VirB9-1 protein was expressed as a GST-tagged protein. GST is a 26 kDa protein naturally found 
in eukaryotic cells. The gene of GST from Schistosoma japonicum was used in the development of 
the pGEX vectors (Smith and Johnson, 1988), which was used in this PhD study for the expression 
of VirB9-1 protein. GST has a strong affinity to glutathione and can bind to glutathione Sepharose 
columns under mild, non-denaturing conditions. This binding can be reversed and the bound proteins 
can be eluted by elution buffer with additional reduced glutathione. Due to these properties, the 
downstream purification of proteins tagged with GST can be simplified and purification can be 
carried out under non-denaturing conditions by using affinity chromatography.  
The expression and purification of VirB9-1 was based on methods previously used and further 
developed by our group (CBE, Centre for Biomolecular Engineering, AIBN, The University of 
Queensland) (Sambrook and Russell, 2001, Chuan et al., 2008) and further modified for optimised 
results. The harvest cell pellets of VirB9-1 were thawed on ice and resuspended and sonicated in L 
buffer (40 mM Tris-base, 200 mM NaCl, 1 mM EDTA, 5% (v/v) glycerol, 5 mM DTT, pH 8.0). The 
cell lysates were then centrifuged at 27,000 g, 4 °C for 20 min and the supernatant was filtered through 
a 0.45 µm filter. The clear filtered lysates were then loaded onto a GST affinity column (GSTrap HP 
5 mL, GE Healthcare, Amersham, England, UK) pre-equilibrated with five column volumes of L 
buffer. The column was washed with four column volumes of L buffer and then eluted with E buffer 
(40 mM Tris-base, 50 mM NaCl, 1 mM EDTA, 5% (v/v) glycerol, 5 mM DTT, 10 mM GSH) pH 
8.5).  
The fractions collected from GST affinity chromatography were then further purified by size-
exclusion chromatography (SEC) using a Superdex 200 10/300 GL column (GE Healthcare, 
Amersham, England, UK). SEC is a chromatographic method to separate large molecules, such as 
proteins, by their size and molecular weight. The SEC column is usually packed with tiny porous 
polymer beads providing many pores of different sizes. When the solution containing molecules of 
different size travels down the SEC column, the large molecules can only enter those large pores and 
therefore bypass the small pores. While small molecules can enter smaller pores and remain longer 
in the column. Larger molecules therefore flow through the column more quickly than smaller 
molecules. Figure 3-2 is a typical chromatogram from a function test of Superdex 200 10/300 GL 
obtained from the manufacture’s manual, showing samples of different relative molecular mass 
eluting at different volume.  
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Figure 3-2. Typical chromatogram from a function test of Superdex 75 10/300 GL. 
Sample: 1. BSA (Mr 67,000) 8 mg/mL; 2. Ovalbumin (Mr 43,000) 2.5 mg/mL; 3. 
Ribonuclease A (Mr 13,700) 5 mg/mL; 4. Aprotinin (Mr 6,512) 2 mg/mL; 5. Vitamin 
B12 (Mr 1,355) 0.1 mg/mL. Sample volume: 500 µL. Eluent: 0.05 M phosphate buffer, 
0.15 M NaCl, pH 7.0. Flow rate: 0.4 mL/min (obtained from Instructions 71-5017-96 
AG, GE Healthcare, Amersham, England, UK).  
 
For VirB9-1 purification, the SEC column was pre-equilibrated with one column volume of buffer 
(40 mM Tris-base, 50 mM NaCl, 1 mM EDTA, 5 mM DTT, pH 8.5) and the fractions collected from 
GST affinity chromatography were loaded at a sample volume of 500 µL and eluted at a flow rate of 
0.5 mL/h. Elution fractions were collected and stored in -80 °C. 
3.9.2 VirB9-2 protein purification 
The VirB9-2 protein was expressed as inclusion bodies. Inclusion bodies are usually dense aggregates 
of misfolded insoluble proteins located in the bacterial cytoplasm (Middelberg, 2002, Singh and 
Panda, 2005). They are a common result of high-level expression of recombinant proteins in E. coli, 
formed because the aggregating characteristics of the heterologous protein being expressed and/or 
the inability of the cellular processes to ensure that the expressed polypeptide is soluble and folded 
correctly (Middelberg, 2002, Baneyx, 1999, Middelberg et al., 1991). Recombinant proteins having 
disulphide bonds often result in protein aggregates as inclusion bodies, since the reducing redox 
environment in the cytosol of E. coli inhibits the formation of disulphide bonds (Fahnert et al., 2004). 
Outer membrane proteins also likely form inclusion bodies when overexpressed due to their surface-
exposed hydrophobic regions. The diameter of bacterial inclusion bodies varies from 0.4–3.0 µm and 
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they have a density of about 1300 kg/m3 (Taylor et al., 1986), which is heavier than many of the 
cellular components. Thus, inclusion bodies can be easily separated by centrifugation after cell 
disruption. Therefore, inclusion bodies of VirB9-2 were collected by a simple method of 
centrifugation, followed by several washing steps for further purification.  
The harvest cell pellets of VirB9-2 were thawed on ice and resuspended and sonicated in L buffer (40 
mM Tris-base, 200 mM NaCl, 1 mM EDTA, 5% (v/v) glycerol, 5 mM DTT, pH 8.0). The cell lysates 
were then centrifuged at 27,000 g, 4 °C for 20 min and the pellets containing the inclusion bodies 
were collected. The pellets were then resuspended and washed once in 0.1% Triton X-100 and twice 
in 2 M urea buffer (2 M urea, 50 mM Tris-base, 100 mM NaCl, 1 mM EDTA, 10 mM DTT, pH 8.0). 
Each time after a wash step, the pellets were collected by centrifugation at 27,000 g, 4 °C for 20 min. 
Finally, VirB9-2 inclusion bodies were solubilised in 8 M urea buffer (8 M urea, 50 mM Tris-base, 
100 mM NaCl, 1 mM EDTA, 10 mM DTT, pH 8.0) and stored at -80 °C. 
3.10 Tobacco etch virus protease (TEVp) cleavage protocol 
TEVp is a highly sequence-specific cysteine protease from Tobacco Etch Virus. It has a strict 7 amino 
acid cleavage recognition sequence of Glu-Asn-Leu-Tyr-Phe-Gln-\-Gly (Ser) (Carrington and 
Dougherty, 1988), and can be used to remove the fusion tags from recombinant proteins. Previous 
work done by my University of Queensland colleague Natalie Connors on tag cleavage strategies 
showed that, compared to thrombin, the cost of TEVp is lower and the sequence specificity of TEVp 
is more stringent (Connors et al., 2014). In addition, TEVp is relatively easy to produce and can be 
prepared in laboratory at large scale (Cabrita et al., 2007). The TEVp used in this PhD study was 
produced in our lab (CBE, Centre for Biomolecular Engineering, AIBN, The University of 
Queensland) by Fiona Hughes. 
The VirB9-1 protein stored at -80 °C after purification was thawed on ice. 50 µL of VirB9-1 sample 
was mixed with 2.5 µL of TEVp (1.9 µg/µL), then vortexed gently and incubated on a heating block 
(Ratek dry block heater model DBH20D, Ratek Instruments, Boronia, Victoria, Austraila) at 30 °C 
for 2 hours. Sample after incubation was centrifuged at 27,000 g, 4 °C for 5 min and the cleavage 
result was analysed by SDS-PAGE. 
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Chapter 4 
Expression and purification of soluble VirB9-1 protein 
4.1 Introduction 
As described previously in Chapter 2, VirB9-1 is an outer membrane protein of Anaplasma 
marginale. It belongs to the Type IV secretion system (T4SS), which is a multi-protein complex 
utilized for transporting proteins or DNA across the bacterial cell envelope of gram-negative bacteria 
(Christie et al., 2005, Fronzes et al., 2009, Low et al., 2014, Christie and Vogel, 2000). Studies have 
shown that T4SS plays an important role in intracellular survival and virulence of many gram-
negative bacteria, such as Legionella pneumophila, Helicobacter pylori, Bordetella pertussis, and 
Brucella suis (Lopez et al., 2007). Although the function of T4SS in A. marginale is not fully 
explored, it is believed to be essential to invasion and pathogenesis (Lockwood et al., 2011), so 
targeting and neutralizing T4SS proteins with antibodies may be devastating to bacterial survival and 
dissemination. Also T4SS is highly conserved among A. marginale strains, so vaccines targeting 
T4SS proteins may be widely protective (Lopez et al., 2007, Sutten et al., 2010, Morse et al., 2012b).  
Among all T4SS proteins of A. marginale, VirB9-1 is one of the most immunogenic (Morse et al., 
2012b, Lopez et al., 2007). It has been reported that VirB9-1, together with VirB9-2 and VirB10, can 
elicit significant CD4+ T-lymphocyte proliferation, interferon γ (IFN-γ) secretion and IgG2 
production in outer membrane-immunized cattle, all associated with protective immunity (Morse et 
al., 2012a, Morse et al., 2012b). Vaccines using VirB9-1 as antigen may very likely be protective 
against A. marginale. However, VirB9-1 is an outer membrane protein, which is generally difficult 
to express. Finding an efficient way to produce VirB9-1 is a challenging yet critical task. 
To find a feasible way to express VirB9-1, we must first understand the characteristics of outer 
membrane proteins. Outer membrane proteins are embedded within the lipid bilayer of the bacterial 
outer membrane. Surrounded by lipids in a hydrophobic environment, most outer membrane proteins 
form β-barrels composed of antiparallel amphipathic β-strands with the hydrophobic residues facing 
outwards (Tommassen, 2010, Koebnik et al., 2000). The outer surface of the β-barrel is strongly 
hydrophobic, leading outer membrane proteins to have very low solubility in aqueous solutions (Bond 
and Sansom, 2004). In nature, outer membrane proteins are produced with an N-terminal signal 
sequence which directs them to the membrane, where they are folded and inserted into the outer 
membrane (Borel and Simon, 1996, Do et al., 1996). Compared to soluble proteins, the folding of 
outer membrane proteins in the membrane is poorly understood. This poor understanding causes 
many problems in expression of outer membrane proteins, and overexpressed outer membrane 
proteins usually end up in an inactive form as inclusion bodies (Bannwarth and Schulz, 2003, 
Grisshammer and Tateu, 1995). As described previously in Chapter 2, inclusion bodies are dense 
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aggregates of misfolded insoluble recombinant proteins which need to be “refolded” to restore the 
protein’s native 3D structure prior application (Middelberg, 2002, Singh and Panda, 2005). However, 
there is no universal method for refolding proteins and this process may involve expensive chemicals 
and still result in significant decrease of yields. Thus, this is a result that we should avoid and focus 
on soluble expressions of VirB9-1, if technically possible. 
Currently, there are four main expression systems: mammalian cells, insect cells, yeast, and 
Escherichia coli. They have been previously introduced in Chapter 2. Mammalian cell expression 
systems have been widely used to produce biopharmaceutical products (Almo and Love, 2014, Zhu, 
2012), as well as express many membrane proteins (Grisshammer and Tateu, 1995). The main 
advantage of mammalian cells is that the signals for synthesis, processing and secretion of eukaryotic 
proteins can be properly and efficiently recognised (Verma et al., 1998), which benefits the folding 
of membrane proteins. However, mammalian cell expression systems are very expensive and difficult 
to scale-up (Grisshammer and Tateu, 1995, Verma et al., 1998). This makes them unsuitable for 
expressing antigens for animal vaccines, where cost-effectiveness is a top priority.  
The baculovirus-mediated insect cell expression system is another popular system used for membrane 
protein expression (Grisshammer and Tateu, 1995). In comparison to mammalian cells, insect cell 
expression systems have higher expression levels, but still have issues of being too expensive (Verma 
et al., 1998, Jarvis, 2009).  
Yeast expression systems have the advantage of being both a microorganism and a eukaryote (Verma 
et al., 1998). Yeast can grow robust on simple media and is a much cheaper host than mammalian 
cells and insect cells, yet not as cheap as E. coli (Vogl et al., 2013). Compared to the other expression 
systems, few membrane proteins have been expressed in yeast (Grisshammer and Tateu, 1995).  
E. coli is one of the most widely used and well-established recombinant protein expression hosts. 
Many outer membrane proteins have been expressed in E. coli (Bannwarth and Schulz, 2003, 
Grisshammer and Tateu, 1995). The yield of these expressions in laboratory settings can vary from 
0.25 mg/L to 170 mg/L as listed in Table 4-1. Due to the ease and low cost associated with the 
cultivation of this organism, it is by far the cheapest and most efficient way to produce proteins 
(Rosano and Ceccarelli, 2014, Baneyx, 1999, Verma et al., 1998). E. coli also are Food and Drug 
Administration (FDA)-approved for human applications (Marisch et al., 2013) and have been widely 
used for industrial production of many biopharmaceutical proteins which have been reviewed by 
F. R. Schmidt (Schmidt, 2004) as listed in Table 4-2. Thus, E. coli is an ideal expression system for 
VirB9-1. If VirB9-1 can be successfully expressed in E. coli, not only the cost of preparation can be 
greatly reduced, but also very likely to scale up the expression for commercialization.  
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Table 4-1. Yield of several outer membrane protein expressions in E. coli. 
Protein Yield (mg/L) Reference 
OmpA 7 (Pautsch et al., 1999) 
OmpX 150 (Pautsch et al., 1999) 
OmpLA 35 (Dekker et al., 1995) 
OmpT 170 (Kramer et al., 2000) 
TolC 1-2 (Koronakis et al., 1997) 
FhuA 8 (Ferguson et al., 1998) 
FepA 0.25 (Smith et al., 1998) 
 
Table 4-2. Overview of the several worldwide commercialized recombinant 
pharmaceuticals produced in E. coli expression systems. 
Product Company 
Calcitonin Unigene 
Growth factors (GCSF, GMCSF) Novartis/Essex/Amgen/Roche 
Growth hormones (somatotropines) Pharmacia & Upjohn/Lilly/Novo-
Nordisk/Ferring/Genentech 
Insulin and muteins Aventis/Lilly/Berlin-Chemie 
Insulin Bio-Technology General Corp 
Interferon alpha and muteins Roche/Essex/Yamanouchi 
Interferon beta Schering 
Interferon gamma (mutein) Amgen/Boehringer 
Interleukin 2 Chiron 
OP-1 (osteogenic, neuroprotective factor) Curis/Striker 
Recombinant plasminogen-activator Genentech/Roche/Boehringer 
Tumor necrosis factor Boehringer 
 
Previously, several researchers have expressed VirB9-1 in E. coli. However, these reports of VirB9-
1 expression in E. coli all resulted in low yield and poor solubility (Sutten et al., 2010, Lopez et al., 
2007, Morse et al., 2012a, Morse et al., 2012b). Although E. coli is potentially an ideal expression 
system for VirB9-1, there still lie difficulties in improving the yield and solubility of VirB9-1 
expression. The main reason is when a recombinant protein expressed in E. coli, it is synthesised in 
the cytoplasm of the bacteria (Sørensen and Mortensen, 2005, Baneyx, 1999), and with predominantly 
hydrophobic surfaces, outer membrane proteins such as VirB9-1 are likely to aggregate together and 
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form inclusion bodies, limiting the yield of soluble products. For other outer membrane proteins, 
researchers tend to express the protein as inclusion bodies, then renature the protein through refolding 
process. However, this kind of method may not be suitable for VirB9-1, since there is no universal 
method for refolding proteins and this process may likely result in decrease of yield. This conflicts 
with the concept of VirB9-1 as an animal vaccine antigen being high-yielding and cost-efficient. 
Furthermore, as described previously in Chapter 2 literature review, VirB9-1 may possess the key B-
cell epitopes that lead to protective immunity against A. marginale. Soluble expressed proteins folded 
by E. coli in vivo are likely to have the correct nature structure and have high chance to present the 
correct key B-cell epitopes. Thus, developing methods for soluble expression of VirB9-1 proteins in 
E. coli at high yield is most important.  
Different strategies have been reported in the literature to improve the solubility of recombinant 
proteins in E. coli, including optimizing the culture medium composition, altering the temperature 
and duration of induction, changing the timing of induction and concentration of inducer, choosing 
suitable strain as expression hosts, and using fusion tags (Baneyx, 1999, Papaneophytou and 
Kontopidis, 2014, Rosano and Ceccarelli, 2014). Fusion tags are frequently used in the expression of 
recombinant proteins in E. coli. Using fusion tags not only provides for simple downstream 
purification process by affinity chromatography, but also can improve the yield and enhance the 
solubility of the target protein (Papaneophytou and Kontopidis, 2014).  
The most widely used affinity tags are His-tags. However, previous reports of expression of VirB9-1 
using His-tags did not result in high yield and solubility (Morse et al., 2012a, Morse et al., 2012b). 
Another commonly used affinity tag is the glutathione S-transferase (GST) affinity tag (Esposito and 
Chatterjee, 2006, Terpe, 2003, Baneyx, 1999). It has been reported that fusing the target protein with 
a highly soluble GST-tag can improve the overall solubility of the recombinant protein (Smith and 
Johnson, 1988, Guan and Dixon, 1991). The downstream purification process can also be simplified 
as the target protein can be easily purified from crude bacterial extracts under non-denaturing 
conditions by GST affinity chromatography (Smith and Johnson, 1988). In addition, our group (CBE, 
Centre for Biomolecular Engineering, AIBN, The University of Queensland) has years of experience 
in expression and purification of GST-tag fusion proteins (Lipin et al., 2008, Lipin et al., 2009, Liew 
et al., 2010, Middelberg et al., 2011, Wibowo et al., 2013, Connors et al., 2014), and have developed 
a simple and low cost strategy for high-level expression of soluble viral structural protein in E. coli 
using GST-tag (Chuan et al., 2008). Furthermore, previously, there was no report of using GST-tag 
for expression of VirB9-1. Thus, the possibility of achieving soluble expression of VirB9-1 as a GST-
tagged recombinant protein was considered worth investigating. 
In this chapter, the expression and purification of VirB9-1 as a GST-tagged protein was investigated. 
Section 4.2 describes the expression of GST-VirB9-1 under different expression conditions and using 
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different E. coli strains as expression host. The expression condition was optimised by controlling the 
expression temperature and induction optical density (OD) to obtain high expression yield and high 
solubility. Section 4.3 describes the lysis buffer screening of different pH and salt concentrations that 
was performed to prevent aggregation and precipitation of VirB9-1 during cell lysis and prior to 
purification, and to further increase the solubility of VirB9-1 in aqueous buffers. Section 4.4 describes 
a series of experiments using GST affinity chromatography to purify VirB9-1. After several 
unsuccessful attempts, the condition was finally optimised and GST-VirB9-1 was obtained at high 
yield. Then the GST-VirB9-1 was further purified by size-exclusive chromatography and achieved 
high purity. Finally, in Section 4.5, the GST tag was cleaved from VirB9-1. However, there is 
difficulty in separation of GST tag and VirB9-1. Whether the cleavage of the GST affinity tag is 
necessary will be discussed in subsequent chapters, where the possibility of immunising with a GST-
linked antigen is explored. 
4.2 Expression of VirB9-1 in E. coli 
4.2.1 Design of the expression vector 
As discussed in the introduction, VirB9-1 as an outer membrane protein is generally very difficult to 
express in E. coli at high yield and high solubility. However, soluble expression is important for 
correct folding of VirB9-1 to deliver the key B-cell epitopes that may lead to protective immunity 
against A. marginale. Therefore, when designing the expression vector for VirB9-1, enhancement of 
target protein solubility must be considered. The GST tag is a commonly used fusion tag that is well-
known for its ability to improve the solubility and the expression stability of the fusion protein. Thus, 
the pGEX-4T-1 GST tag vector is a reasonable choice for VirB9-1 expression. The original pGEX-
4T-1 vector contains a thrombin cleavage site. However, the use of thrombin for cleavage is rather 
expensive. Especially for proteins such as VirB9-1, which should be ideally cheap in order to be used 
for animal vaccination. To lower the cost of tag cleavage during purification, the thrombin recognition 
site was changed into a Tobacco etch virus protease (TEVp) recognition site by site-directed 
mutagenesis before gene insertion. Furthermore, a flexible linker G4S was introduced to each side of 
the TEVp recognition site to allow the VirB9-1 protein to fold more independently, more likely to 
maintain native structure after expression in E. coli. Another advantage of using GST tag vector is 
that our group has previously developed a simple and low cost downstream purification procedure 
for GST-tagged protein (Chuan et al., 2008). This experience on using GST tag will be helpful when 
developing purification methods for VirB9-1 after expression.  
The detailed construct of GST-VirB9-1 was described previously in Section 3.2 of Chapter 3 and the 
molecular weight of GST-VirB9-1 was estimated to be 56 kDa. The cloning work was performed by 
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the Protein Expression Facility (PEF, The University of Queensland) as described previously in 
Section 3.2 of Chapter 3. Sequencing was conducted by the Australian Genome Research Facility 
(AGRF). The cloned DNA sequences and translated protein sequences are listed in Appendix B.  
4.2.2 Expression at 26 °C 
Different strains of E. coli have different advantages in protein expression. E. coli strain Rosetta 
(DE3) pLysS is supplied with tRNAs for six rare codons AUA, AGG, AGA, CUA, CCC, and GGA, 
that can enhance the correct folding of disulphide-bonded recombinant proteins (Rosano and 
Ceccarelli, 2014). This strain is ideal for VirB9-1 expression as it can enhance the folding VirB-9-1 
and increase solubility. The plasmid of GST-VirB9-1 was transformed into Rosetta (DE3) pLysS 
competent cells according to the protocols described previously in section 3.3 and 3.4 of Chapter 3.  
The common expression temperature for E. coli is 37 °C. However, lower expression temperatures 
have been reported to favour protein solubility due to slower expression rates which allow for 
improved protein folding (Rosano and Ceccarelli, 2014, Baneyx, 1999). To further enhance the 
solubility of VirB9-1, the expression temperature was set at 26 °C instead of 37 °C. The expression 
was performed following the protocols described previously in Section 3.5 of Chapter 3. After 
expression, the final OD600 was measured to be 3.98, and the cells were collected by centrifugation. 
After harvest, VirB9-1 need to be released from the cells for purification. A lysis buffer is needed to 
create an environment that can keep the proteins stable. The cells were lysed in L buffer (40 mM Tris-
base, 200 mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 5% (v/v) glycerol, 5 mM 
dithiothreitol (DTT), pH 8.0) by sonication and lysate was analysed by SDS-PAGE performed 
following the protocols described previously in Section 3.7 of Chapter 3. 
The gel result showed a pronounced band at 56 kDa in the total protein sample and no band in the 
pre-induction sample, indicating that GST-VirB9-1 was successfully expressed (Figure 4-1). By 
estimate, the total expression yield of GST-VirB9-1 was around 100 mg/L. However, the solubility 
of GST-VirB9-1 was poor. There was no obvious band at 56 kDa in the soluble protein sample, and 
the band in the insoluble protein sample was approximately equivalent to the band in the total protein 
sample. This result indicated that most of the GST-VirB9-1 proteins expressed were insoluble. As 
discussed previously, soluble expression of VirB9-1 is important for the correct folding of native 
structure to deliver the key B-cell epitopes, and for economic reasons. The design of the GST-tagged 
expression vector and the choice of strain Rosetta (DE3) pLysS were all aiming for a soluble 
expression, yet the result was still insoluble. 
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Figure 4-1. Solubility of GST-VirB9-1 expression at 26 °C. 8 µL/well of samples 
were loaded to 10% SDS-PAGE gels, and stained with Coomassie Brilliant Blue dye. 
 
The insolubility of GST-VirB9-1 may be caused by many different reasons. The GST-VirB9-1 
proteins could be insoluble when expressed inside the E. coli cells, or they may be soluble during 
expression but lose solubility after they were released into unsuitable lysis buffer. Other than 
changing the design of the expression vector, some factors, such as expression temperature, induction 
OD, and IPTG concentration, can also affect the solubility of the target protein during expression. 
Other factors, such as the pH and salt concentration of lysis buffer, can affect the solubility of the 
target protein after release from the cells (Leibly et al., 2012, Rosano and Ceccarelli, 2014). Altering 
these factors may achieve soluble expression and might be more feasible than redesigning a new 
vector.  
4.2.3 Expression at lower temperatures 
Expression temperature has a major effect on the solubility of protein expression in E. coli. 
Precipitation of proteins is a concentration-dependent process. At low temperatures, the growth rate 
of E. coli is slowed down, as well as the rate of protein expression. Expression at lower temperatures 
can in some cases reduce the total concentration of recombinant protein in the bacterial cytoplasm 
(Vera et al., 2007), therefore reduce the chance of precipitation and improve protein solubility.  
Initially, the expression temperature was decreased from 37 °C to 26 °C to enhance the solubility of 
GST-VirB9-1. But this was not enough, as results showed that most of the GST-VirB9-1 product was 
still insoluble. Therefore, the expression temperature was further decreased to 20 °C and 15 °C. 
Expressions of GST-VirB9-1 were carried out at 20 °C and 15 °C following the protocols described 
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previously in Section 3.5 of Chapter 3, respectively. SDS-PAGE analysis of the expressions showed 
that the solubility of GST-VirB9-1 increased significantly as the expression temperature decreased 
(Figure 4-2). At 15 °C, the solubility of GST-VirB9-1 was about 85% (estimated by Image Lab 
Software, Bio-Rad). This was a great improvement of the solubility.  
 
Figure 4-2. Solubility of GST-VirB9-1 expression at different temperatures. All 
expressions were disrupted in pH 8.5 200 mM NaCl Tris-base buffer, 8 µL/well of 
samples were loaded to 10% SDS-PAGE gels, and stained with Coomassie Brilliant 
Blue dye.  
 
However, the yield of VirB9-1 decreased as the expression temperature dropped due to the growth of 
E. coli slowing down at low temperature. The harvest OD600 was only 1.63 for expression at 15 °C, 
much lower than that of 26 °C, which should be about 4.0. In order to increase the yield, the induction 
OD600 was increased from 0.5 to 0.8 for expression at 15 °C. In this way, the harvest OD600 was 
increased to 3.38, more than doubled compared to previous results, and the solubility of GST-VirB9-
1 remained the same. By estimate, with such harvest OD, the total expression yield of VirB9-1 was 
approximately 70 mg/L. 
Lower expression temperatures, such as 12 °C, were also explored. However, results showed that the 
solubility of GST-VirB9-1 did not increase much compared to 15 °C expression. Moreover, the low 
temperature decreased the absolute expression yield even further. Thus, the optimised expression 
temperature for GST-VirB9-1 was chosen to be 15 °C with induction OD600 of 0.8. 
4.2.4 Expression in strain BL21 (DE3) 
Different E. coli strains have different effects on protein expression. E. coli strain BL21 (DE3) 
generally has higher growth rate and higher expression yield in comparison to the Rosetta strain. 
GST-VirB9-1 has been successfully expressed in strain Rosetta and the expression condition has been 
optimised and achieved high yield and high solubility in Section 4.2.3. If GST-VirB9-1 can be 
expressed in strain BL21, the yield may be likely to further improve. Thus, it is worthwhile 
investigating the expression of GST-VirB9-1 in strain BL21. 
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The GST-VirB9-1 construct plasmid was transformed into E. coli strain BL21 (DE3) and expression 
was performed according to the protocols described previously in Section 3.4 of Chapter 3. Based on 
the experience of expression in Rosetta, the expressions in BL21 were carried out at 26 °C with 
induction OD600 of 0.5 and 15 °C with induction OD600 of 0.8, respectively. After harvest, the 
solubility of GST-VirB9-1 was analysed by SDS-PAGE. Results showed GST-VirB9-1 was insoluble 
when expressed at 26 °C. When the expression temperature decreased to 15 °C, GST-VirB9-1 became 
soluble and the solubility was approximately 40% (estimated by Image Lab Software, Bio-Rad), 
lower than expression in Rosetta under the same conditions (Figure 4-3). Although due to the faster 
growth rate, BL21 achieved a harvest OD600 of 5.0 at 15 °C with induction OD600 of 0.8, which was 
higher than that of Rosetta (OD600 of 3.4), the total expression yield of GST-VirB9-1 did not increase. 
From the SDS-PAGE gel, the GST-VirB9-1 band in the total protein samples of both strains was 
equivalent (Figure 4-3). This result indicated that more BL21 cells were harvested, but each cell 
expressed less GST-VirB9-1.  
 
Figure 4-3. Expression of GST-VirB9-1 in Rosetta and BL21 strain at 15 °C. All 
expressions were disrupted in pH 8.5 200 mM NaCl Tris-base buffer, 8 µL/well of 
samples were loaded to 10% SDS-PAGE gel, and stained with Coomassie Brilliant 
Blue dye. 
 
To further understand the cause of this result, anti-GST Western blotting was performed to examine 
the expression of both strains according to the protocols described previously in Section 3.8 of 
Chapter 3. This blotting can detect the GST sequence in the target proteins and show bands relevant 
to the GST amount detected. The Western blotting results showed a clear band at 56 kDa representing 
GST-VirB9-1 in sample of both strains (Figure 4-4). This confirmed the expression of GST-VirB9-
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1. The GST-VirB9-1 band in the soluble sample of Rosetta is thicker than that of BL21, indicating 
that both the yield and solubility of GST-VirB9-1 expressed in Rosetta is higher than that of BL21. 
This corresponded with the previous SDS-PAGE results (Figure 4-3). Other than the GST-VirB9-1 
band, a small band was observed at around 27 kDa (Figure 4-4). This band could be detected by anti-
GST Western blot indicating that it contained the GST sequence and was likely a truncated product 
from expression. The Western blotting result showed that this truncation band was hard to see in the 
Rosetta samples, but obvious in the BL21 samples, especially in the soluble sample. This might be 
the explanation to why the harvest OD of BL21 is higher, but the yield of GST-VirB9-1 is lower, for 
the truncation rate of GST-VirB9-1 was higher in BL21 than in Rosetta. This truncation band was 
later identified as the 26 kDa GST tag by mass spectrometry. Concluding these results, strain Rosetta 
is favoured over strain BL21 for expression of VirB9-1. Future expressions of GST-VirB9-1 were all 
carried out using the Rosetta strain at 15 °C with induction OD600 of 0.8. 
 
Figure 4-4. Anti-GST Western blotting of the expression of GST-VirB9-1 in Rosetta 
and BL21 strains at 15 °C.  
 
4.3 Optimisation of lysis buffer condition 
The expression condition had been optimised for GST-VirB9-1 and achieved high yield soluble 
expression. So the next step would be purification of GST-VirB9-1. In order to purify the expressed 
GST-VirB9-1 protein, first product must be released from the E. coli cells into aqueous buffers. 
During this process, the proteins that were stable inside the cells may become unstable once they are 
released from the cell cytoplasm into the in vitro environment and then may quickly aggregate and 
precipitate, causing a loss of solubility and yield. To prevent this from happening, the lysis buffer 
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conditions needed to be screened and optimised to maintain the stability and solubility of the 
expressed GST-VirB9-1 proteins.  
The lysis buffer for GST-VirB9-1 is a Tris-base buffer. Tris is a widely-used buffer in biochemistry 
and bioengineering. Tris has a pKa of 8.07 at 25 °C, making it an effective buffer in the range of pH 
7–9, which is suitable for the majority of biological processes, including the downstream purification 
of GST-VirB9-1. Several additives were also added to the lysis buffer to enhance protein stability, 
including EDTA, DTT and glycerol. EDTA in a complexing agent for divalent cations. It can inhibit 
enzymes such as proteases and protects the proteins in buffer (Bernkop-Schnürch, 1998). DTT is a 
reducing agent that can reduce the disulphide bonds of proteins and prevent aggregation caused by 
interaction between disulphide bonds formed by the cysteine residues of proteins (Konigsberg, 1972). 
It also inhibits microchemical changes in proteins due to oxidation of surface-exposed methionine 
and cysteine residues within proteins (Middelberg, 2002). Glycerol also can reduce protein 
aggregation and protect proteins during freezing by inhibiting ice crystal formation (Strambini and 
Gabellieri, 1996).  
Besides additives, protein solubility is greatly affected by the buffer pH and salt concentrations. 
Buffer pH determines the type and total charge on the protein and affects stability through 
electrostatic interactions. The pH ranges for proteins to remain stable and soluble in aqueous buffers 
are often narrow and proteins may aggregate rapidly outside these pH ranges (Chi et al., 2003). Salts 
have complex effects on protein stability and solubility. The concentration of salts can affect the 
solubility of proteins both ways through salting-in or salting-out effects. Usually at low concentration, 
salt ions can increase the ionic strength of a solution and increase protein solubility. A high salt 
concentration can lead to a sharp decrease of protein solubility. In addition, salt ions can bind to 
proteins and interact with unpaired charged side chains on the protein surface, which can lead to either 
stabilisation or destabilization of the protein native state (Maclean et al., 2002, Curtis et al., 2002, Chi 
et al., 2003). Due to these complex effects of pH and salt concentration on protein solubility, it is 
important to screen for the optimised pH and salt concentration that leads to high solubility of GST-
VirB9-1, which is the main objective of this buffer screening.  
Lysis buffer of different pH and salt concentrations were tested to investigate their effects on the 
solubility of GST-VirB9-1. All lysis buffers tested contained 40 mM Tris, 1 mM EDTA, 5 mM DTT 
and 5% (v/v) glycerol. They were adjusted to different pH and provided with different concentrations 
of NaCl. Cell pellets of expression were lysed in these buffers and the solubility of GST-VirB9-1 was 
analysed by SDS-PAGE according to the protocols described previously in Section 3.6 of Chapter 3. 
The gel results showed that the increase of lysis buffer pH increased the solubility of GST-VirB9-1 
(Figure 4-5A). This effect of pH on GST-VirB9-1 solubility is due to the increase of surface charge 
of the protein. As the theoretical isoelectric point (pI) of GST-VirB9-1 is 5.51 (obtained from 
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ProtParam tool, URL: https://web.expasy.org/protparam), when the pH of the lysis buffer increased, 
the surface charge of GST-VirB9-1 became higher causing protein–protein interactions that form 
aggregation to became energetically unfavourable (Chi et al., 2003), therefore favouring its solubility. 
In contrast, an increase of salt concentration in lysis buffer decreased the solubility of GST-VirB9-1. 
When the concentration of NaCl increased from 50 mM to 200 mM, the solubility of VirB9-1 
decreased significantly (Figure 4-5B). This is potentially due to the presence of salt ions causing 
competition between protein molecules for molecules of water (Chi et al., 2003, Timasheff, 1993). 
Lower salt concentration with less competition favoured GST-VirB9-1 solubility. Concluding the 
buffer screening results, an optimised lysis buffer condition of pH 9.0 with 50 mM NaCl can achieve 
over 95% solubility of GST-VirB9-1 (Figure 4-5B, estimated by Image Lab Software, Bio-Rad, US).  
 
Figure 4-5. (A) Solubility of GST-VirB9-1 expression at different pH. All expressions 
were expressed at 15 °C, disrupted in 200 mM NaCl Tris-base buffer of different pH, 
8 µL/well of samples were loaded to 10% SDS-PAGE gel, and stained with Coomassie 
blue dye. (B) Solubility of GST-VirB9-1 expression at different salt concentration. All 
expressions were expressed at 15°C, disrupted in pH 9.0 Tris-base buffer of different 
NaCl concentration, 8 µL/well of samples were loaded to 10% SDS-PAGE gel, and 
stained with Coomassie Brilliant Blue dye. 
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4.4 Purification of GST-VirB9-1  
4.4.1 GST affinity chromatography 
The expression of VirB9-1 as a GST-tagged recombinant protein not only benefits solubility, but also 
simplifies downstream purification, improving overall yield and purity. Single-step purification of 
GST-tagged recombinant protein was first described by Smith and Johnson in 1988 (Smith and 
Johnson, 1988). GST can bind with high affinity to glutathione immobilized in a Sepharose matrix 
column via the enzyme-substrate binding reaction. By using affinity chromatography, the GST-
tagged protein can be extracted from crude cell lysate under non-denaturing conditions.  
From previous buffer screening results, GST-VirB9-1 achieved highest solubility in pH 9.0, 50 mM 
NaCl lysis buffer condition. Such buffer was therefore used for GST-VirB9-1 purification. A pellet 
of 400 mL culture from 15 °C expression was resuspended in 40 mL of lysis buffer (40 mM Tris-
base, 50 mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 5% (v/v) glycerol, 5 mM 
dithiothreitol (DTT), pH 9.5) and lysed with sonication on ice. Followed by purification method using 
GST affinity chromatography according to the protocols described previously in Section 3.9.1 of 
Chapter 3. The chromatogram results showed a high loading absorbance of over 3,500 mAU (Figure 
4-6A). However, there was no obvious elution peak detected with only very low absorbance readings 
of less than 50 mAU within the elution range (Figure 4-6B). 
 
Figure 4-6. (A) Chromatogram of GST-VirB9-1 purification by GST affinity 
chromatography under lysis buffer condition of pH 9.0 and 50 mM NaCl. (B) Enlarged 
chromatogram of elution peak. 
 
The concentration of protein sample loaded and eluted can be determined by the UV absorbance at 
280 nm based on Lambert-Beer’s Law (Aitken and Learmonth, 2009), 
A = ε × b × C 
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where A is the UV absorbance at 280 nm, ε is the molar extinction coefficient of the protein sample, 
b is the path length of the sample, and C is the concentration of the sample. When the value of path 
length 1 cm, the equation can be derived to 
(A / εpercent) 10 = concentration in mg/ml 
where  
(εmolar) 10 = (εpercent) × (molecular weight of protein) 
The theoretical molecular weight of GST-VirB9-1 is 5,6546.14 g/mol and the molar extinction 
coefficient of GST-VirB9-1 is 7,1085 M-1 cm-1, both obtained from ProtParam tool (Gasteiger et al., 
2005). Thus, the εpercent of GST-VirB9-1 is 12.57.  
The loading sample is a protein mixture. According to the Practical Handbook of Biochemistry and 
Molecular Biology, most protein extinction coefficients (εpercent) fall in the range 4.0-24.0 (Fasman, 
1992). Therefore, the average εpercent for a mixture of many different proteins will likely be close to 
10. 
The path length of the UV flow cell of the chromatography system used for purification is 2 mm 
(ÄKTAxpress, GE Healthcare, Amersham, England, UK).  
Therefore, the concentration of the loading sample was estimated to be over 17.5 mg/mL and the 
concentration of the eluted sample was estimated to be less than 0.2 mg/mL. Further SDS-PAGE 
analysis of the elution factions showed clear lanes with no bands and no presence of GST-VirB9-1.  
It was assumed that this result was caused by the unsuccessful binding of the GST tag in GST-VirB9-
1 to the column, as the binding of GST to glutathione is most effective at pH 7.5. The recommended 
working condition of the GST affinity column is in range of pH 6.5-8.0. Lysis buffer condition of pH 
9.0 was too high for the GST-VirB9-1 to bind effectively to the column. Although the solubility of 
GST-VirB9-1 was the highest at pH 9.0, this lysis buffer condition could not be used for affinity 
chromatography purification. To achieve effective binding, the buffer pH had to be decreased. 
However, decreasing pH means decreasing the solubility and the yield of GST-VirB9-1. So it is 
necessary to find the highest pH condition that GST-VirB9-1 can bind effectively to the column and 
retain the solubility as much as possible. Lysis buffer of pH 8.5 was tested, but the binding result was 
still poor. So the buffer pH was then compromised to pH 8.0. Moreover, it was observed that salt 
concentration also affected the binding of GST-VirB9-1. Lysis buffer of low NaCl concentration (50-
100 mM) showed poor binding results. Although low salt concentration favoured the solubility of 
GST-VirB9-1, in order to bind effectively to the column, the salt concentration was compromised to 
200 mM NaCl. Under such buffer condition (pH 8.0, 200 mM NaCl), the chromatography results 
showed a clear elution peak (Figure 4-7). SDS-PAGE analysis of the peak fractions show the GST-
VirB9-1 band at 56 kDa (Figure 4-8). These results indicated that GST-VirB9-1 can successfully bind 
to the column.   
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Figure 4-7. (A) Chromatogram of GST-VirB9-1 purification by GST affinity 
chromatography under lysis buffer condition of pH 8.0 and 200 mM NaCl. (B) 
Enlarged chromatogram of elution peak. 
 
 
Figure 4-8. SDS-PAGE analysis of GST-VirB9-1 expression and affinity 
chromatography. M: Ladder marker; Pre: Pre-induction sample; T: Total protein 
sample; S: Soluble protein sample; E: Elution peak fraction sample. Pre-induction 
sample and elution sample were loaded 8 µL/well, total and soluble protein samples 
were loaded 15 µL/well to 10% SDS-PAGE gel, stained with Coomassie blue dye. 
 
However, the reading of the elution peak was only about 230 mAU, much lower than expected. By 
calculation, the average GST-VirB9-1 concentration of the peak fractions was about 0.46 mg/mL. 
This corresponded with the figure estimated from the SDS-PAGE result, which was about 0.5 mg/mL 
(Figure 4-8, Lane S). The total fraction volume was 2 mL. Therefore, the yield of GST-VirB9-1 after 
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GST affinity chromatography was around 0.95 mg (including contaminants). This yield was much 
lower than the amount of soluble GST-VirB9-1 in a pellet of 400 mL culture. The expression yield 
of GST-VirB9-1 was approximately 70 mg/L, and from the results of lysis buffer screening, GST-
VirB9-1 had about 40% solubility under this lysis buffer condition, by which the amount of soluble 
GST-VirB9-1 should be about 11 mg.  
The SDS-PAGE analysis showed that solubility of GST-VirB9-1 after lysis was less than 10% (Figure 
4-8, estimated by Image Lab Software, Bio-Rad). This low solubility of GST-VirB9-1 may explain 
the low yield after chromatography. However, the solubility was inconsistent with the lysis buffer 
screening results. The difference between the two experiments was the volume of lysis buffer used. 
As described in Section 3.6 of Chapter 3, the lysis buffer screening used 30 mL buffer to resuspend 
30 mL culture pellet. Although for purification, 400 mL culture pellet was resuspended in 40 mL lysis 
buffer. The high concentration oversaturated GST-VirB9-1 and resulted in a great amount of GST-
VirB9-1 being precipitated which was then lost during centrifugation. Furthermore, The GSTrap HP 
5 mL GST affinity column has a binding capacity of approximately 10 mg GST-tagged protein. 
Overloaded GST-VirB9-1 did not bind to the column and was lost to flowthrough.  
Therefore, a smaller pellet from expression should be resuspended in larger volume of lysis buffer to 
lower the overall concentration of GST-VirB9-1 and improve its solubility. A 2:1 ratio of cell culture 
volume to lysis buffer volume was tested, with 200 mL culture pellet of 15 °C expression resuspended 
in 100 mL of lysis buffer (L buffer, 40 mM Tris-base, 200 mM NaCl, 1 mM 
ethylenediaminetetraacetic acid (EDTA), 5% (v/v) glycerol, 5 mM dithiothreitol (DTT), pH 8.0). 
Then the resuspended cells were lysed by sonication and purified by GST affinity chromatography 
according to the protocols described previously in Section 3.9.1 of Chapter 3. The chromatography 
results showed a clear elution peak of about 600 mAU (Figure 4-9A), much higher than previous 
elution results for the 400 mL pellet. SDS-PAGE analysis of the elution fractions showed high yield 
of GST-VirB9-1 protein was obtained after GST affinity chromatography (Figure 4-9B). However, 
other than the GST-VirB9-1 band (56 kDa), the elution fractions contained two contaminant bands 
(45 kDa and 26 kDa). Anti-GST Western blot analysis confirmed that all three bands contained GST-
tag. The two contaminant bands were believed to be truncations from expression. The elution 
fractions needed further purification to remove these contaminants and obtain pure GST-VirB9-1. 
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Figure 4-9. (A) Chromatogram of VirB9-1 purification by GST affinity 
chromatography. (B) SDS-PAGE analysis of elution peak fractions. M: Ladder 
marker; S: Fraction sample. Sample was diluted 3 times and loaded 8 µL/well to 10% 
SDS-PAGE gel, stained with Coomassie blue dye. 
 
4.4.2 Size-exclusive chromatography 
As the two contaminant bands were different molecular weight then GST-VirB9-1, size-exclusive 
chromatography was used to separated them from GST-VirB9-1. The elution fractions collected from 
the GST affinity chromatography were loaded to a Superdex 200 10/300 GL column and size-
exclusive chromatography was performed according to the protocols described previously in section 
3.9.2 of Chapter 3. The chromatography results showed that four peaks were obtained (Figure 4-
10A). The fractions of each peak were further analysed by SDS-PAGE to identify the components 
(Figure 4-10B).  
Lanes 2 and 3 of Figure 4-10B were fractions from the first two peaks of the size-exclusion 
chromatography. They both contain the GST-VirB9-1 band and the 45 kDa contaminant band. 
According to Superdex 200 10/300 GL column manufacturer’s instructions, peaks eluted at this 
volume represented molecular weights of approximately 700 and 400 kDa, respectively. As these 
sizes are much larger than that of GST-VirB9-1, they are believed to be soluble aggregates. This 
result also indicated that the presence of the 45 kDa contaminant may cause aggregation of GST-
VirB9-1. 
Lanes 4, 5 and 6 were fractions from the third peak in the order of left to right, respectively. Lane 4 
only showed band of GST-VirB9-1, while lane 5 and 6 showed the 26 kDa contaminant band in 
addition to the GST-VirB9-1 band. This contaminant was caused by the overlapping of the fourth 
peak, which was identified to be the truncated GST tag (Figure 4-10 Lane 7). According to 
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manufacturer’s instructions, the third peak represented molecule weight of approximately 110 kDa, 
which is about twice the size of GST-VirB9-1. Literature show that GST-tagged protein tends to form 
dimers in aqueous solutions (Terpe, 2003) and other researchers reported that E. coli expressed 
recombinant VirB9-1 protein and native VirB9-1 protein naturally form dimers (Morse et al., 2012b). 
This confirmed that this third elution peak were soluble GST-VirB9-1 dimers. Therefore, through this 
two-step chromatography purification, GST-VirB9-1 was successfully separated from aggregates and 
contaminants and obtained in high purity.  
 
Figure 4-10. (a) Chromatogram of GST-VirB9-1. GST-VirB9-1 eluted from Superdex 
200 10/300 GL column. (b) SDS-PAGE analysis of fractions from size-exclusion 
chromatography. L: ladder marker; 1: total sample before applying to column; 2: 
excluded peak fractions; 3: aggregates peak fractions; 4, 5 & 6: dimer peak fractions; 
7: GST peak fractions. 
 
4.5 Cleavage of the GST tag 
Usually after expression or purification, the fusion tag is cleaved from the target protein. The GST-
VirB9-1 construct was designed with a TEVp cleavage site to remove the GST tag. After purification, 
the GST-VirB9-1 was incubated with TEVp for cleavage of the GST tag according to the protocols 
described previously in Section 3.10 of Chapter 3. After 2 h of incubation at 30 °C, the sample was 
analysed using SDS-PAGE. Results showed the 56 kDa band of GST-VirB9-1 disappeared and a new 
band appeared at 31 kDa (Figure 4-11). This result indicated that cleavage of the GST tag was 
successful. However, because the size of VirB9-1 (31 kDa) and GST tag (26 kDa) were close to each 
other, they could not be separated by size-exclusive chromatography. This brought difficulty to 
purification of the cleaved VirB9-1.  
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Figure 4-11. TEVp cleavage of GST-VirB9-1. L: ladder marker; 1: GST-VirB9-1 
sample before cleavage; 2: total sample of GST-VirB9-1 after cleavage; 2: soluble 
sample of GST-VirB9-1 after cleavage (after centrifugation of 27,000 g, 4 °C for 5 
min). 8 µL/well of samples were loaded to 10% SDS-PAGE gels, and stained with 
Coomassie Brilliant Blue dye. 
 
4.6 Conclusions 
This chapter demonstrated the expression and purification of VirB9-1 as a GST-tagged protein and 
achieved high purity VirB9-1 protein. The design of VirB9-1 as a GST-tagged protein aiming for 
soluble expression and simplified downstream purification was proven to be successful, yet the path 
was not easy and entailed significant problem solving based on understanding of the science 
underpinning protein and purification behaviours.  
As an outer membrane protein, VirB9-1 was very difficult to express at high solubility in E. coli. To 
achieve a satisfactory outcome, the expression temperature had to be decreased multiple times (from 
37 °C to 15 °C) in the sacrifice of yield. In order to restore the lost yield, several approaches were 
trialled. By optimising the induction OD of expression, increasing from 0.5 to 0.8, the harvest yield 
of GST-VirB9-1 was doubled, achieving a total expression yield of around 70 mg/L. However, the 
attempt of using E. coli strain BL21 (DE3) to increase yield was unsuccessful.  
After expression, GST-VirB9-1 needed to be released into a suitable buffer. Therefore, lysis buffer 
screening was performed. Findings showed that high pH and low salt concentration of lysis buffer 
favoured the solubility GST-VirB9-1. Over 95% of solubility was achieved at pH 9.0, 50 mM NaCl 
lysis buffer condition. However, purification using GST affinity chromatography under this buffer 
condition was unsuccessful. GST-VirB9-1 did not bind to the GST affinity column. This was because 
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the binding of the GST tag to the glutathione embedded in the column is most effective at pH 7.5 and 
the recommended working condition of the GST affinity column is in range of pH 6.5-8.0. 
Furthermore, results showed that binding was poor at low salt concentration. A certain level of salt 
concentration was needed for effective binding. Although decreasing pH and increasing salt 
concentration both decreased the solubility of GST-VirB9-1, this sacrifice of solubility was the only 
way to purify GST-VirB9-1 by GST affinity chromatography. After many unsuccessful attempts, the 
final lysis buffer condition was compromised to be pH 8.0 and 200 mM NaCl. Under such buffer 
conditions, GST-VirB9-1 maintained about 40% solubility, and could bind effectively to the column. 
The elution fractions showed a high level of GST-VirB9-1, but also contained some contaminants. 
To remove these contaminants and further purify GST-VirB9-1, size-exclusion chromatography was 
applied. Four peaks were eluted from size-exclusion chromatography, of which the third peak was 
GST-VirB9-1 of high purity. Thus, pure soluble GST-VirB9-1 was finally obtained. This was the first 
time VirB9-1 was solubly expressed and purified as a GST-tagged protein using E. coli. 
The GST affinity tag was successfully cleaved from VirB9-1 by using TEVp. However, after 
cleavage, the GST tag and VirB9-1 were mixed together and could not be easily separated. This may 
cause problems in the application of VirB9-1 as antigen later on.  
This raises an interesting opportunity for refinement of the approach. Given the complexity and 
additional steps associated with separating GST and VirB9-1 after cleavage, why not leave them 
fused together in the first place? GST is a common protein found in most mammalian cells (Salinas 
and Wong, 1999) and studies showed that the GST tag often does not affect the activity of the protein 
of interest and consequently GST fusions are often used uncleaved for biochemical or kinetic studies 
(Bichet et al., 2000). If it can be proven that the presence of GST does not have a negative effect on 
the immunogenicity of VirB9-1, and the health of the animals, then leaving the GST tag uncleaved 
could also be acceptable here. Unlike human vaccines where the most important element is the health 
and safety of the patient, animal vaccines, especially livestock vaccines, focus more on the cost-
beneﬁt outcomes resulting from vaccination and improving overall production for the primary 
producers (Meeusen et al., 2007). By leaving the GST tag uncleaved, the use of TEVp for cleavage 
can also be eliminated from the VirB9-1 preparation process, providing a further source of bioprocess 
efficiency. Combined, these simplifications might significantly reduce the cost of antigen preparation. 
Furthermore, literature showed that the GST tag may also provide some level of adjuvanting effect 
(Yuan et al., 2001), which may benefit the immunogenicity of VirB9-1. Therefore, the GST tag will 
be retained until further investigation on the immunogenicity of VirB9-1 in in animal models, which 
will be pursued in the next chapter. 
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Abstract 
Anaplasma marginale is the most prevalent tick-borne livestock pathogen and poses a significant 
threat to cattle industry. In contrast to currently available live blood-derived vaccines against A. 
marginale, alternative safer and better-defined subunit vaccines will be of great significance. Two 
proteins (VirB9-1 and VirB9-2) from the Type IV secretion system of A. marginale have been shown 
to induce humoral and cellular immunity. In this study, Escherichia coli were used to express VirB9-
1 and VirB9-2 proteins. Silica vesicles having a thin wall of 6 nm and pore size of 5.8 nm were used 
as the carrier and adjuvant to deliver these two antigens both as individual or mixed nano-
formulations. High loading capacity was achieved for both proteins, and the mouse immunisation 
trial with individual as well as mixed nano-formulations showed high levels of antibody titres over 
107 and strong T-cell responses. The mixed nano-formulation also stimulated high-level recall 
responses in bovine T-cell proliferation assays. These results open a promising path towards the 
development of efficient A. marginale vaccines and provide better understanding on the role of silica 
vesicles to deliver multivalent vaccines as mixed nano-formulations able to activate both B-cell and 
T-cell immunity, for improved animal health. 
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Introduction 
Anaplasma marginale is the most prevalent tick-borne livestock pathogen which causes an infection 
within cattle, commonly known as “Tick Fever” (Palmer et al., 1999, Kocan et al., 2003). The disease 
results in significant morbidity and mortality in worldwide cattle populations, causing huge economic 
losses per year estimated to be over $300 million US dollars in the United States, over $100 million 
in Australia, and approximately $800 million in Latin America (Kocan et al., 2003). Cattle that 
recover from acute infection remain persistently infected without clinical signs and serve as 
reservoirs for biological transmission by ticks (Brayton et al., 2005, Marcelino et al., 2012). 
Currently, the commercially-available vaccines are live blood- derived vaccines, which have the 
potential for transmission of other pathogens and reversion to virulence (Marcelino et al., 2012). 
Combavac 3 in 1 live tick fever vaccine (Department of Agriculture Fisheries and Forestry AU, 2007) 
is one of the marketed vaccines against A. marginale. It has many disadvantages, such as cold chain 
for transport and storage, a short shelf life after thawing, and the requirement of multiple doses for 
vaccination (Department of Agriculture Fisheries and Forestry AU, 2007). For these reasons, the 
currently available vaccines for A. marginale are considered neither safe nor efficacious (Kocan et 
al., 2003, Marcelino et al., 2012). 
Studies have shown immunisation with purified A. marginale outer membranes (OM) can induce 
complete protection against infection by homologous strains (Brown et al., 1998). This protection is 
believed to be associated with CD4+ T-lymphocyte-mediated interferon gamma (IFN-γ) activating 
macrophages and immunoglobulin G2 (IgG2) antibody against outer membrane protein epitopes. 
However, a vaccine based on the purified OM cannot be cost-effectively manufactured due to the 
high cost of purification of A. marginale from erythrocytes and the complex method of purification. 
A promising way to overcome these problems is to use A. marginale recombinant proteins as subunit 
vaccines in combination with the design of novel delivery systems. 
Recently, researchers have identified over 20 novel antigenic proteins in a complex A. marginale 
OM immunogen by using mass spectrometry and genomic mapping techniques (Lopez et al., 2005). 
Among them, proteins VirB9-1 and VirB9-2 of the type IV secretion system (T4SS) were 
demonstrated to be two of the most promising candidate antigens (Lopez et al., 2005, Morse et al., 
2012b). The T4SS is a membrane protein complex usually comprising 12 proteins which have been 
found in many gram-negative bacteria (Fronzes et al., 2009, Chandran et al., 2009). The function of 
the T4SS in A. marginale is transportation of macromolecules, proteins or DNA across the bacterial 
cell envelope into host cells, which is considered essential for virulence and intracellular survival 
(Morse et al., 2012b, Fronzes et al., 2009, Chandran et al., 2009, Lopez et al., 2007). Targeting and 
neutralising T4SS proteins with antibodies may adversely affect bacterial survival and dissemination. 
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Studies have shown that proteins VirB9-1 and VirB9-2 together with VirB10 are the most 
immunogenic of the T4SS proteins (Morse et al., 2012b, Lopez et al., 2007). They elicit significant 
CD4+ T-lymphocyte proliferation, IFN-γ secretion and IgG2 production in outer membrane-
immunised cattle, responses that are associated with protective immunity (Morse et al., 2012b, Lopez 
et al., 2007). These proteins that associate to form the outer cap of the T4SS complex are believed to 
be surface-exposed due to the lack of surface lipopolysaccharide in A. marginale, and are highly 
conserved among A. marginale strains (Fronzes et al., 2009, Chandran et al., 2009, Lopez et al., 
2007). Furthermore, the proteins VirB9-1 and VirB92 are associated in the OM and VirB9-2 can 
provide T- cell help to produce VirB9-1-specific IgG through linked recognition (Morse et al., 2012a, 
Morse et al., 2012b). Therefore, both proteins are potentially excellent vaccine candidates. 
Recombinant proteins alone are often not sufficiently immunogenic, and require adjuvants or carriers 
in subunit vaccine formulations to enhance the activation of dendritic cells to generate strong antigen 
specific immune responses (Mody et al., 2014, Zhao et al., 2014). In recent years, many types of 
nanoparticles have been explored as nanocarriers for vaccine delivery (Zhao et al., 2014, Cohen et 
al., 1994, Rice-Ficht et al., 2010). An advantage is nanoparticles' similar size (50–200 nm) to that of 
cellular components, giving them the ability to enter living cells using the cellular endocytosis 
mechanism (Cohen et al., 1994). This allows nanoparticles to improve antigen stability and 
immunogenicity by presenting antigens very efficiently to antigen presenting cells (Rice-Ficht et al., 
2010). In particular, silica-based nanoparticles can be designed into various sizes, shapes, and surface 
properties suitable for targeted delivery and slow release (Zhao et al., 2014). Silica nanoparticles are 
also non-toxic and have excellent biocompatibility (Zhao et al., 2014). These unique properties make 
silica nanoparticles excellent nanocarriers for subunit vaccine formulations. 
In this study, we have utilised silica vesicles SV-100 (Zhang et al., 2014) to load two A. marginale 
protein antigens, VirB9-1 and VirB9-2, that were expressed in E. coli as soluble and insoluble 
proteins, respectively. The immunogenicity of each protein and the combination of both proteins 
were studied in mice, and compared with a conventional adjuvant Quil A (a saponin purified from 
Quillaja saponaria Molina bark). To the best of our knowledge, this is the first time to demonstrate 
the effect of the combination of two proteins injected as mixed formulation with nanoparticle system 
on immunogenicity. 
Materials and Methods 
Production of VirB9-1 
The coding region of VirB9-1 was amplified from a plasmid containing the VirB9-1 gene (Lopez et 
al., 2007) by polymerase chain reaction (PCR). The amplified DNA fragments were cloned into 
pGEX-4T1 glutathione S-transferase (GST) tagged expression vector with the thrombin recognition 
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site sequence mutated into tobacco etch virus (TEV) protease recognition site sequence. The cloning 
was performed by The University of Queensland’s Protein Expression Facility (PEF, The University 
of Queensland). Purified plasmid DNA was sequenced using ABI BigDye Terminator v3.1 
Sequencing (Australian Genome Research Facility (AGRF), Brisbane, Australia). 
The plasmid constructs were transformed into E. coli strain Rosetta (DE3) pLysS. A single colony 
from the transformation plate was inoculated into 5 mL TB media (12 g/L tryptone, 24 g/L yeast 
extract, 0.4% (v/v) glycerol, 2.31 g/L KH2PO4, 12.54 g/L K2HPO4) and incubated at 30 °C on a 
rotary shaker at 180 rpm for 16 hours. A culture of 800 mL TB media was inoculated with 800 µL 
of overnight culture and incubated at 37 °C, 180 rpm. When the OD600 reached 0.7–0.8, the culture 
was cooled in a cold water bath prior to induction with 0.2 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) and then incubated at 15 °C 180 rpm for 17 hours. Cell pellets were 
harvested by centrifugation at 6,000 g, 4 °C for 20 minutes and stored at -80 °C until further use. All 
media for culture were supplemented with 50 µg/mL ampicillin and 34 µg/mL chloramphenicol. 
VirB9-1 was expressed as a GST-tagged protein and purified using affinity chromatography. The 
cell pellets were resuspended in L buffer (40 mM Tris-base, 200 mM NaCl, 1 mM 
ethylenediaminetetraacetic acid (EDTA), 5% (v/v) glycerol, 5 mM dithiothreitol (DTT), pH 8.0) and 
sonicated with a Branson Sonifier 450 cell disruptor (Branson Ultrasonics Corporation, Connecticut, 
USA) at output 30 for 4 cycles of 40 seconds. Lysates were centrifuged at 27,000 g, 4 °C for 20 
minutes and the supernatant was filtered through a 0.45 µm filter. The clear filtered lysate was then 
loaded onto a GST affinity column (GS Trap HP 5 mL, GE Healthcare, UK) pre-equilibrated with 
five column volumes of L buffer. The column was washed with four column volumes of L buffer to 
remove unbound contaminants before the GST-tagged VirB9-1 (GST-VirB9-1) protein was eluted 
with E buffer (40 mM Tris-base, 50 mM NaCl, 1mM EDTA, 5% (v/v) glycerol, 5 mM DTT, 10 mM 
glutathione, pH 8.5). Purified GST-tagged VirB9-1 proteins were separated from aggregates and 
truncations through size-exclusion chromatography (Superdex 200 10/300 GL, GE Healthcare, UK). 
The fractions were concentrated by spin columns (Vivaspin2, GE Healthcare, UK), then dialysed 
against phosphate-buffered saline (PBS, pH 6.5, 300 mM NaCl) with a 10,000 MWCO snakeskin 
dialysis membrane (Thermo Scientific) overnight with minor stirring at 4 °C. Endotoxin removal 
was performed by using Vivapure Q Mini H spin columns (Sartorius Stedim Biotech). Protein 
integrity was determined by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) and the yield was determined by colorimetric assay (BioRad DC protein assay Kit, Hercules, 
USA). 
Production of VirB9-2 
The coding region of VirB9-2 was amplified from a plasmid containing the VirB9-2 gene (Lopez et 
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al., 2007). The template DNA was amplified using 1 unit of Taq polymerase (NEB Biolabs) and 
associated buffer (1x), 0.5µM of each primer; VirB9-2-Fwd: (AAAAACTTGCTTGCGTGC) and 
VirB9-2-Rev: (GATAAGCACCGTATTCACTAC) and 0.1 mM dNTP. PCR cycling conditions 
comprised of an initial incubation at 95 °C for 5 minutes, followed by 35 cycles at 94 °C for 30 
seconds, 44 °C for 30 seconds and 72 °C for 90 seconds. The resultant 820 bp product was ligated 
into the pET-SUMO vector (Invitrogen, Carlsbad, USA). The ligation products were subsequently 
transformed into electrocompetent E. coli strain DH10B (Invitrogen). Positive clones were 
confirmed by sequencing (AGRF, Brisbane, Australia) and transformed into E. coli strain BL21 
(DE3, Invitrogen) cells for protein expression. 
A 2.5 mL overnight culture of E. coli BL21 (DE3) containing pET-SUMO-VirB9-2 was used to 
inoculate four 250 mL cultures of LB Miller broth (Amresco, Solon, USA) containing 50 mg/ L 
kanamycin-sulphate (Amresco). These cultures were grown at 37 °C to an OD600 between 0.4 to 0.6, 
then induced with 1mM IPTG and grown for a further 4 hours. The bacterial pellet was collected by 
centrifugation at 3,800 g, at 4 °C for 15 minutes in 4 × 250 mL centrifuge tubes. Total protein was 
extracted by resuspending bacterial pellets in 50 mL E. coli lysis buffer (50 mM KPO4 phosphate, 
400 mM NaCl, 100 mM KCl, 10% (v/v) glycerol, 0.5% (v/v) Triton X-100, 10 mM Imidazole, pH 
7.8), with the addition of 12.5 mg Lysozyme and 750 units of Benzonase nuclease (Novagen-Merck, 
Darmstadt, Germany). The bacterial suspensions were incubated in lysis buffer for 20 minutes with 
gentle shaking. 
The samples were frozen in liquid nitrogen, and thawed at 42 °C three times. The resultant solution 
was centrifuged at 37,000 g at 4 °C for 15 minutes. 
The insoluble protein fraction, containing inclusion-bodies (IB) was purified using BugBuster 
(Novagen-Merck, Darmstadt, Germany) according to the manufacturers' protocol and as previously 
described (Cavallaro et al., 2011). Purified IB pellets were dissolved in Tris buffer (50 mM Tris, 100 
mM DTT, 1% (w/v) SDS, 10% (v/v) glycerol, pH 6.8), followed by incubation at 37 °C for 20 
minutes. The resulting solubilised protein was dialysed at room temperature, with three buffer 
changes over 24 hours against PBS (pH 7.4). Protein integrity was determined by SDS-PAGE and 
yield determined by colorimetric assay. Endotoxin levels were determined by PEF using the 
Endosafe-PTS Limulus Amebocyte Lysate assay kit. 
Nanoparticle preparation 
The silica nanoparticles (SV-100) were synthesised as reported previously (Zhang et al., 2014). In 
brief, 0.5 g of EO39BO47EO39 and 0.852 g of Na2SO4 were dissolved in 30 g of pH 4.7 NaAc-HAc 
buffer solution ([NaAc] = [HAc] = 0.40 M) to form a homogenous solution under stirring at 10 °C. 
3.57 mL (3.33 g) of tetraethyl orthosilicate (TEOS) was added to the above solution with continuous 
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stirring for 24 hours. The reaction mixture was then moved to an autoclave and hydrothermally 
treated at 100 °C for another 24 hours. The as-synthesised samples were collected by filtration and 
thoroughly washed with deionised water to remove the added salts. The samples were then dried in 
air. The final products were obtained by calcination at 550 °C for 5 hours in air. 
Nanoparticle characterization 
Field-emission scanning electron microscope (FE-SEM) images were obtained using JEOL JSM 
7800 operated at 0.6 kV. Transmission electron microscopy (TEM) images were obtained with JEOL 
2100 operated at 200 kV. The samples for TEM measurements were prepared by dispersing and 
drying the powder samples-ethanol dispersion on carbon film on a Cu grid. nitrogen adsorption-
desorption isotherms were measured at 77 K by using a Micromeritics Tristar II system. Samples 
were degassed at 453 K overnight on a vacuum line prior to the nitrogen sorption analysis. The total 
pore volume was calculated from the amount adsorbed at a maximum relative pressure (P/P0) 
calculate the entrance size from the desorption branches of the isotherms, and the Brunauere-
Emmette-Teller (BET) method was utilised to calculate the specific surface areas. Zeta potential 
measurements were conducted on a Zetasizer Nano ZS analyser (Malvern Instruments, 
Worcestershire, UK). 
Adsorption and desorption 
The adsorption studies used 2 mg of SV-100, with 1,000 µg of GST-VirB9-1 and 1000 µg of SUMO-
VirB9-2 in sterile PBS (pH 7.4), respectively. The particle-protein suspension was placed on a Ratek 
orbital shaker at 4 °C and 200 rpm. After 12 hours, a sample of particle-protein slurry (50 µL) was 
removed and centrifuged at 16,200 g for 1 minute. The supernatants were assessed by colorimetric 
assay using the BioRad DC protein assay kit (Hercules, USA), and amount of the unbound proteins 
was determined. 
The adsorbed VirB9-1 and VirB9-2 SV-100s were resuspended in 1 mL PBS and incubated at 37 °C 
for 24 hours at 200 rpm. The samples were centrifuged at 16,200 g for 1 minute and the supernatants 
were analysed by colorimetric assay using the BioRad DC protein assay to determine the amount of 
desorbed proteins. 
Immunisation 
Eight-week-old female C57BL/6J mice were purchased from and housed in the Biological Resource 
Facility (The University of Queensland, Brisbane, Australia) under specific pathogen-free 
conditions, with 5 animals per cage in an environmentally controlled area with a cycle of 12 hours 
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of light and 12 hours of darkness. All animal experimental work was reviewed and approved by The 
University of Queensland Animal Ethics Committee (AEC Approval Number: AE04071). All 
animals were cared for humanely in accordance with the Australian Code of Practice for the Care 
and Use of Animals for Scientific Purposes 8th Edition 2013 (National Health and Medical Research 
Council, 2013). Eight groups of five mice were immunised with different prototype nanovaccine 
formulations as shown in Table 5-1. 
Table 5-1. Immunisation groups in mice trial. 
 
All doses were administered with 100 µL saline. VirB9-1/SV-100 and VirB9-2/SV-
100 refer to VirB9-1 and VirB9-2 adsorbed to SV-100, respectively. 
 
Three subcutaneous injections were given at the tail base on days 0, 21 and 42. All nanovaccine 
formulations were prepared in sterile injectable saline on the day of the injection. Blood samples 
were collected by retro-orbital bleeds after anaesthetisation by methoxyfluorane inhalation on days 
0, 21 and 35. Final blood samples were collected on day 56 by heart puncture. All mice were 
euthanized by carbon dioxide inhalation on day 56, spleens were removed and collected. The animals 
were weighed weekly and monitored three times per week for their health during the study. A score 
sheet system was used to monitor the mice on their eating, locomotion, behaviour, appearance and 
weight. If any mice were scored to be ill or moribund, then it would have been euthanized prior to 
the experimental endpoint. All animals remained in good health for the duration of the study with no 
visible deleterious health effects. 
Enzyme-linked immunosorbent assay (ELISA) 
Mouse sera were tested by ELISA in duplicates for the detection of VirB9-1-specific and VirB9- 2-
specific antibodies. ELISAs were performed by coating microtitre plates (96 well, Nunc, Max-isorb, 
Roskilde, Denmark) with 50 µL VirB9-1 or VirB9-2 antigen solution (2 ng/µL) in PBS (pH 7.4) 
overnight at 4 °C. The coating solution was removed and the plates were washed once with PBS-T 
(1× PBS, 0.1% Tween-20, Sigma-Aldrich), followed by blocking with 5% Bovine Serum Albumin 
(Sigma-Aldrich) and 5% skim milk powder (Fonterra, Auckland, New Zealand) in PBS-T for 1 hour 
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with gentle shaking at room temperature. Plates were washed three times with PBS-T after blocking. 
Mouse serum samples were diluted from 1:1,000 to 1:16,384,000 in 50 µL PBS and each dilution 
was added to the wells of the blocked plates followed by incubation for 2 hours at room temperature 
with gentle shaking. The plates were washed three times with PBS-T after incubation, then HRP 
conjugated polyclonal rabbit anti-mouse IgG antibodies (Sigma-Aldrich) were added to each well at 
1:100,000 dilutions in PBS-T, followed by incubation for 1 hour at room temperature with gentle 
shaking. Plates were washed three times with PBS-T. 100 µL of TMB substrate (Life Technologies) 
was added to each well and incubated for 6 minutes at RT; 100 µL of 1 N HCl was added to the wells 
after 6 minutes to stop the chromogenic reaction. The plates were read at 450 nm on the BioTek 
microplate reader (Winooski, US). Statistical analysis was performed using GraphPad Prism Version 
5.03 (GraphPad Software Inc., USA). Comparison between two groups was performed with t test 
where p < 0.05 was considered statistically significant. 
Isolation of murine splenocytes and enzyme-linked immunosorbent spot (ELISPOT) assay 
Spleens were aseptically removed and collected from the immunised mice following euthanasia and 
placed into 5 mL ice cold Dulbecco's modified Eagle's medium (DMEM) supplemented with foetal 
bovine serum (FBS, 10%), 20 mM HEPES (pH 7.3), 1 M sodium pyruvate, 1 M Glu-tamax, 100 
units/mL penicillin G, 100 µg/mL streptomycin, 0.25 µg/mL Fungizone. Spleens were gently 
disrupted and passed through a 100 µm nylon mesh (Becton Dickinson, Franklin Lakes, NJ). Spleen 
cells were washed with 5 mL DMEM and centrifuged at 800 g, 4 °C for 5 minutes. Cells were then 
resuspended in 1 mL lysis buffer (0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM EDTA) for 5 minutes at 
room temperature. Cell numbers were determined by staining with 0.2% trypan blue. ELISPOT 
assays were performed by using Mabtech ELISPOT kit (Mab- tech, Sweden). ELISPOT plates pre-
coated with monoclonal IFN-γ capture antibody were conditioned with complete DMEM medium 
for 30 minutes at room temperature. Spleen cells from each mouse were seeded at 100,000 cells/well 
in triplicate into the ELISPOT plates. Cells were incubated in complete DMEM medium at 37 °C 
and 5% CO2 for 48 hours in the presence or absence of 10 µg/mL VirB9-1 antigen or VirB9-2 
antigen, or the polyclonal activator concavalin A (Con A, 1 µg/mL, Sigma Aldrich) as a positive 
control. Detection of spots was performed according to manufacturer’s specifications. The ELISPOT 
plates were read on an ELISPOT reader (Autoimmun Diagnostika, Strassburg, Germany). Results 
are presented as the mean number of spot forming cells (SFC) per million spleen cells. Statistical 
analysis was per- formed using GraphPad Prism Version 5.03. Comparison between the groups was 
performed with one way ANOVA, and p < 0.05 was considered statistically significant. 
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A. marginale-specific T-lymphocyte proliferation assays 
Holstein cattle 48422, 48432, and 583 were immunised with A. marginale St. Maries strain OM as 
described (Morse et al., 2012b) with the exception that animals 48422 and 48432 were immunised 
four times at three week intervals with 60 µg OM in saponin, whereas animal 583 was immunised 
for a prior study with the same antigen dose and adjuvant four times at two-week intervals (Morse et 
al., 2012b). Two-week T-cell lines were obtained by stimulating 4x106 peripheral blood mononuclear 
cells (PBMC) in complete RPMI-1640 medium with 5 µg/mL OM for one week in 1.5 mL volumes 
in 24-well plates. Cells were harvested and washed in complete RPMI-1640 medium, and viable 
cells obtained after Ficoll-Hypaque purification, if needed. Viable cells were recultured at 7.5x105 
cells per well with 2x106 irradiated autologous PBMC in 1.5 mL complete RPMI-1640 without 
antigen for one week (resting). Cells were harvested and viable cells were cryopreserved in liquid 
nitrogen in a mixture of 10% dimethyl sulfoxide (DMSO) in foetal bovine serum for use in 
proliferation assays.  
Proliferation assays were carried out in replicate wells of round-bottomed 96-well plates for 3 days 
using cryopreserved two-week T-lymphocyte lines from calves 48422, 48432, and 583 as described 
previously (Morse et al., 2012b). T-cells (2x104 cells) were cultured in replicate wells in a total 
volume of 100 µl of complete RPMI-1640 medium containing antigen and 2x105 irradiated 
autologous PBMC as a source of antigen presenting cells. The VirB9-1 and VirB9-2 proteins were 
used at a final concentration of 1 and 10 µg/mL in complete RPMI-1640 medium or a mixture of the 
two at a final protein concentration of 2 and 20 µg/mL. Positive controls include A. marginale OM 
used at 1 µg/mL and negative controls included uninfected red blood cell membranes (URBC), and 
recombinant Babesia bovis merozoite surface antigen-1 (MSA-1) used at 1 and 10 µg/mL. 
Nanoparticles loaded with VirB9-1, VirB9-2, or a mixture of the two were tested at final 
concentrations of VirB9 proteins of 1 and 10 µg/mL or 2 and 20 µg per mL for the mixture. Empty 
nanoparticles tested at 2.5, 5.0, 7.5, 10, 25, 50, 75, and 100 µg/mL were used as negative controls. 
T-cell proliferation was quantified by incorporation of 0.25 µCi/well 3H- thymidine (Dupont, New 
England Nuclear) during the last 6 hours of culture. The radiolabeled DNA was harvested (Tomtec 
Cell harvester) on glass filters and the emitted β-particles were counted with liquid scintillation. 
Results are presented as the mean counts per minute (CPM) +/- 1 SD. The cpm of the different 
antigens were compared to the cpm for the matching concentration of MSA1 with Boneferroni-Holm 
(one way ANOVA with posthoc test). Statistically significant T-cell stimulation by an antigen was 
set at a p-value < 0.05. 
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Results 
Protein antigens 
Preparation of VirB9-1. Our laboratory has developed a simple and low cost technology for 
high-level expression of soluble VirB9-1 protein in E. coli using the GST tag (Chuan et al., 2008). 
SDS-PAGE analysis (Figure 5-1a) shows the expression result for the VirB9-1-GST construct, 
demonstrating its high expression yield with a dominant band at approximately 56 kDa, 
corresponding to the predicted molecular weight of the construct. By estimate, the total expression 
yield of VirB9-1 is 70 mg/L of culture for a final culture OD600 nm of approximately 3.5. Figure 5-
1 also shows that VirB9-1 had a good solubility of about 50% under pH 8.0 buffer conditions 
(according to BIO-RAD Image Lab© software). The solubility of VirB9-1 can be further increased 
to over to 90% using pH 9.0 buffer (data not shown). However, high pH is not suitable for 
downstream purification as the GST affinity column optimally works in the range of pH 6.5–8.0, 
therefore pH 8.0 buffer was chosen for protein purification. 
GST-VirB9-1 protein was purified using a two-step chromatography method, by first passing 
supernatant of the cell lysis after sonication through a GST affinity column, followed by a size 
exclusion column purification step. Figure 5-2 shows the size exclusion purification results, where 
four peaks were of approximately 700, 400, 110 and 55 kDa were obtained (the molecule weights 
were estimated based on the manufacturer’s instructions of the Superdex 200 10/300 GL column). 
The components of these four peaks were further analysed using the SDS-PAGE (Figure 5-2b), and 
were identified to be large GST-VirB9-1 soluble aggregates (Figure 5-2b lane 2), small GST-VirB9-
1 soluble aggregates (Figure 5-2b lane 3), GST-VirB9-1 dimers (Figure 5-2b lane 4–6), and GST 
dimers (Figure 5-2b lane 7), respectively. The dimer peak including three fractions (F1, F2 and F3) 
was collected as the protein antigen. F1 fraction (Figure 5-2b, lane 4) contains mainly GST-VirB9-
1 with the highest purity. F2 and F3 fractions (Figure 5-2b, lanes 4 and 5) contain not only VirB9-1 
but also a 27 kDa GST protein, which confirmed by mass spectrometry and western blot analysis. It 
is most likely truncated from the GST fusion protein during expression. F1, F2 and F3 fractions were 
all collected to achieve a high yield of about 2 mg/L of culture of the GST-VirB9-1 protein. 
Preparation of VirB9-2. Our initial expression studies showed high expression of VirB9-2 at 4 
hours post induction with IPTG, as inclusion bodies (Figure 5-1b). The fusion protein encoded by 
pET-SUMO-VirB9-2 has a hypothetical MW of 43.9 kDa which is consistent with the western blot 
analysis (Figure 5-3). The insoluble protein was solubilised using a DTT buffer followed by dialysis 
into PBS, resulting in a pure and soluble protein. Following dialysis, the final yield of VirB9-2 was 
15 mg/L of culture. 
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Figure 5-1. a) Expression of VirB9-1 protein. L: ladder marker; P: uninduced total E. 
coli cell lysate; T: induced total E. coli cell lysate; S: supernatant of E. coli cell lysate 
after centrifugation at 27,000 g, 4 °C for 5 minutes. 6 µL of the ladder was loaded, 
while the other samples were all 8 µL. GST-tagged VirB9-1 protein is approximately 
56 kDa as labelled. b) Expression of VirB9-2 protein. Top: uninduced sample; Bottom: 
induced sample. L: ladder marker; S: soluble fraction; P: pellet fraction; 0-S: 0 h 
supernatant; 0-P 0 h pellet; 4-S: 4 h supernatant; 4-P: 4 h pellet. VirB9-2 protein is 
approximately 44 kDa as labelled. 
 
 
Figure 5-2. a) Size-exclusion chromatogram of GST-tagged VirB9-1. GST-VirB9-1 
dimers were separated from aggregates and GST in size exclusion chromatography 
pre-equilibrated with L buffer. b) SDS-PAGE analysis of fractions from size-
exclusion chromatography. L: ladder marker; 1: fraction from GST affinity 
chromatograph; 2: excluded peak; 3: aggregates peak; 4: F1 of dimer peak; 5: F2 of 
dimer peak; 6: F3 of dimer peak; 7: GST peak. 
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Figure 5-3. Western blot analysis of pET-SUMO-VirB9-2 expression. Purified 
protein was separated on a SDS-PAGE gel, transferred to nitrocellulose and probed 
with Anti-His antibodies. Supernatant (S) and pellet (P) fractions show that the protein 
is expressed as insoluble inclusion bodies. 
 
Silica vesicles as nanocarriers and adjuvants 
Characterisation of SV-100. The SV-100 silica vesicles have a hollow spherical structure 
with uniform particles of ~50 nm size and wall thickness of ~6 nm, as measured by the SEM and 
TEM analyses (Figure 5-4a and 4b). The nitrogen sorption analysis of SV-100 shows representative 
type IV isotherms with type H3 hysteresis loop (Figure 5-4c). The adsorption branch shows major 
capillary condensation step at relative pressure (P/P0) of ~0.9. The average pore size, or entrance 
size, was calculated by the Barrett-Joyner-Halanda (BJH) method (Barrett et al., 1951) from the 
desorption branch to be 5.8 nm (Figure 5-4d), suitable for GST-VirB9-1 protein and SUMO-VirB9-
2 protein loading. The Brunauer-Emmett-Teller (BET) surface area of SV-100 is 487 m2/g, the total 
pore volume is 1.31 cm3/g, and the Zeta potential is -18.1 mV (Table 5-2).  
The SV-100 silica vesicles were tested for adsorption capabilities of GST-VirB9-1 and SUMO-
VirB9-2 proteins in PBS at 4 °C. Figure 5-5 shows that SV-100 particles have an adsorption for 
GST-VirB9-1 of 268 µg/mg particle and for SUMO-VirB9-2 of 410 µg/mg particle. This 
demonstrates the high loading capacity of SV-100 particles by virtue of the hollow structure. The 
desorption of the VirB9-1 and VirB9-2 loaded SV-100 particles was the same as previously reported 
(Mody et al., 2014), there was no desorption of the two protein in PBS at 37 °C. 
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Figure 5-4. a) FE-SEM and b) TEM image of SV-100; c) Nitrogen sorption isotherm 
of SV-100; d) Barrett-Joyner-Halanda pore size distribution curve calculated from the 
desorption branch of SV-100 (the detailed calculation is included in Appendix C). 
 
Table 5-2. Structural information from nitrogen sorption results of SV-100. 
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Figure 5-5. Adsorption amount of VirB9-1 and VirB9-2 proteins onto SV-100 
nanoparticles. Data determined by protein assay. 
 
Immunisation Studies 
ELISA results. The immune responses of the VirB9-1 and VirB9-2 prototype nanovaccine 
formulations were investigated using C57BL/6J female mice. Eight groups of five mice received 
three subcutaneous immunisations of the various formulations (Table 5-1) at three-week intervals. 
The endotoxin level of the protein antigens used were 104 EU/mL for VirB9-1 and 115 EU/mL for 
VirB9-2, equivalent to 3.64 EU per 50 µg injected dose of VirB9-1 and 2.68 EU per 50 µg dose of 
VirB9-2. The level of endotoxin present in VirB9-1 and VirB9-2 was within safe levels as shown by 
Schadlich et al (Schädlich et al., 2009). We compared the SV-100 formulation against a conventional 
adjuvant Quil A, which has been widely used in animal vaccine studies (Spickler and Roth, 2003). 
The sera collected from the immunised mice were analysed by both anti-VirB9-1 and anti-VirB9-2 
ELISA to detect the total IgG responses. As both antigens may be required to achieve protective 
immunity, we not only included each single antigen with Quil A or silica vesicles, but also designed 
two groups which combined VirB9-1 and VirB9-2 into one mixed formulation to investigate the 
interaction between them. Figure 5-6a shows that the VirB9-1-specific IgG response of the VirB9-
1/SV-100 group was comparable to that of the VirB9-1 plus Quil A group with a titre of 105, and no 
significant difference (p < 0.05) was observed. After three injections, the VirB9-1/SV-100 group 
demonstrated an antibody titre of 107. For the VirB9-2-specific IgG response of the VirB9-2 plus 
Quil A group and VirB9-2/SV-100 group, there were no significant differences (p < 0.05) observed 
between the two groups. After three injections, the overall antibody responses showed titres of over 
105 (Figure 5-6b). The groups receiving mixed formulation (VirB9-1 and VirB9-2 loaded separately 
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to SV-100 and mixed before injection) showed both strong VirB9-1-specific antibody responses and 
strong VirB9-2-specific antibody responses, with average endpoint titres of 106 after three injections. 
The titres of the double antigen groups showed no significant difference (p < 0.05) to the single 
antigen groups. The negative control group receiving only SV-100 as control and the unimmunised 
group showed no VirB9-1-specific or VirB9-2-specific antibody responses. A Quil A negative 
control group was not included in this study, for Quil A by itself without antigens does not induce 
specific antibody responses as reported previously (Heath et al., 2012). 
 
Figure 5-6. a) VirB9-1-specific antibody end point titres in C57BL/6J mice for 
different vaccine formulation groups. b) VirB9-2-specific antibody end point titres in 
C57BL/6J mice for different vaccine formulation groups. 
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ELISPOT results. In addition to antibody-mediated immunity, cell-mediated immunity in 
response to the nanovaccine formulations was investigated. Splenocytes were analysed by ELISPOT 
assay to determine the T-helper type 1 (Th1) cell mediated IFN-γ responses to VirB9-1 and VirB9-
2 antigen. All mice in the VirB9-1 plus Quil A group, VirB9-1/SV-100 group, VirB9-1/9-2 plus Quil 
A group, and VirB9-1/9-2/SV-100 group showed very high cell-mediated immune responses to 
VirB9-1 antigen, as indicated by the number of cells producing IFN-γ, ranging from 6,650 to over 
10,000 SFC/million cells (extending beyond the axis of the graph) (Figure 5-7a). These four groups 
all showed significant differences (p < 0.0001) to the two negative control groups (SV-100 and 
unimmunised) and the two groups that only received VirB9-2 antigen. The VirB9-1/9-2/SV-100 
group showed the highest response where all five animals had over 10,000 IFN-γ SFC/million spleen 
cells, indicating a very strong cell-mediated immune response. A significant difference (p < 0.05) 
was observed when comparing the VirB9-1/9-2/SV-100 group to the VirB9-1/SV-100 group, but no 
significant difference (p < 0.05) was observed when comparing to the VirB9-1 plus Quil A group 
and the VirB9-1/9-2 plus Quil A group. The VirB9-2 plus Quil A group, the VirB9-2/SV-100 group, 
and the two negative control groups only produced background IFN-γ response to VirB9-1 antigen, 
much lower than the positive control Con A. Figure 5-7b shows that all mice in VirB9-2 plus Quil 
A group, VirB9-2/SV-100 group, VirB9-1/9-2 plus Quil A group and VirB9-1/9-2 SV-100 group 
induced high cell-mediated immune responses to VirB9-2 antigen, as indicated by the number of 
cells producing IFN-γ, ranging from 6,686 to over 10,000 SFC/million spleen cells (extending 
beyond the axis of the graph). These four groups all showed significant differences (p < 0.0001) 
when compared to the two negative control groups and the two groups that only received VirB9-1 
antigen, but no significant differences (p < 0.05) were observed when comparing them to each other. 
The background IFN-γ response to VirB9-2 antigen was lower than that to VirB9-1, only a few 
animals in the two negative control groups and the two groups that only received VirB9-1 antigen 
had an obvious background response. The detailed statistical analysis of each group can be seen in 
S1 Table. 
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Figure 5-7. a) Detection of VirB9-1-specific IFN-γ secretion by ELISPOT assay of 
murine splenocytes from immunised mice. b) Detection of VirB9-2-specific IFN-γ 
secretion by ELISPOT assay of murine splenocytes from immunised mice. 1 to 5 are 
the individual mice in each group. See S1 Table for statistical analysis. 
 
T-lymphocyte proliferation assay results. Both VirB9-1 and VirB9-2 stimulated recall responses 
in OM-immunised calves 48422 and 48432 (Figure 5-8). VirB9-2 stimulated slightly higher T-cell 
proliferation than VirB9-1. There was no cumulative effect in combining the antigens. For animal 
48422 (Figure 5-8a), there was no significant difference observed between VirB9-2 alone and the 
combination of VirB9-1 and VirB9-2 treatment. However, a significant difference was observed 
between VirB9-1 and VirB9-2 combination group and VirB9-1 treatment only (p < 0.0001 for 1 
µg/mL and P = 0.0009 for 10 µg/mL). In contrast, animal 48432 (Figure 5-8b) showed a significant 
response when comparing the combination of VirB9-1 and VirB9-2 to VirB9-1 (p = 0.0004 for 1 
µg/mL and p = 0.0002 for 10 µg/mL) and to VirB9-2 (p = 0.016 for 1 µg/mL and p = 0.01 for 10 
µg/mL). The responses to VirB9-1 and VirB9-2-loaded SV-100 either alone or in combination were 
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similar to the responses induced by the recombinant proteins for both animals, and there was no 
response to any concentration of empty SV-100 tested (data not shown and Figure 5-8a and 5-8b). 
Animal 583 did not respond to VirB9-1 but had a significant T-cell response to VirB9-2 using both 
1 and 10 µg/mL antigen-loaded nanoparticles (Figure 5-8c). These data are consistent with previous 
studies using VirB9-1 and VirB9-2 expressed from the pBAD/TOPO ThioFusion vector (Morse et 
al., 2012b) and in peptide mapping studies (Morse et al., 2012a), where animal 583 never responded 
to VirB9-1 but had strong responses to VirB9-2. The lack of response to recombinant MSA-1 for 
animals 48422 and 48432, together with the predicted lack of response of animal 583 to recombinant 
VirB9-1 show there is no nonspecific proliferation to the E. coli-expressed fusion proteins. 
  
131 
 
 
 
Figure 5-8. Two-week T-cell lines established from A. marginale OM-vaccinated 
calves proliferate in response to VirB9-1 and/or VirB9-2 loaded nanoparticles. T-cells 
from cattle 48422 (a), 48432 (b) were tested for proliferation to 1 (black bars) µg/mL 
URBC and purified OM, and to 1 (black bars) and 10 (white bars) µg/mL recombinant 
B. bovis MSA-1, and A. marginale VirB9-1 and VirB9-2, and VirB9-1 and VirB9-2 
loaded onto SV-100 nanoparticles. A mixture of VirB9-1 plus VirB9-2 and VirB9-1-
SV-100 plus VirB9-2-SV-100 was also used. SV-100 tested at final concentrations of 
5 and 50 µg/mL are shown. A two-week T-cell line from animal 583 (c) was tested 
with VirB9-1 and VirB9-2 loaded nanoparticles to rule out nonspecific stimulation by 
the E. coli-expressed protein, as this animal does not respond to VirB9-1. 
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Discussion 
VirB9-1 and VirB9-2 are OM proteins of A. marginale. Due to their intrinsic properties, they are 
generally difficult to express at high solubility and yield. In this paper we have successfully produced 
high yielding soluble VirB9-1 and VirB9-2 utilising two different expression and purification 
systems. 
Previous expression studies of VirB9-1 using FLAG-tag or His-tag have resulted in insoluble 
proteins which were purified using denaturing methods (Lopez et al., 2007, Morse et al., 2012a, 
Morse et al., 2012b, Sutten et al., 2010). However, for vaccination, soluble proteins as antigens have 
great potential to include native structural elements that may be able to induce protective immunity. 
Therefore, it is essential to develop an approach for producing soluble VirB9-1 proteins that present 
the key B-cell epitopes that rely on three-dimensional structures. Thus, in this study a VirB9-1-GST 
fusion protein was designed and expressed in E. coli, as the use of GST fusion tags can simplify 
downstream purification, improving overall yield and solubility of the target protein. This is the first 
time that the VirB9-1 protein has been expressed in E. coli at high yield and high solubility (Lopez 
et al., 2007, Sutten et al., 2010). The yield is about 70 mg/L of culture after low-density shake-flask 
expression and about 2 mg/L of culture after purification. 
Because of the presence of the GST tag, GST-VirB9-1 proteins can form as a soluble dimer structure 
with high purity, which is similar to the dimerisation reported previously in aqueous solutions (Terpe, 
2003). It was also previously observed that E. coil expressed recombinant VirB9-1 and native VirB9-
1 naturally form dimers (Morse et al., 2012b). Therefore, after size-exclusion chromatography, the 
GST-VirB9-1 peak appeared at about 110 kDa, whereas the size of the protein dimer is 112 kDa. 
The GST tag was not cleaved to simplify the preparation method and reduce the cost of purification 
by not using expensive enzymes for cleavage. Furthermore, the GST tag may also provide some level 
of adjuvanting effect (Yuan et al., 2001). 
VirB9-2 contains linear T-cell epitopes (Morse et al., 2012a), so high expression, even as an insoluble 
protein could refold and retain the linear epitopes. Our previous work has shown pET-SUMO has 
high expression and we have previously used this system to express optiE2 (Cavallaro et al., 2011). 
Similarly, pET-SUMO-VirB9-2 was found to be expressed as insoluble inclusion bodies, and 
following refolding produced soluble VirB9-2 of suitable quality. 
Silica nanoparticles have been established as excellent nanocarriers for protein antigen delivery and 
subsequent induction of antibody and cell-mediated immune responses in mice (Mody et al., 2014, 
Mahony et al., 2013, Mahony et al., 2014) and sheep (Mahony et al., 2015), for their attractive 
properties, such as tuneable size and structure, various surface modifications, and excellent 
biocompatibility (Zhao et al., 2014, Slowing et al., 2008). The next generation SV-100 type silica 
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vesicles with increased protein adsorption capacities (Zhang et al., 2014) have been shown to be 
potent adjuvants, inducing high levels of both antibody and cell-mediated immune responses in mice 
with no detrimental effects (Mody et al., 2014). 
We have developed a facile method to synthesise the SV-100 nanoparticles with precise control of 
both the particle size and the entrance size. The 50 nm size of SV-100 nanoparticles is very efficient 
for uptake by dendritic cells, and the spherical shape similar to a virus also enhances higher antibody 
response when compared with other shapes of similar size (Zhao et al., 2014). Entrance size is an 
important factor for protein loading, studies show that silica vesicles with an entrance size close the 
size of the target protein had the highest loading capacity (Zhang et al., 2014). SV- 100 nanoparticle 
has an entrance size of 5.8 nm, which is close to the size of the two proteins. Both GST-VirB9-1 and 
SUMO-VirB9-2 achieved high adsorption to SV-100 nanoparticles (Figure 5-5). The adsorption of 
VirB9-2 was higher, possibly due to its smaller size than VirB9-1 (44 kDa compared to 56 kDa), 
enabling the smaller protein to have a better chance of entering the SV-100 nanoparticle. 
No desorption was observed from the protein loaded SV-100 nanoparticles in PBS at 37 °C. This is 
likely because the majority of protein was entrapped inside the hollow structures instead of adsorbing 
at the outer interface. The strong binding also suggests the protein-loaded SV-100 nanoparticles have 
a good chance of being taken up by dendritic cells for antigen presentation. 
Here, using VirB9-1 or VirB9-2 bound separately to SV-100 nanoparticles, we have demonstrated 
the versatility of the system by demonstrating, to the best of our knowledge for the first time, that it 
is possible to induce discrete immune responses using a mixed nano-formulation. The mice were 
injected subcutaneously three times with 50 µg of either VirB9-1 or VirB9-2 adsorbed to SV-100 
nanoparticle. The adsorption capacities differed for the two proteins with 53% higher adsorption for 
VirB9-2 (Figure 5-5), so that the dose of the injected protein was kept constant across all eight of the 
groups at a 50 µg dose. 
The total IgG responses over time were measured by VirB9-1 and VirB9-2-specific ELISAs and we 
demonstrated the development of VirB-specific antibodies three weeks after a single injection for 
both VirB9-1 (Figure 5-6a) and VirB9-2 (Figure 5-6b). The antibody titre was lower with average 
end-point titre of 104 for VirB9-2 compared to 105 for VirB9-1 after a one injection. This could be 
due to 150 µg SV-100 nanoparticles in the VirB9-2 injection doses compared to 250 µg in the VirB9-
1 SV-100 nanoparticle injection doses. This seems to be the case since the level of responses for the 
groups injected with VirB9-1 Quil A and VirB9-2 Quil A are very similar for both VirB9-1 and 
VirB9-2. With subsequent injections there is very little difference in the titre levels for VirB9-1 and 
VirB9-2 and showed that SV-100 nanoparticles act as a comparable adjuvant to Quil A. Whereas 
Quil A retains a certain level of toxicity and undesirable side effects (Petrovsky and Aguilar, 2004, 
Kensil et al., 1991) it is likely that SV-100 nanoparticles will have a lower toxicity profile and better 
134 
 
safety (Mody et al., 2014). 
The combination of mixed nano-formulation did not interfere with the VirB9-1- or VirB9-2-specific 
antibody levels. In addition, as shown previously (Morse et al., 2012a) there was no cross reaction 
between the two antigens and animals receiving only VirB9-1 showed no response to VirB9-2 and 
vice versa.  
The cell-mediated immune responses were measured by VirB9-1 and VirB9-2-specific IFN-γ 
ELISPOT. Results show that antigen-loaded SV-100 nanoparticles can induce high levels cell- 
mediated immunity similar to antigens administered with Quil A, resulting in over 10,000 SFC/ 
million splenocytes. The mixed nano-formulation groups had high numbers of IFN-γ SFC to both 
VirB9-1 and VirB9-2 antigens, indicating that there was no interference between the two antigens 
and that they can be injected together in a mixed formulation. The VirB9-1-specific cell-mediated 
immune responses for the mixed nano-formulation group were even significantly higher than when 
the antigen was injected singly with SV-100 nanoparticles (Figure 5-7a). These results show that 
designing an A. marginale vaccine using both VirB9-1 and VirB9-2 as antigen is not only feasible, 
but also may induce better cell-mediated immune responses than using a single antigen. The IFN-γ 
responses of some mice from the control groups to VirB9-1 antigen were slightly high. This may be 
due to the higher endotoxin level of the VirB9-1 stimuli (0.15 EU per well) than that of the VirB9-2 
stimuli (0.11 EU per well) used in the ELISPOT assay. A higher endotoxin level stimulates the cells 
and induced higher IFN-γ responses (Eisenbarth et al., 2002). 
The bovine T-lymphocyte proliferation assay results further confirmed the benefits of using a mixed 
nano-formulation to generate cell-mediated immunity. In animal 48422 where VirB9-2 stimulated a 
much higher T-cell proliferative response than VirB9-1, the mixed formulation achieved an 
equivalently high response (Figure 5-8a). In animal 48432 where VirB9-2 stimulated a slightly 
higher T-cell proliferative response than VirB9-1, the mixed formulation induced an even higher 
response (Figure 5-8b). 
Conclusions 
This study investigated the immunogenicity of combined VirB9-1 and VirB9-2 antigens in 
formulation with specially designed silica vesicles. Our findings showed that the combined antigen 
formulation can induce an equivalent level of antibody and better cell-mediated immune responses 
(IFN-γ SFC, T-lymphocyte proliferation) than single antigen formulations. This result of combining 
VirB9-1 and VirB9-2 opens a possible pathway towards developing a new generation of subunit 
vaccines against A. marginale using recombinant protein antigens. Furthermore, SV-100 
nanoparticles can induce high levels of IgG and cell-mediated immune responses that are comparable 
to those induced by Quil A, yet are advantageous over Quil A because they are non-toxic and of low 
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cost. These findings can provide a better understanding of the adjuvanting effect of silica 
nanoparticles and may lead to improvements in future animal vaccine formulations. 
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Abstract 
Anaplasma marginale is a devastating tick-borne pathogen causing anaplasmosis in cattle and results 
in significant economic loss to the cattle industry worldwide. Currently, there is no widely accepted 
vaccine against A. marginale. New generation subunit vaccines against A. marginale, which are much 
safer, more efficient and cost-effective, are in great need. The A. marginale outer membrane protein 
VirB9-1 is a promising antigen for vaccination. We previously have shown that soluble recombinant 
VirB9-1 protein can be expressed and purified from Escherichia coli and induce a high level of 
humoral and cellular immunity in mice. In this study, we re-formulated the nanovaccines using the 
partially-purified VirB9-1 protein as the antigen and hollow nano-size silica vesicles (SV-100) as the 
adjuvant. We simplified the purification method to obtain the partially-purified antigen VirB9-1 with 
a six-fold higher yield. The new formulations using the partially-purified VirB9-1 protein achieved 
higher antibody and cell-mediated immune responses compared to the purified ones. This finding 
suggests that the partially-purified VirB9-1 protein performs better than the purified ones in the 
vaccination against A. marginale, and a certain level of contaminants in the protein antigen can be 
self-adjuvant and boost immunogenicity together with the nanoparticle adjuvant. This may lead to 
finding a “Goldilocks” level of contaminants. The new nanovaccine formulation using partially-
purified antigens along with nanoparticle adjuvants offers an alternative strategy for making cheaper 
veterinary vaccines. 
 
  
142 
 
1. Introduction 
Anaplasma marginale is a tick-transmitted riskettsial pathogen causing anaplasmosis in cattle. This 
disease results in anaemia, abortions, and death in cattle and threatens the cattle industry worldwide 
with significant morbidity and mortality, resulting in tremendous economic losses (Palmer et al., 
1999, Kocan et al., 2003). Currently, there is no widely accepted vaccine against A. marginale. The 
only effective immunization method is achieved by immunising cattle with live vaccines based on 
the Anaplasma centrale strain, which leads to mild anaplasmosis (Molad et al., 2006, Shkap et al., 
2008, Marcelino et al., 2012). Live vaccines also have the risk of transmitting other pathogens and 
reversion to virulence, therefore cannot be licensed in countries such as the United States (Kocan et 
al., 2003, Marcelino et al., 2012). Some studies showed that immunisation with purified outer 
membranes of A. marginale can induce complete protection against infection by homologous strains 
(Brown et al., 1998). However, due to the high cost of production, A. marginale outer membranes for 
vaccination cannot be easily marketed.  
Other studies focused on developing subunit vaccines against A. marginale by using proteins from 
the major surface protein family as antigens, such as MSP1a (Palmer et al., 1986). However, later 
studies showed that these MSP proteins failed to provide consistent and complete protective immunity 
(Palmer et al., 1999, Lopez et al., 2007). Recent studies identified other highly immunogenic outer 
membrane proteins as antigens, including VirB9-1, one of the Type IV secretion system (T4SS) 
proteins of A. marginale (Lopez et al., 2005, Lopez et al., 2007, Morse et al., 2012). The function of 
T4SS in A. marginale is transporting macromolecules, proteins, or DNA across the bacterial cell 
envelope into the host cell, which is considered essential for virulence and intracellular survival 
(Lopez et al., 2007, Fronzes et al., 2009, Chandran et al., 2009). VirB9-1, as the most immunogenic 
protein of the T4SS, is a promising antigen candidate for vaccines against A. marginale (Morse et al., 
2012). Previously we have demonstrated expression and purification of the recombinant protein 
VirB9-1 in Escherichia coli of high solubility and purity (Zhao et al., 2016). However, the low yield 
and expensive purification method limit the application of the VirB9-1 protein as the antigen for low-
cost animal vaccines. One promising way to overcome this is to reduce the purification steps and use 
partially-purified VirB9-1 protein as the antigen, which is of lower purity but higher yield. 
Additionally, the contaminants in the partially purified product, such as aggregates and endotoxin, 
have the potential to enhance specific antibody responses (Schädlich et al., 2009, Rosenberg, 2006). 
Also, to further enhance the immunogenicity of the recombinant protein antigen in the subunit 
vaccines, silica nanoparticles can be used as self-adjuvants (Zhao et al., 2016).  
In this study, we used a simplified purification method to obtain partially-purified VirB9-1 protein 
antigen. To enhance the immunogenicity of the subunit antigen, nano-size hollow silica vesicles (SV-
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100) were used as the adjuvant compared to a standard adjuvant Quil A. The interaction between the 
partially purified VirB9-1 protein and the silica nanoparticles was investigated, as well as the efficacy 
of using partially purified antigens in comparison with the purified antigen in terms of antibody 
response and cellular response. The dosing effect was also studied. 
2. Material and methods 
2.1. Preparation of VirB9-1 protein 
The expression vector generated by inserting the gene sequence encoding VirB9-1 into the pGEX-
4T1 expression vector was provided by the Protein Expression Facility at The University of 
Queensland. The expression vector was transformed into E. coli strain Rosetta (DE3) pLysS and 
glutathione S-transferase (GST) tagged recombinant VirB9-1 protein was expressed as previously 
described (Zhao et al., 2016).  
VirB9-1 was purified by a two-step chromatography method. The cell pellets from expression were 
resuspended in lysis buffer (40 mM Tris-base, 200 mM NaCl, 1 mM ethylenediaminetetraacetic acid 
(EDTA), 5% (v/v) glycerol, 5 mM dithiothreitol (DTT), pH 8.0) and lysed on ice by sonication using 
a Branson Sonifier 250 ultrasonicator (Branson Ultrasonics Corporation, Connecticut, US) at an 
energy output of 60 W for four bursts of 40 s. Lysates were centrifuged at 27,000 g, 4 °C for 20 min 
and the supernatant was collected and filtered through a 0.45 µm filter. The clear supernatant was 
then loaded onto a GSTrap HP 5 mL GST affinity column (GE Healthcare, UK) pre-equilibrated with 
five column volumes of lysis buffer. The column was washed with four column volumes of lysis 
buffer to remove unbound contaminants before the GST-tagged VirB9-1 protein was eluted with the 
elution buffer (40 mM Tris-base, 50 mM NaCl, 1 mM EDTA, 5% (v/v) glycerol, 5 mM DTT, 10 mM 
GSH, pH 8.5). The elution fractions were then applied onto a Superdex 200 10/300 GL gel filtration 
column (GE Healthcare, UK) pre-equilibrated with one column volume of the elution buffer. The 
column was washed with the same buffer to separate VirB9-1 proteins from aggregates and smaller 
contaminants. After this two-step chromatography purification method, purified VirB9-1 was 
obtained. The product obtained after the first chromatography (GST affinity column) step was used 
as the partially-purified VirB9-1 protein. 
2.2. Endotoxin removal for VirB9-1 
The purified VirB9-1 protein was concentrated using spin columns (Vivaspin 2, GE Healthcare, UK), 
then dialysed against phosphate-buffered saline with extra salts (PBS, pH 6.5, 300 mM NaCl) in a 
10,000 MWCO snakeskin dialysis membrane (Thermo Scientific, US) overnight with gentle stirring 
at 4 °C. Endotoxin removal was performed using Vivapure Q Mini H spin columns (Sartorius Stedim 
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Biotech, Germany) according to the manufacturer’s instructions. One pass through the column was 
enough to remove endotoxin for the purified VirB9-1 protein sample.  
The partially-purified VirB9-1 protein was dialysed against phosphate-buffered saline with extra salts 
(PBS, pH 6.5, 300 mM NaCl) in a 10,000 MWCO snakeskin dialysis membrane (Thermo Scientific, 
US) overnight with gentle stirring at 4 °C, then mixed with Q (quaternary ammonium) Sepharose 
resin (GE Healthcare, Sweden) and incubated at 4 °C for 15 min. The mixture was then centrifuged 
at 500 g for 5 min and the supernatant was collected. This step was repeated four times. Endotoxin 
levels were determined using the Endosafe-PTS Limulus Amebocyte Lysate assay kit (Charles River 
Laboratories, US). 
2.3. Preparation of silica nanoparticles 
SV-100 was synthesised as reported previously (Zhang et al., 2014). In brief, 0.5 g of 
EO39BO47EO39 and 0.852 g of Na2SO4 were added to 30 g of pH 4.7NaAc-HAc buffer solution 
([NaAc] = [HAc] = 0.40 M) and dissolved under stirring at 10 °C to form a homogenous solution. 
Then 3.57 mL (3.33 g) of tetraethyl orthosilicate (TEOS) was added to the solution and stirred 
continuously for 24 h. The reaction mixture was then transferred into an autoclave and hydrothermally 
treated at 100 °C for another 24 h. The as-synthesised samples were collected by filtration and washed 
thoroughly with deionized water, and then dried in air. The final product was obtained by calcination 
at 550 °C for 5 h in air. 
2.4. Adsorption of VirB9-1 
Adsorption studies used 200 µg of SV-100, with 200 µg of purified VirB9-1 and 200 µg partially-
purified VirB9-1 in PBS (pH 7.4), respectively. The particle-protein suspension was placed on an 
orbital platform shaker (Edwards Instrument Company, Australia) set at 200 rpm at 4 °C. After 12 h, 
the samples were centrifuged at 16,200 g for 5 min. The supernatants were assessed by colorimetric 
assay using the BioRad DC protein assay kit (Hercules, US), and the amount of the unbound proteins 
was determined. Then the amount of adsorbed proteins was calculated. 
2.5. Immunisation 
Eight-week-old female C57BL/6J mice were purchased from and housed in the Biological Resource 
Facility (The University of Queensland, Brisbane, Australia) under specific pathogen-free conditions, 
with 5 animals per cage in an environmentally controlled area with a cycle of 12 h of light and 12 h 
of darkness. Ten groups of five mice were immunised with different antigen formulations as shown 
in Table 6-1. Three subcutaneous injections were given at the tail base on days 0, 21 and 42. All 
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formulation samples were prepared in sterile injectable saline on the day of the injection. Blood 
samples were collected by retro-orbital bleeds after anaesthetization by methoxyflurane inhalation on 
days 0, 21 and 42. All mice were euthanized by carbon dioxide inhalation on day 56. Blood samples 
were collected by heart puncture, and spleens were aseptically removed and collected. The animals 
were weighed weekly and monitored three times per week for their health during the study. All 
animals remained in good health with no visible deleterious health effects for the duration of the 
study. All animal experimental work in this study was reviewed and approved by The University of 
Queensland Animal Ethics Committee (Approval Number: AIBN/338/15). All animals were cared 
for humanely in accordance with the Australian Code of Practice for the Care and Use of Animals for 
Scientific Purposes (2013). 
Table 6-1. Immunisation groups and endotoxin level in mice trial. 
Group Antigen Adjuvant Endotoxin 
1 Purified VirB9-1 (20 µg) None 0.3 EU 
2 Purified VirB9-1 (20 µg) Quil A (10 µg) 0.3 EU 
3 Purified VirB9-1 (20 µg) SV-100 (100 µg) 0.3 EU 
4 Purified VirB9-1 (50 µg) SV-100 (250 µg) 0.5 EU 
5 
Partially-purified VirB9-1 (20 
µg) 
None 87.3 EU 
6 
Partially-purified VirB9-1 (20 
µg) 
Quil A (10 µg) 87.3 EU 
7 
Partially-purified VirB9-1 (20 
µg) 
SV-100 (100 µg) 87.3 EU 
8 
Partially-purified VirB9-1 (50 
µg) 
SV-100 (250 µg) 218.2 EU 
9 None SV-100 (250 µg) None 
10 Unimmunised None None 
 
2.6. Evaluation of IgG antibody response 
To detect specific IgG antibodies against the VirB9-1 protein, an enzyme-linked immunosorbent 
assay (ELISA) was performed. Microtitre plates (96 well, Nunc, Maxisorb, Roskilde, Denmark) were 
coated with 50 µL VirB9-1 (2 ng/µL) in PBS (pH 7.4) overnight at 4 °C. Plates were blocked with 
PBST containing 5% skim milk and 5% BSA for 2 h at room temperature and washed 3 times with 
PBST. Plates were incubated with mouse sera initially at 100-fold dilution followed by three-fold 
serial dilutions for 2 h at room temperature. After washing 3 times with PBST, HRP conjugated 
polyclonal rabbit anti-mouse IgG antibodies (Sigma-Aldrich) were added 1:100,000 dilutions in 
PBST, followed by incubation for 1 h at room temperature. Plates were washed 3 times with PBST 
before the addition of TMB substrate (Life Technologies) and incubated for 7 min in the dark prior 
to absorbance measurement at 450 nm. Measurement of absorbance at 450 nm was performed in a 
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BioTek microplate reader (Winooski, US). The cutoff value to identify a positive antibody response 
was established as the mean OD450 of the negative-control sera plus three times the standard deviation. 
Statistical analysis was performed using GraphPad Prism Version 5.03 (GraphPad Software Inc., 
USA). Comparison between two groups was performed with t test where p < 0.05 was considered 
statistically significant. 
2.7. Measurement of cells secreting IFN-γ 
Enzyme-linked immunosorbent spot (ELISPOT) assay was performed as previously reported (Zhao 
et al., 2016). In brief, ELISPOT plates pre-coated with monoclonal IFN-γ capture antibody were 
conditioned with complete DMEM medium for 30 min at 37 °C. Spleen cells from each mouse were 
seeded at 250,000 cells per well in triplicate into the ELISPOT plates and then were incubated in 
complete DMEM medium at 37 °C and 5% CO2 for 48 h in the presence or absence of 10 µg/mL 
VirB9-1 antigen. Polyclonal activator concavalin A (Con A, 2 µg/mL, Sigma Aldrich) were used as 
a positive control. Detection of spots was performed according to manufacturer’s specifications. The 
ELISPOT plates were read on an ELISPOT reader (Autoimmun Diagnostika, Germany). Statistical 
analysis was performed using GraphPad Prism Version 5.03. Comparison between two groups was 
performed with t test where p < 0.05 was considered statistically significant. 
3. Results and discussion 
3.1. Preparation of VirB9-1 protein 
VirB9-1 protein is a potential antigen for vaccines against A. marginale in cattle. In our previous 
study, we reported the successful expression of VirB9-1 in E. coli at a high expression level of 70 
mg/L of culture and high solubility of over 90% at certain buffer conditions (Zhao et al., 2016). The 
purification method we developed was a two-step chromatography purification method (Figure 6-1). 
Firstly, the E. coli cells were lysed using sonication and then centrifuged to remove cell debris and 
insoluble proteins. Then, a GST affinity chromatography step was then used to extract the GST-
tagged VirB9-1 protein from other E. coli protogenetic proteins and a single elution peak was 
obtained (Figure 6-2A). The elution fractions from the GST affinity chromatography was further 
purified by size-exclusion chromatography, and four peaks were obtained (Figure 6-2B). Based on 
the manufacturer’s instructions of the Superdex 200 10/300 GL column for the size-exclusion 
chromatography, the four peaks in Figure 6-2B were of 700, 400, 110 and 55 kDa molecular weight. 
According to the SDS-PAGE (Figure. 6-2C), the four peaks were identified as large GST-VirB9-1 
aggregates (lane B1), small soluble GST-VirB9-1 aggregates (lane B2), GST-VirB9-1 dimer (lane 
B3) and GST-dimers (lane B4) considering the molecular weight of GST-tagged VirB9-1 is 
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approximately 56 kDa and the GST is a 27 kDa protein. The peak 3 in Figure 6-2B was collected as 
the highly purified VirB9-1 protein (Figure 6-2B). The yield of the purified VirB9-1 was about 2 
mg/L of expression culture. 
 
Figure 6-1. Process flow diagram of the purification process of recombinant GST-
tagged VirB9-1 protein. 
 
To reduce the cost of vaccines, the purity of the protein antigen and its yield is always a trade-off. 
When pursuing higher purity, yield is sacrificed. However, for protein antigens used in animal 
vaccines, less purity can be acceptable as long as the vaccines have high enough efficacy but with 
reasonably low adverse effects. In this way, antigen production yield can be increased and the overall 
cost of an animal vaccine can be reduced. In our study, the proteins obtained after the GST 
chromatography mainly consist of the highly purified VirB9-1 as well as its aggregates and truncated 
proteins (Figure 6-2B). Although an extra size-exclusion chromatography could make the protein 
much purer (Figure 6-2C), the yield would be significantly decreased. Considering the main 
components of the GST-chromatography purified product were still VirB9-1 but in different forms 
(Figure 6-2C), it could be possible to use the partially-purified protein as the antigen. Therefore, a 
simplified purification approach was adopted in this study (Figure 6-1). The size-exclusion 
chromatography step was eliminated. As a result, we could obtain VirB9-1 protein with good purity 
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(Figure 6-2C, lane 1) but a six-fold higher yield (about 12 mg/L of culture). Then the eluted product 
after the GST chromatography step was dialysed against PBS followed by endotoxin removal. 
The endotoxin in the purified VirB9-1 protein preparation was removed by ion exchange using Q 
spin columns as previously described (Zhao et al., 2016). However, this process cannot be applied 
for the partially-purified VirB9-1 protein, as the aggregates will be lost to the compacted column 
membrane. So alternatively, Q resin was used to reduce the endotoxin level of the partially-purified 
VirB9-1 protein to an acceptable level for injection to mice (Figure 6-1). 
 
Figure 6-2. (A) GST affinity elution chromatogram of GST-tagged VirB9-1. (B) Size-
exclusion chromatogram of GST-tagged VirB9-1. (C) SDS-PAGE analysis of 
fractions from chromatography. M: ladder marker; A: fraction from the GST affinity 
chromatograph; B1-4: fractions from the four peaks of the size-exclusion 
chromatography. The molecular weight of GST-tagged VirB9-1 is approximately 56 
kDa. 
 
3.2. Antigen loaded nanovaccines 
In this study, we used the SV-100 nanoparticles as the adjuvant to investigate the immune response 
of the partially-purified VirB9-1 protein, as SV-100 has been demonstrated to have excellent 
performance in enhancing both antibody and cell-mediated immune responses in mice (Zhao et al., 
2016, Mody et al., 2014). Firstly, the partially-purified VirB9-1 protein was tested for adsorption to 
SV-100 nanoparticles in comparison with the purified VirB9-1 proteins. The adsorption experiments 
were performed in PBS buffer at 4 °C. Results showed that 1 mg of SV-100 can adsorb 386 µg of 
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purified VirB9-1 and 307 µg of partially-purified VirB9-1, respectively, demonstrating both the 
purified and partially-purified VirB9-1 can be adsorbed to SV-100 at high capacity. For the animal 
trial study, we used 5:1 (w/w) ratio of the nanoparticle to the protein antigen to ensure complete 
adsorption of both purified and partially-purified VirB9-1 proteins. 
3.3. Immunisation study 
In order to evaluate the performance of the partially-purified VirB9-1 protein, the animal experiments 
were designed to have 10 groups (Table 6-1). The partially-purified VirB9-1 protein was compared 
with the purified VirB9-1 protein under different conditions: without adjuvant (Groups 1, 5); with a 
conventional adjuvant Quil A (Groups 2, 6), which has been widely used in animal vaccine studies 
(Spickler and Roth, 2003); and after being adsorbed to SV-100 at 20 µg or 50 µg dose (Groups 3, 4, 
and 7, 8). 20 µg dose of the antigen was selected based on our previous trial. In our previous study, 
50 µg of the purified VirB9-1 antigen gave extremely high antibody titer up to 107 after three 
injections (Zhao et al., 2016). In this study, the effects of the protein antigen VirB9-1 at a lower dose 
(20 µg) were investigated, to see if it is possible to reduce the dosage and therefore reduce the cost. 
The trial was performed using eight-week-old C57BL/6J female mice. Ten groups of five mice 
received three subcutaneous immunisations of the various antigen formulations (Table 6-1) and the 
injection samples were confirmed by SDS-PAGE analysis (Figure 6-3). The sera collected from the 
immunised mice were analysed using anti-VirB9-1 and ELISA to detect the total IgG responses 
(Figure 6-4). The ELISA result showed that after one injection, the partially-purified VirB9-1 groups 
induced significantly higher antibody immune responses (p < 0.05) than the purified VirB9-1 groups. 
This could be due to the presence of aggregates and higher endotoxin in the partially-purified VirB9-
1, which may provide an initial adjuvanting effect, thus enhancing the immune response even in the 
absence of any added adjuvants (Wibowo et al., 2015). However, after three injections, the titer of 
the purified VirB9-1 groups converged and no significant difference can be observed between the 
two groups. The Quil A groups showed no significant difference compared to the no adjuvant groups 
for both the purified and partially-purified VirB9-1 throughout the trial. In contrast, the SV-100 
groups showed significantly higher titers (p < 0.05) compared to the no adjuvant groups, and there 
were no significant difference observed when the dose was increased from 20 µg to 50 µg. The only 
exception was the partially-purified VirB9-1 (the 50 µg dose, Group 8) with SV-100 group after three 
injections, which showed significantly higher titers (p < 0.05) than the 20 µg dose group (Group 7). 
These results demonstrated that the SV-100 nanoparticles had excellent adjuvanting efficacy and 20 
µg dose of antigen was enough to induce a relevantly high antibody titer. In addition, SV-100 has 
other advantages such as being non-toxic, easy and cheap production, and the ability to control its 
pore size suitable for antigens with different sizes (Zhao et al., 2016, Zhang et al., 2014). The ELISA 
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result also showed that the partially-purified VirB9-1 can successfully induce excellent antibody 
immune response similar to the purified VirB9-1, with even higher titers for the first two injections. 
For cellular immunogenicity, splenocytes collected from the immunised mice were analysed using 
the ELISPOT assay to determine the T-helper type 1 (Th1) cell mediated IFN-γ responses to the 
VirB9-1 antigen (Figure 6-5). The ELISPOT result showed that without any adjuvants, the purified 
VirB9-1 and partially-purified VirB9-1 groups show no significant difference compared to the 
negative control groups. The Quil A group and the SV-100 groups showed significant difference (p 
< 0.05, p < 0.01 and p < 0.001, respectively) compared to the no antigen groups for both the purified 
VirB9-1 and the partially-purified VirB9-1. The titers of the 50 µg dose SV-100 groups seemed 
slightly lower than the 20 µg dose groups, but no significance was observed. The performance of the 
partially-purified VirB9-1 with SV-100 as the adjuvant was slightly better than the purified VirB9-1 
with SV-100. 
 
Figure 6-3. SDS-PAGE analysis of the injected samples of each group in the mice 
trial. M: ladder marker; Lane 1: Purified VirB9-1; Lane 2: Purified VirB9-1 with Quil 
A; Lane 3: Purified VirB9-1 loaded SV100; Lane 4: Purified VirB9-1 loaded SV100 
(50 µg dose); Lane 5: Partially-purified VirB9-1; Lane 6: Partially-purified VirB9-1 
GST with Quil A; Lane 7: Partially-purified VirB9-1 loaded SV100; Lane 8: Partially-
purified VirB9-1 loaded SV100 (50 µg dose). 
 
These ELISA and ELISPOT results showed that the partially-purified VirB9-1 with SV-100 can 
induce excellent antibody and cellular immune responses same as the purified VirB9-1. In addition, 
the yield of the partially-purified VirB9-1 is 6 times higher than the purified antigen. Furthermore, 
the partially-purified VirB9-1 required less purifications steps by reducing a costly step of 
chromatography, which could benefit the production of VirB9-1-based subunit vaccines for practical 
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applications. Thus, partially-purified VirB9-1 protein may be a more ideal antigen for animal vaccines 
than the purified ones. 
 
Figure 6-4. VirB9-1-specific antibody end point titres in C57BL/6J mice for different 
vaccine formulation groups. 
 
 
Figure 6-5. Detection of VirB9-1 IFN-γ secretion by ELISPOT assay of murine 
splenocytes from immunised mice. *p < 0.05; **p < 0.01; ***p < 0.001. 
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4. Conclusion 
This study investigated the efficacy of using the partially-purified VirB9-1 protein as the antigen for 
vaccines against A. marginale. Our results showed that the partially-purified VirB9-1 with a certain 
level of aggregation and endotoxin can induce higher antibody and cell-mediated immune responses 
in mice than the purified ones. These results suggest that contaminants within the safety level for 
veterinary vaccines, such as protein aggregations and endotoxin, can provide an excellent boosting 
effect together with adjuvants. It is possible that there is a Goldilocks window of contaminant level 
in veterinary vaccines formulations (Wibowo et al., 2015), and that its definition can lead to the 
development of cost-effective animal vaccines. In addition, the partially-purified VirB9-1 is easier to 
produce and the yield is six-fold higher than the purified ones, making it a more promising antigen 
candidate for vaccines against A. marginale. 
The SV-100 nanoparticles that were used in this study showed better performance than Quil A and 
can induce high levels of IgG titer and IFN-γ secretion with only a small dosage of the antigen. 
Furthermore, SV-100 is non-toxic and has good biocompatibility, and their size and pore size of SV-
100 can be easily controlled (Zhao et al., 2014). These findings can provide a better understanding of 
the adjuvanting effect provided by silica nanoparticles and the interaction with contaminants in 
protein antigen, and may lead to improvements in future veterinary vaccine formulations. 
Acknowledgements 
This work was supported by the Queensland Government Research Partnerships grant (Project 
013936_471). We also thank Prof. Ian Frazer and Dr Kate Kollar for the use of the ELISPOT reader 
system at the Translational Research Institute Australia. 
References 
Brown, W. C., Shkap, V., Zhu, D., Mcguire, T. C., Tuo, W., Mcelwain, T. F. & Palmer, G. H. 1998. 
CD4+ T-lymphocyte and immunoglobulin G2 responses in calves immunized with 
Anaplasma marginale outer membranes and protected against homologous challenge. 
Infection and Immunity, 66, 5406-5413. 
Chandran, V., Fronzes, R., Duquerroy, S., Cronin, N., Navaza, J. & Waksman, G. 2009. Structure of 
the outer membrane complex of a type IV secretion system. Nature, 462, 1011. 
Fronzes, R., Schäfer, E., Wang, L., Saibil, H. R., Orlova, E. V. & Waksman, G. 2009. Structure of a 
type IV secretion system core complex. Science, 323, 266-268. 
153 
 
Kocan, K. M., De La Fuente, J., Guglielmone, A. A. & Meléndez, R. D. 2003. Antigens and 
alternatives for control of Anaplasma marginale infection in cattle. Clinical Microbiology 
Reviews, 16, 698-712. 
Lopez, J. E., Siems, W. F., Palmer, G. H., Brayton, K. A., Mcguire, T. C., Norimine, J. & Brown, W. 
C. 2005. Identification of novel antigenic proteins in a complex Anaplasma marginale outer 
membrane immunogen by mass spectrometry and genomic mapping. Infection and Immunity, 
73, 8109-8118. 
Lopez, J. E., Palmer, G. H., Brayton, K. A., Dark, M. J., Leach, S. E. & Brown, W. C. 2007. 
Immunogenicity of Anaplasma marginale type IV secretion system proteins in a protective 
outer membrane vaccine. Infection and Immunity, 75, 2333-2342. 
Marcelino, I., De Almeida, A. M., Ventosa, M., Pruneau, L., Meyer, D. F., Martinez, D., Lefrançois, 
T., Vachiéry, N. & Coelho, A. V. 2012. Tick-borne diseases in cattle: applications of 
proteomics to develop new generation vaccines. Journal of Proteomics, 75, 4232-4250. 
Mody, K. T., Mahony, D., Zhang, J., Cavallaro, A. S., Zhang, B., Popat, A., Mahony, T. J., Yu, C. & 
Mitter, N. 2014. Silica vesicles as nanocarriers and adjuvants for generating both antibody 
and T-cell mediated immune resposes to Bovine Viral Diarrhoea Virus E2 protein. 
Biomaterials, 35, 9972-9983. 
Molad, T., Mazuz, M., Fleiderovitz, L., Fish, L., Savitsky, I., Krigel, Y., Leibovitz, B., Molloy, J., 
Jongejan, F. & Shkap, V. 2006. Molecular and serological detection of A. centrale-and A. 
marginale-infected cattle grazing within an endemic area. Veterinary Microbiology, 113, 55-
62. 
Morse, K., Norimine, J., Palmer, G. H., Sutten, E. L., Baszler, T. V. & Brown, W. C. 2012. 
Association and evidence for linked recognition of type IV secretion system proteins VirB9-
1, VirB9-2, and VirB10 in Anaplasma marginale. Infection and Immunity, 80, 215-227. 
Palmer, G. H., Barbet, A. F., Davis, W. C. & Mcguire, T. C. 1986. Immunization with an isolate-
common surface protein protects cattle against anaplasmosis. Science, 231, 1299-1302. 
Palmer, G., Rurangirwa, F., Kocan, K. & Brown, W. 1999. Molecular basis for vaccine development 
against the ehrlichial pathogen Anaplasma marginale. Parasitology Today, 15, 281-286. 
Rosenberg, A. S. 2006. Effects of protein aggregates: an immunologic perspective. The AAPS 
Journal, 8, E501-E507. 
Schädlich, L., Senger, T., Kirschning, C. J., Müller, M. & Gissmann, L. 2009. Refining HPV 16 L1 
purification from E. coli: reducing endotoxin contaminations and their impact on 
immunogenicity. Vaccine, 27, 1511-1522. 
154 
 
Shkap, V., Leibovitz, B., Krigel, Y., Molad, T., Fish, L., Mazuz, M., Fleiderovitz, L. & Savitsky, I. 
2008. Concomitant infection of cattle with the vaccine strain Anaplasma marginale ss centrale 
and field strains of A. marginale. Veterinary Microbiology, 130, 277-284. 
Spickler, A. R. & Roth, J. A. 2003. Adjuvants in veterinary vaccines: modes of action and adverse 
effects. Journal of Veterinary Internal Medicine, 17, 273-281. 
Wibowo, N., Wu, Y., Fan, Y., Meers, J., Lua, L. H. & Middelberg, A. P. 2015. Non-chromatographic 
preparation of a bacterially produced single-shot modular virus-like particle capsomere 
vaccine for avian influenza. Vaccine, 33, 5960-5965. 
Zhang, J., Karmakar, S., Yu, M., Mitter, N., Zou, J. & Yu, C. 2014. Synthesis of silica vesicles with 
controlled entrance size for high loading, sustained release, and cellular delivery of 
therapeutical proteins. Small, 10, 5068-5076. 
Zhao, L., Seth, A., Wibowo, N., Zhao, C.-X., Mitter, N., Yu, C. & Middelberg, A. P. 2014. 
Nanoparticle vaccines. Vaccine, 32, 327-337. 
Zhao, L., Mahony, D., Cavallaro, A. S., Zhang, B., Zhang, J., Deringer, J. R., Zhao, C.-X., Brown, 
W. C., Yu, C., Mitter, N. & Middelberg, A. P. J. 2016. Immunogenicity of Outer Membrane 
Proteins VirB9-1 and VirB9-2, a Novel Nanovaccine against Anaplasma marginale. PLoS 
One, 11, e0154295. 
 
 
 
  
155 
 
Chapter 7 
Expression of VirB9-2 protein as inclusion bodies and direct binding to mesoporous silica 
nanoparticles under denatured conditions 
7.1 Introduction 
Similar to VirB9-1, VirB9-2 is also an outer membrane protein of Anaplasma marginale. It is located 
closely to VirB9-1 in the Type IV secretion system (T4SS), which is a multi-protein complex utilized 
for transporting proteins or DNA across the bacterial cell envelope of gram-negative bacteria and is 
essential for intracellular survival and virulence (Christie and Vogel, 2000, Christie et al., 2005, 
Fronzes et al., 2009, Low et al., 2014). Studies have shown that T4SS is highly conserved among A. 
marginale strains (Lopez et al., 2007, Sutten et al., 2010). Vaccines targeting T4SS proteins may be 
widely protective (Morse et al., 2012b). Although the exact function of VirB9-2 is still not well 
understood, it has been proven that VirB9-2 is one of the most immunogenic proteins in the T4SS 
and is associated with protective immunity (Lopez et al., 2007, Morse et al., 2012b). Furthermore, it 
has been reported that VirB9-2 showed linked recognition with VirB9-1 in inducing T-cell response 
to help IgG production against VirB9-1 (Morse et al., 2012a, Morse et al., 2012b). This finding 
suggests that VirB9-2 may possess the key T-cell epitopes that lead to protective immunity against 
A. marginale, making it a promising antigen candidate for vaccination. Thus, it is reasonable to seek 
to develop a vaccine based on VirB9-1 and VirB9-2 associating together as antigen, which is also the 
main purpose of this PhD study.  
However, as an outer membrane protein, VirB9-2 is embedded within the lipid bilayer of the bacterial 
outer membrane and contains many hydrophobic domains making it very difficult to express as a 
soluble protein (Bond and Sansom, 2004). Currently, there has been no report of successful 
expression of VirB9-2 at high yield and solubility. As described in Chapter 2, many expression 
systems have been examined for the expression of outer membrane proteins, including mammalian 
cells, insect cells, yeast, and Escherichia coli. Among them, the E. coli system is by far cheapest and 
most well-established (Baneyx, 1999), which suits the aim of being cost-effective for animal 
vaccines. The wide use of E. coli for industrial production of many biopharmaceutical proteins also 
shows a promising path towards scale-up and industrialized (Schmidt, 2004). Furthermore, as 
previously demonstrated in Chapter 4, VirB9-1 has been successfully expressed at high yield and 
with high solubility as a glutathione S-transferase (GST) -tagged protein in E. coli. This result showed 
a possible approach for the expression of VirB9-2. If VirB9-2 could also be expressed as a GST-
tagged protein at high yield and high solubility in E. coli, then the mature purification methods of 
VirB9-1 might be able to apply for VirB-2 as well. This will greatly simplify the preparation of 
antigen and the overall cost of vaccination against A. marginale. However, the success with VirB9-1 
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cannot guarantee that VirB9-2 will be successful too, for each protein has its own unique structure. 
Although VirB9-1 and VirB9-2 are both proteins of the T4SS, their structures may still be of great 
difference, causing difficulties in soluble expression of VirB9-2 in E. coli. Whether GST-tagged 
VirB9-2 can be expressed soluble in E. coli is still unknown, but definitely worthwhile investigating.  
Alternatively, insoluble expression of VirB9-2 may still be acceptable. This thesis aims to use VirB9-
2 as antigen to provide the key T-cell epitopes that lead to protective immunity in a vaccine 
formulation together with VirB9-1 providing the key B-cell epitopes. Unlike B-cell epitopes, T-cell 
epitopes are based on primary amino acid sequence of the protein, which do not require the tertiary 
protein structure (Livingstone and Fathman, 1987, Rothbard and Taylor, 1988, Schwartz, 1985). 
Proteins that are misfolded and insoluble still have the same primary amino acid sequence as those 
that are soluble. Therefore, even if soluble expression of VirB9-2 cannot be achieved, it is still 
possible to obtain the protective T-cell epitopes needed from insoluble expressions of VirB9-2. This 
may be an alternative path for preparation of VirB9-2. Compared to soluble expression, insoluble 
expression has the advantage of achieving a much higher level of expression, yet often results in 
dense aggregates of misfolded insoluble recombinant proteins, which are known as inclusion bodies 
(Middelberg, 2002, Singh and Panda, 2005). These proteins from inclusion bodies usually need to be 
processed and re-activated before use, if tertiary structure is important. 
Traditional methods of processing proteins from inclusion bodies involve purification of inclusion 
bodies by centrifugation or filtration, which are then solubilised by the use of a high concentration of 
denaturants such as urea or guanidine hydrochloride, prior to “refolding” to restore the protein’s 
native 3D structure (Middelberg, 2002, Singh and Panda, 2005) (Figure 7-1). However, there is no 
universal method for refolding proteins and this process may involve expensive chemicals and still 
result in significant decrease of yields (Middelberg, 2002). Thus, the refolding process is often 
considered as a major bottleneck in overall protein preparation.  
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Figure 7-1.  The traditional method of preparing proteins from inclusion bodies. 
 
As recombinant proteins, VirB9-2 by itself is likely to be not immunogenic enough. It would need to 
be combined with adjuvants to enhance its immunogenicity. In this PhD study, mesoporous silica 
nanoparticles (MSNs) are chosen as adjuvant. Silica nanoparticles have the advantage of bio-
compatibility and non-toxic as described in Chapter 2 (Zhao et al., 2014). The mesoporous structure 
provides high specific surface area which can ensure high adsorption capacity. Previously in Chapters 
5 and 6, we demonstrated high adsorption of soluble GST-VirB9-1 to SV-100 particles and induced 
high levels of both antibody and cell-meditated immune responses. Thus, it is reasonable to adsorb 
VirB9-2 to MSNs to investigate its immunogenicity. Furthermore, as VirB9-2 protein is designed as 
T-cell epitopes reliant on the primary amino acid sequence of the protein, they do not require refolding 
to restore the native 3D structure. If methods can be developed to adsorb VirB9-2 to MSNs directly 
under denatured conditions, then it may be possible to avoid the refolding process. This approach 
would increase the overall vaccine yield greatly and simultaneously also reduce the cost of protein 
preparation.  
In this chapter, the expression and purification of VirB9-2 as a GST-tagged protein was investigated.  
Section 7.2 describes the design of the expression vector and the expression of VirB9-2 in E. coli. 
Results showed that soluble expression of VirB9-2 was difficult to achieve and may take much effort 
to optimise for soluble expression conditions. Alternatively, VirB9-2 was expressed as inclusion 
bodies and purification methods was developed in Section 7.3, following endotoxin removal of the 
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purified GST-VirB9-2. Section 7.4 describes the adsorption of GST-VirB9-2 to MSNs under 
denatured conditions. The adsorption condition was optimised and achieved high binding capacity.  
7.2 Expression of VirB9-2 
7.2.1 Design of expression vector 
The GST tag is a commonly used fusion tag that is well-known for its ability to improve the solubility 
and the expression stability of the fusion protein. Previously in Chapter 4, expression of soluble GST-
tagged VirB9-1 in E. coli was demonstrated. This result suggested that the attempt of using GST tag 
to improve solubility and stability was effective. Thus, a similar GST-tagged VirB9-2 construct was 
designed using the same vector for VirB9-1. The thrombin recognition site of the original pGEX-4T-
1 vector was mutated into a TEVp recognition site to reduce to cost of cleavage if necessary and 
flexible G4S linkers was were added on both sides of the TEVp recognition site to allow the VirB9-
2 protein to fold more independently, more likely to maintain native structure after expression in E. 
coli.  
The detailed construct of GST-VirB9-2 was described previously in Section 3.2 of Chapter 3 and the 
molecular weight of GST-VirB9-2 was estimated to be 56 kDa. The cloning work was performed by 
the Protein Expression Facility (PEF, The University of Queensland) as described previously in 
Section 3.2 of Chapter 3. Sequencing was conducted by the Australian Genome Research Facility 
(AGRF). The cloned DNA sequences and translated protein sequences are listed in Appendix B. 
7.2.2 Expression of GST-VirB9-2 at 26 °C  
As discussed in the Introduction, similar to VirB9-1, VirB9-2 as an outer membrane protein is 
generally very difficult to express in E. coli as high yield and high solubility. However, since the 
soluble expression of VirB9-1 was successful in Chapter 4, it was worthwhile investigating the 
expession of VirB9-2 under the same conditions. 
The initial expression of VirB9-2 followed the method developed for VirB9-1 as previously 
demonstrated in Chapter 4. E. coli strain Rosetta (DE3) pLysS was chosen, as it was successful for 
expression of soluble VirB9-1. This strain is supplied with tRNAs for six codons AUA, AGG, AGA, 
CUA, CCC, and GGA, which are rare in E. coli and can enhance the correct folding of disulphide-
bonded recombinant proteins (Rosano and Ceccarelli, 2014). Thus, strain Rosetta (DE3) pLysS is 
ideal for VirB9-2 expression. The plasmid of GST-VirB9-2 was transformed into Rosetta (DE3) 
pLysS competent cells according to the protocols described previously in Section 3.3 and 3.4 of 
Chapter 3. 
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The common expression temperature for E. coli is 37 °C, which ususally can obtain the highest yield. 
However, overexpression often results in poor solubility of recombinant proteins. While studies 
showed that lower expression temperatures favoured protein solubility due to slower expression rates 
which allowed for improved protein folding (Baneyx, 1999, Rosano and Ceccarelli, 2014). For an 
outer membrane protein such as VirB9-2, it is likely that the expression temperature need to be 
decreased in order to achieve soluble expression. Therefore, the expression of GST-VirB9-2 was first 
carried out at 26 °C according to the protocols described previously in Section 3.5 of Chapter 3. After 
harvest, the cells were resuspended in lysis buffer (40 mM Tris-base, 200 mM NaCl, 1 mM 
ethylenediaminetetraacetic acid (EDTA), 5% (v/v) glycerol, 5 mM dithiothreitol (DTT), pH 8.0) and 
disrupted by sonication. Then the solubility of the expression was analysed by SDS-PAGE according 
to the protocols described previously in Section 3.7 of Chapter 3. The SDS-PAGE analysis results 
showed obvious bands at around 56 kDa in the total and insoluble protein samples (Figure 7-2). The 
band in the total protein sample indicated that GST-VirB9-2 was successfully expressed at a decent 
yield. However, there was barely any band showing at 56 kDa in the soluble protein sample, and the 
band in the insoluble protein sample was roughly the same size as in the total protein sample. This 
indicated that most of the GST-VirB9-2 expressed 26 °C was insoluble.  
 
Figure 7-2. Expression of GST-VirB9-2 at 26 °C. Lanes: M: Marker ladder; Pre: Pre-
induction sample; T: Total protein sample; S: Soluble protein sample; In: Insoluble 
protein sample. All samples were loaded 8 µL/well of to 10% SDS-PAGE gels, stained 
with Coomassie Brilliant Blue dye. 
 
As previously discussed, if VirB9-2 could be expressed as soluble proteins, then the purification 
method developed for VirB9-1 could be used. It will not only benefit the downstream purification by 
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saving time and efforts for developing new methods, but also provide a better chance to present the 
correct key epitopes of VirB9-2 that are essential for protective immunity against A. marginale. 
Currently, a successful expression of GST-VirB9-2 was achieved in E. coli, but the solubility was 
unsatisfactory. Thus, further experiments were carried out to optimise the expression condition and 
try to improve the solubility of GST-VirB9-2. 
7.2.3 Expression of GST-VirB9-2 at 12 °C 
Previously in Chapter 4, GST-VirB9-1 was also poor in solubility when expressed at 26 °C. But when 
the expression temperature decreased from 26 °C to 12 °C, the solubility increased significantly. 
Therefore, it is reasonable to investigate the expression of GST-VirB9-2 at lower temperatures and 
see if the solubility can increase by decreasing the expression temperature.  
The expression temperature of GST-VirB9-2 was decreased to 12 °C and the expression was 
performed as the protocols described previously in Section 3.5 of Chapter 3, followed by solubility 
test of the expression according to the protocols described previously in Section 3.7 of Chapter 3. The 
SDS-PAGE analysis result of 12 °C expression showed that there was no obvious band of GST-
VirB9-2 at 56 kDa in the soluble protein sample (Figure 7-3). This result indicated that the solubility 
of GST-VirB9-2 was still very poor at 12 °C and did not improve compared to 26 °C expression. 
Most of the GST-VirB9-2 were insoluble as the 56 kDa band in the insoluble protein sample 
indicated.  
 
Figure 7-3. Expression of GST-VirB9-2 at 12 °C. Lanes: M: Marker ladder; 1: Total 
protein sample; 2: Soluble protein sample; 3: Insoluble protein sample. All samples 
were loaded 8 µL/well of to 10% SDS-PAGE gels, stained with Coomassie Brilliant 
Blue dye. 
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Since expression at 12 °C did not improve the solubility of VirB9-2, maybe trying lower expression 
temperatures could make a change. However, even if the solubility could be increased by this way, 
the loss of expression yield due to the low temperature will lead to a non-economic outcome. Thus, 
it could be concluded that the attempt to increase the solubility of GST-VirB9-2 by decreasing the 
expression temperature was unsuccessful and continuing to explore the expression of GST-VirB9-2 
at lower temperature would be unnecessary. As each protein is unique, though the solubility of VirB9-
1 could be significantly increased by decreasing the expression temperature, the method was proven 
not effective for VirB9-2. In comparison with VirB9-1, VirB9-2 may possess more hydrophobic 
domains, making this outer membrane protein extremely difficult to be expressed in E. coli in soluble 
form. Although the expression of VirB9-2 at low temperature was disappointing, such results was 
still within expectations. Outer membrane proteins are generally very difficult to be solubly expressed 
and there is no guaranteed method for soluble expression. 
There are other means to increase the solubility of recombinant proteins expressed in E. coli, such as 
reducing the concentration of isopropyl β-D-1-thiogalactopyranoside (IPTG) for induction, changing 
the E. coli strain, trying a different fusion tag and screening for an optimised lysis buffer condition. 
However, would these attempts to achieve a soluble expression of VirB9-2 be worthwhile? Is soluble 
VirB9-2 really necessary? Currently, no soluble expression of VirB9-2 protein in E. coli or other 
expression systems has been reported. Optimising for soluble expression of VirB9-2 could be very 
difficult and time consuming, yet may still lead to failure. While as previously described in the 
Introduction, VirB9-1 and VirB9-2 are associated outer membrane proteins that showed linked 
recognition in VirB9-2 providing increased T-cell help for IgG production against VirB9-1 (Morse 
et al., 2012b). A protective vaccine is likely to require linked T- and B-cell epitopes derived from 
associated outer membrane proteins (Morse et al., 2012a). In this case, the soluble VirB9-1 that has 
been prepared previously in Chapter 4 provides the B-cell epitopes, and VirB9-2 provides the T-cell 
epitopes. Unlike B-cell epitopes that rely on the native 3D structure of the protein, T-cell epitopes are 
based only on the liner structure of the protein (Livingstone and Fathman, 1987). This means that 
misfolded insoluble VirB9-2 proteins without native structure can potentially still provide the 
essential T-cell epitopes that can induce protective immunity against A. marginale. This opens an 
alternative path for VirB9-2 expression: instead of putting great effort on optimising soluble 
expression for GST-VirB9-2 yet still results in failure, a more promising way would be to start with 
the insoluble GST-VirB9-2 expression that have already achieved and then develop methods to purify 
VirB9-2 from these insoluble products and apply as antigens. 
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7.3 Purification of GST-VirB9-2 from inclusion bodies 
Insoluble expression of recombinant proteins in E. coli usually forms dense aggregates called 
inclusion bodies. Expression of recombinant proteins as inclusion bodies has advantages such as very 
high level expression yield and protection of the protein product from proteolytic degradation (Clark, 
1998). However, proteins from inclusion bodies often require further purification and processing 
before they can be used.  
The conventional strategy to purify proteins from inclusion bodies involves: (i) disruption of E. coli 
cells to release the inclusion bodies; (ii) isolation of inclusion bodies from cells by centrifugation or 
filtration; (iii) washing steps to remove contaminants; (iv) solubilisation of inclusion bodies using 
high concentrations of denaturants and chaotropes; (v) finally, “refolding” of the denatured proteins 
to recover the native structure and restore bioactivity (Middelberg, 2002, Singh and Panda, 2005, 
Middelberg et al., 1991). Among all these steps, protein refolding is the most critical step and is 
consider as the “bottleneck” of the overall protein preparation process, which determines the whole 
efﬁciency and yield of the process. However, there is no universal method for protein refolding. 
Developing a proper refolding method would require extensive testing and may involve expensive 
chemicals, yet still resulting in significant decrease of yields (Middelberg, 2002). As described 
previously in Section 7.1, the VirB9-2 protein is designed as T-cell epitopes in the vaccine 
formulation for A. marginale, and T-cell epitopes are based on the primary amino acid sequence of 
the protein, which do not require the native 3D structure. While using denautred antigens can still 
induce immune responses, the denatured forms were found to be less immunogenic and had a lower 
epitope density than native ones (Koch et al., 1996). Nevertheless, whether refolding is necessary for 
VirB9-2 is debatable and there could be a possibility to avoid the tricky refolding process and directly 
use denatured VirB9-2 as antigen. 
The purification of VirB9-2 from inclusion bodies was investigated and the process was optimised as 
shown in Figure 7-4. After expression in E. coli at 26 °C for 17 h, cells were harvested by 
centrifugation and lysed in lysis buffer (40 mM Tris, 200 mM NaCl, 1 mM EDTA, 5 mM DTT and 
5% (v/v) glycerol, pH 8.0) by sonication. Then the VirB9-2 inclusion bodies were collected by 
centrifugation and washed in 1% Triton X-100 and twice in 2 M urea buffer to remove cell debris 
and contaminants, respectively. Finally, the VirB9-2 inclusion bodies were solubilised in 8 M urea 
buffer. The expression and purification results were analysed by SDS-PAGE (Figure 7-5). Results 
showed that most of the GST-tagged VirB9-2 proteins (56 kDa) were insoluble (Figure 7-5 Lane 3). 
Because the insoluble pellet was rather pure of GST-VirB9-2, thus a simple method of centrifugation 
was enough to separate and collect the GST-VirB9-2 inclusion bodies. Since inclusion bodies 
collected by centrifugation may contain certain amounts of contaminants, two washing steps of 1% 
163 
 
Triton X-100 and 2 M urea buffer were introduced to remove the contaminants and improve the purity 
of GST-VirB9-2. After wash, the discarded supernatant was analysed by SDS-PAGE. Gel results 
showed that the supernatant sample was rather clear with almost no band of GST-VirB9-2 at 56 kDa 
(Figure 7-5 Lane 4 & 5), which suggested that yield of GST-VirB9-2 did not decrease during the 
washing steps. Finally, 8 M urea buffer was used to solubilise the GST-VirB9-2 inclusion bodies. 
The buffer solution after solubilisation was observed to be clear with no precipitates visible. The 
SDS-PAGE analysis results showed decent bands of GST-VirB9-2 at 56 kDa in both the total protein 
and soluble protein samples of equal size, indicating that GST-VirB9-2 was completely solubilised 
in the 8 M urea buffer (Figure 7-5 Lane 6 & 7). 
 
Figure 7-4. Process flow diagram of the preparation process of GST-VirB9-2 protein. 
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Figure 7-5. Expression and purification of GST-VirB9-2. Lanes: M: Marker; 1: Total 
protein of expression; 2: Soluble protein of expression; 3: Insoluble protein of 
expression; 4: Supernatant of Triton X-100 wash; 5: Supernatant of 2 M urea wash; 6: 
Total protein in 8 M urea; 7: Soluble protein in 8 M urea. 
 
7.4 Endotoxin removal 
Purified GST-VirB9-2 was obtained, but in order to be safely used for an animal trial, the endotoxin 
of VirB9-2 must be reduced to a safe level. As stated previously in Chapter 5 and 6, the endotoxin of 
GST-VirB9-1 was removed by using Vivapure Q Mini H spin columns (Q column, Sartorius Stedim 
Biotech). However, whether this method could be used for endotoxin removal of denatured GST-
VirB9-2 in 8 M urea buffer still needs to be investigated. It is worth noting, that urea rather than 
HdHCl was chosen as the denaturant so as to not interfere with any ion exchange process required 
during processing, for example for the binding of LPS. 
The solubilised GST-VirB9-2 in 8 M urea buffer was added to the Q column and centrifuged 
according to the according to the manufacturer's instructions to remove endotoxin. The process was 
repeated three times. The SDS-PAGE analysis results showed that after passing through Q column 
for three times, the yield of GST-VirB9-2 did not decrease (Figure 7-6). The endotoxin level was 
determined using the Endosafe-PTS Limulus Amebocyte Lysate assay kit (Charles River 
Laboratories, US) according to the manufacturer's instructions. The initial endotoxin level of GST-
VirB9-2 was not measured. From literature, the endotoxin level of cell culture supernatants can be 
over 1,000,000 EU/mL (Petsch and Anspach, 2000), which greatly depends upon the cell 
concentration. The endotoxin level of the GST-VirB9-2 sample was measured to be over 1,000 
EU/mL after passing through Q column twice and less than 10 EU/mL after passing through Q column 
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for three times, which is within safe levels for mice (Schädlich et al., 2009). This demonstrated that 
endotoxin could be removed from VirB9-2 under denatured conditions.  
 
Figure 7-6. Endotoxin removal of VirB9-2. Lanes: M: Marker; 1: Before passing Q 
column; 2: Passing through Q column one time; 3: Passing through Q column two 
times; 4: Passing through Q column three times. Endotoxins are approximately 10 kDa 
in size which could not be shown on this SDS-PAGE gel. 
 
7.5 Modification of nanoparticles 
The nanoparticles used as adjuvants in this thesis were mesoporous silica nanoparticles (MSNs) with 
a hollow spherical structure and uniform particles of ~50 nm size. These MSNs (SV-100) have shown 
excellent adjuvanting effect for VirB9-1 in Chapter 5 (Zhao et al., 2016). With a hollow core structure, 
this kind of nanoparticles allows high loading capacity of protein molecules (Zhang et al., 2014). 
Using this particle as both adjuvant and carrier for VirB9-2 may very likely induce a strong immune 
response. Furthermore, if VirB9-2 could be directly adsorbed to MSNs under denatured conditions, 
then the troublesome process of protein refolding would be avoided. This will not only increase the 
yield of VirB9-2 greatly, but also significantly reduce the overall cost of antigen preparation, which 
agrees with the cost-effective concept of animal vaccines. However, the surface of silica nanoparticles 
under normal circumstances are hydrophilic, which could be difficult to adsorb proteins with many 
hydrophobic domains, such as VirB9-2. Thus, the silica nanoparticles should be hydrophobically 
modified in order to adsorb GST-VirB9-2.  
In this study, SV-140 particles (entrance size slightly larger than SV-100) was chosen and the surface 
was modified with octadecyl groups to change the hydrophilic silica surface into a hydrophobic 
surface. The modification was performed in a typical hydrophobic modification process. After 
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modification, the particles were renamed as SV-140-C18. SV-140-C18 was characterized by 
transmission electron microscopy (TEM, JEM-2100, JEOL Ltd., Japan), field-emission scanning 
electron microscope (FE-SEM, JSM-7800, JEOL Ltd., Japan), Fourier-transform infrared 
spectroscopy (FTIR) and nitrogen sorption. The TEM and FE-SEM images showed that after 
modification, SV-140-C18 retained a hollow spherical structure and smooth surface with uniform 
particles of ~50 nm size and wall thickness of ~6 nm (Figure 7-7). The FTIR results showed features 
at 2,849 and 2,918 cm-l for the symmetric and asymmetric methylene stretching (Figure 7-8), 
indicating that the octadecyl groups were successfully attached to the nanoparticles. The nitrogen 
sorption results showed that after modification, the nanoparticles remained their hollow porous 
structure with an entrance size of 14.6 nm, total pore volume of 0.3 cm³/g, and a BET surface area of 
61.1 m²/g (Figure 7-9).  
 
Figure 7-7. (A) TEM and (B) FE-SEM image of SV-140-C18. 
 
Figure 7-8. FTIR spectrum of SV-140-C18. 
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Figure 7-9. (A) Nitrogen sorption isotherm of SV-140-C18; (B) Barrett-Joyner-
Halanda pore size distribution curve calculated from the desorption branch of SV-140-
C18 (the detailed calculation is included in Appendix C).  
 
7.6 Adsorption of VirB9-2 to nanoparticles 
The adsorption of GST-VirB9-2 to SV-140-C18 under denatured conditions was investigated. 
Different amounts of SV-140-C18 were added to the GST-VirB9-2 in 8 M urea buffer followed by 
incubation on a shaking platform for 8 h in room temperature. The samples were then centrifuged and 
the supernatants and pellets were analysed by SDS-PAGE to determine the amount of GST-VirB9-2 
adsorbed (Figure 7-10). Under 8 M urea buffer condition, when the protein to nanoparticle ratio was 
1:2 (w/w), 63.51 µg of the 200 µg GST-VirB9-2 was adsorbed to SV-140-C18 (Table 7-1). When the 
amount of SV-140-C18 increased to a ratio of 1:5 (w/w), the amount of GST-VirB9-2 adsorbed also 
increased to 121.61 µg (Table 7-1). By calculation, both 1:2 and 1:5 ratios gave the same result of an 
adsorption capacity around 150 µg of GST-VirB9-2 per 1 mg of SV-140-C18 under 8 M urea buffer 
condition (Figure 7-11). These results demonstrated that GST-VirB9-2 could be adsorb to SV-140-
C18 under 8 M urea buffer conditions and the adsorption capacity was constant and satisfactory. 
However, whether this capacity could be improved should be further explored. 
Then adsorption of GST-VirB9-2 to SV-140-C18 under different buffer conditions was investigated. 
After adding SV-140-C18 to the GST-VirB9-2 in 8 M urea buffer, the urea concentration of buffer 
was decreased from 8 M to 4 M, followed by incubation on a shaking platform for 8 h in room 
temperature. By reducing the concentration of the denaturant, the solubilised GST-VirB9-2 was more 
likely to be driven out of the buffer solution and bound to the hydrophobic surface of the SV-140-
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C18. The SDS-PAGE analysis results of the supernatants and pellets after incubation showed that 
121.61 µg of the 200 µg GST-VirB9-2 adsorbed to SV-140-C18 at a protein to nanoparticle ratio of 
1:2 (w/w) (Table 7-1). The adsorption capacity under 4 M urea buffer condition was calculated to be 
304 µg of GST-VirB9-2 per 1 mg of SV-140-C18 (Figure 7-11). When the protein to nanoparticle 
ratio increased to 1:5 (w/w), no trace of VirB9-2 could be detected in the supernatant, all 200 µg of 
GST-VirB9-2 was adsorbed (Table 7-1). A control group of only 200 µg of GST-VirB9-2 in 4 M 
urea buffer without adding any SV-140-C18 showed no precipitation of VirB9-2 after 8 h of shaking 
in room temperature, all GST-VirB9-2 remained soluble in the supernatant (Figure 7-12). These 
results indicated that GST-VirB9-2 was stable by itself when the concentration of urea reduced to 4 
M and by decreasing the concentration of urea, the adsorption capacity of GST-VirB9-2 to SV-140-
C18 could be increased to an outstanding level.  
Table 7-1. Quantification of VirB9-2 adsorption. NP: nanoparticle. 
Buffer 
condition 
Ratio 
(protein:NP) Protein used  
NP used  
Protein 
adsorbed  
8 M urea 1:2 200 µg 400 µg 63.51 µg 
8 M urea 1:5 200 µg 1000 µg 151.88 µg 
4 M urea 1:2 200 µg 400 µg 121.61 µg 
4 M urea 1:5 200 µg 1000 µg 200 µg 
4 M urea n/a 200 µg 0 µg 0 µg 
 
 
 Figure 7-10. SDS-PAGE analysis of adsorption. Supernatant (S) and pellets (P) after 
adsorption in 4 M or 8 M urea buffer at 1:2 or 1:5 ratios. M: ladder marker. 
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Figure 7-11. Adsorption capacity of VirB9-2 per mg of SV-140-C18 in 4 M and 8 M 
urea buffer. NP: SV-140-C18 nanoparticle. 
 
 
Figure 7-12. SDS-PAGE gel image of ViB9-2 in 4 M urea buffer after 8 h of shaking in room 
temperature. S: supernatant; P: pellets. 
 
7.7 Conclusions 
Protein refolding has always been the “bottleneck” in the production of recombinant proteins from E. 
coli (Clark, 2001, Middelberg, 2002, Singh and Panda, 2005). The attempt of skipping the refolding 
process by using hydrophobically modified silica nanoparticles (SV-140-C18) to directly adsorb the 
denatured proteins in high urea concentration buffers was demonstrated to be successful in this 
chapter. These results showed that GST-VirB9-2 could be adsorbed to SV-140-C18 at an outstanding 
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capacity of over 300 µg per mg of nanoparticles. Compared to the conventional ways of protein 
refolding, this method of using hydrophobically modified silica nanoparticles to adsorb proteins from 
denatured state is more efficient and economical, especially suitable for T-cell epitope antigens, of 
which the native 3D structure is not essential (Desai and Kulkarni-Kale, 2014). Moreover, denatured 
proteins are often less immunogenic (Koch et al., 1996), which could be perfectly overcome by the 
strong adjuvanting effect of silica nanoparticles.  
It is worth emphasising that this novel approach is likely reasonable for VirB9-2, as it is the protein 
antigen providing the linear T-cell epitopes within a co-formulated vaccine comprising also VirB9-
1. In such a formulation, we would expect that the refolded or soluble structure of VirB9-1 would be 
required, as that antigen is providing B-cell epitopes most likely dependent on secondary and tertiary 
structure for the generation of functional antibodies following immunisation. 
This chapter demonstrated the expression and purification of VirB9-2 protein in E. coli including the 
design and cloning of GST-tagged VirB9-2 construct, optimising expression condition and 
purification process, and the removal of endotoxin. Also, a novel method of using specially modified 
silica nanoparticles to directly adsorb denatured GST-VirB9-2 in urea buffer at high capacity was 
developed, and it was shown that VirB9-2 could effectively be “salted out” of moderated concentrated 
urea solution in the presence of hydrophobically-modified nanoparticles (Figure 7-10 and Figure 7-
12). These positive results showed great potential of opening a pathway towards developing new 
strategies for processing T-cell epitopes from insoluble recombinant protein expressions. However, 
the immunogenicity of the VirB9-2 protein adsorbed to SV-140-C18 still needs to be investigated 
subsequently, and ultimately the protective potential when co-delivered with VirB9-1 bound to 
nanoparticles must be examined. 
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Chapter 8 
Conclusions and Future Work 
Vaccines are considered as one of mankind’s strongest weapons against disease. Many diseases that 
were once common and/or fatal are now rare or under control. Vaccines are not only widely used for 
humans, but also for domesticated animals, such as pets and livestock. However, traditional vaccines 
using live/attenuated or killed pathogen as antigens seemed to have reached their limits. With the 
development of recombinant DNA technology as well as other modern biotechnology and 
nanotechnology, vaccine research and development have moved onto a new era of novel 
subunit/recombinant vaccines. 
8.1 Major research findings in this thesis 
Since the discovery of Anaplasma marginale in 1910 (Theiler, 1910), great efforts have been devoted 
to the development of an efficient vaccine against this bovine pathogen. Yet, over one hundred years 
have passed, no widely accepted vaccine for A. marginale exists on market. This thesis aimed to 
provide foundational studies leading toward development of a novel subunit vaccine against A 
marginale, and focused on exploring the potential of two A marginale outer membrane proteins: 
VirB9-1 and VirB9-2 as antigens. VirB9-1 and 9-2 are components of the type IV secretion system 
(T4SS), a multi-protein complex responsible for transporting macromolecules, such as DNA and 
proteins, across the bacterial membrane. Previous studies have found that VirB9-1 and 9-2 are the 
most immunogenic among T4SS proteins (Morse et al., 2012), making them promising antigen 
candidates for a protective vaccine against A. marginale. 
8.1.1 Expression and purification of VirB9-1 and VirB9-2 
As newly identified outer membrane proteins, currently there is no method for expression of VirB9-
1 and VirB9-2 at high yield and solubility. Although VirB9-1 and 9-2 are similar proteins, the 
optimised expression and purification methods for them are quite different, which should be 
investigated. Chapter 4 describes the development of expression and purification methods for VirB9-
1, while Chapter 7 describes the development of expression and purification methods for VirB9-2.  
In Chapter 4, the expression and purification of VirB9-1 in Escherichia coli were demonstrated. 
Recombinant VirB9-1 was designed as a GST-tagged fusion protein to improve the solubility and 
simplify downstream purification. Detailed expression condition and lysis buffer condition were 
optimised and a high expression yield of approximately 70 mg/L and solubility of over 85% were 
achieved. The purification method for VirB9-1 was developed as a two-step chromatography method. 
First, GST-VirB9-1 was extracted from crude cell lysate by GST affinity chromatography. Then, high 
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purity GST-VirB9-1 dimers were obtained by size size-exclusion chromatography. This is the first 
report of soluble expression of VirB9-1 in E. coli at high yield. The GST tag was left uncleaved from 
VirB9-1 in order to prevent undesirable precipitation after cleavage, which also simplified the 
purification process and reduced the overall cost of VirB9-1 preparation. Animal trial results 
confirmed that the uncleaved GST tag did not have any negative effects on the immunogenicity of 
VirB9-1 nor affect the health of animals. 
In Chapter 7, the expression and purification of VirB9-2 using E. coli was demonstrated. Similar to 
VirB9-1, recombinant VirB9-2 was also designed as a GST-tagged fusion protein and investigated 
for its expression in E. coli. However, soluble expression of VirB9-2 was hard to accomplish. After 
several unsuccessful attempts, VirB9-2 was alternatively expressed as insoluble inclusion bodies. The 
purification of VirB9-2 was performed by isolation of VirB9-2 inclusion bodies followed by 
solubilisation in 8 M urea. Innovatively, instead of refolding the denatured VirB9-2 by traditional 
methods, hydrophobically modified silica nanoparticles were used to directly adsorb the VirB9-2 in 
4 M of urea under denaturing condition, which can then be applied directly as an adjuvant-antigen 
construct. By avoiding the unpredictable refolding process, not only the yield of VirB9-2 could be 
reserved, but also the overall cost of preparation could be reduced. This thesis demonstrated a novel 
method of preparing antigens from inclusion bodies, that could have wide utility especially in cost-
sensitive fields such as animal vaccination, where a higher degree of impurity can be tolerated than 
for human application. 
8.1.2 Adsorption of VirB9-1 and VirB9-2 to silica nanoparticles 
As antigens, recombinant proteins alone are often not immunogenic enough to induce strong immune 
responses that are protective. Thus, adjuvants are needed to enhance the immunogenicity. This thesis 
focused on researching novel mesoporous silica nanoparticles: SV-100 and SV-140-C18 as adjuvants 
for VirB9-1 and 9-2, respectively. Chapter 5 demonstrates the adsorption of VirB9-1 and 9-2 to SV-
100, while Chapter 7 demonstrates the adsorption of VirB9-2 to SV-140-C18 under denaturing 
conditions. The adsorption conditions and protein to nanoparticle ratio were optimised to achieve 
high adsorption capacities. 
8.1.3 Immunogenicity of VirB9-1 and VirB9-2 
The immunogenicity of VirB9-1 and VirB9-2 was both analysed in vivo by mice trials and in vitro 
by A. marginale-specific T-lymphocyte proliferation assays.  
Chapter 5 discusses the immunogenicity of VirB9-1 and VirB9-2 with SV-100 as the adjuvant in 
comparison with a conventional adjuvant Quil A. Mice trial results showed that VirB9-1 and 9-2 can 
induce high levels of both antibody and cell-mediated immune responses in vivo. Moreover, the 
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combination of the two proteins induced even higher immune responses. This is an encouraging result 
as it proved that VirB9-1 and 9-2 can be used together in the same vaccine formulation, without one 
antigen shielding the immunogenicity of the other antigen. In addition, the adjuvanticity of SV-100 
particles was shown to be comparable to Quil A, while SV-100 has better biocompatibility and is 
non-toxic. This result demonstrated that SV-100 is a more promising adjuvant than Quil A. In vitro 
T-lymphocyte proliferation assays using cell lines from cattle immunised with A. marginale outer 
membrane showed similar results. VirB9-1 and 9-2 induced high level of cellular immune responses 
and the combination of both antigens induced even higher responses. The in vitro results further 
confirmed the immunogenicity of VirB9-1 and 9-2.  
Chapter 6 investigated the immunogenicity of partially-purified VirB9-1 proteins. Mice trial results 
showed that the partially-purified VirB9-1 with a certain level of aggregation and endotoxin can 
induce higher antibody and cell-mediated immune responses than the purified ones. These findings 
suggest that contaminants within the safety level for veterinary vaccines, such as protein aggregations 
and endotoxin, can provide an excellent boosting effect together with adjuvants. In addition, the 
partially-purified VirB9-1 is much easier to produce by saving a step of chromatography and the yield 
is six-fold higher than the purified ones, making it a more promising antigen candidate in the 
development of cost-effective vaccines against A. marginale. 
Preliminary results of the immunogenicity of VirB9-2 adsorbed to SV-140-C18 under denatured 
conditions performed by mice trial indicated that VirB9-2/SV-140-C18 induced strong antibody 
immune responses, but failed to induce a strong cell-mediated immune response (data not shown). 
The reason of this result is under further investigation. 
The overall findings indicated that the recombinant VirB9-1 and VirB9-2 produced using the 
expression and purification processes developed in this thesis are promising antigen candidates for 
vaccines against A. marginale. Nano-vaccine formulations using VirB9-1 and 9-2 as antigens with 
SV-100/SV-140-C18 as adjuvants can induce high level immune responses. Yet, an optimised 
vaccine formulation would require further testing in cattle trials and whether the immunity induced 
by VirB9-1 and 9-2 are protective against A. marginale would need to be examined in a challenge 
study. 
8.2 Future Work 
This thesis has contributed understanding toward the ultimate development of A. marginale subunit 
vaccines based on VirB9-1 and VirB9-2 proteins assisted by mesoporous silica nanoparticles as nano-
adjuvants. The expression and purification methods for VirB9-1 and VirB9-2 have been developed 
and the immunogenicity of these two proteins with SV-100/SV-140-C18 as adjuvants have been 
evaluated both in vivo and in vitro, showing promising results. These research outcomes collectively 
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show the potential of a nano-vaccine formulation against A. marginale. However, the realisation of 
an efficient vaccine requires further studies as listed below: 
(1) SV-100 adjuvanted VirB9-1 and VirB9-2 proteins induced high level antibody and cell-mediated 
immune responses in mice. However, whether they can induce high level immune responses in 
cattle needs further investigation. After all, this is a vaccine developed for cattle, which should be 
tested in cattle trials. Furthermore, the actual protective efficacy of VirB9-1 and 9-2 against A. 
marginale must be confirmed in a challenge study. 
(2) Direct adsorption of VirB9-2 to silica nanoparticle adjuvants under denatured conditions provides 
a novel method of preparing antigens from inclusion bodies, particularly where conformational 
epitopes are prospectively not required. However, preliminary mice trial results indicated that 
these VirB9-2 did not induce strong cell-mediated immune responses as expected. The underlying 
reasons require further investigation. 
(3) This thesis has demonstrated the effect of SV-100/SV-140-C18 as nano-adjuvant. Considering 
the large family of mesoporous silica-based nanoparticles, a systematic study to correlate the 
structural parameters of nano-adjuvants and the immune response relationship could provide 
profound knowledge, which should be further investigated. Moreover, besides using 
nanoparticles to enhance the immunogenicity of VirB9-1 and 9-2, there are also bio-methods to 
boost the immune responses, such as using fusion protein technology to form a capsomere 
presenting VirB9-1 and VirB9-2. Studies showed that modular capsomeres presenting the target 
antigen can induce strong specific antibody responses (Middelberg et al., 2011, Wibowo et al., 
2014, Waneesorn et al., 2018). By combining the merits of nanomaterials and bio-methods, the 
immunogenicity of VirB9-1 and 9-2 could be boosted to an even higher level, which could be a 
future research direction.  
(4) In this thesis, the vaccine formulations of VirB9-1 and VirB9-2 were administrated to mice three 
times with three weeks in interval to robust and develop high level immune responses. However, 
multiple injections over the course of several weeks is inefficient and costly for domesticated 
animals, especially for cattle. Therefore, developing a sustained-release formulation to achieve a 
single-shot vaccine would be a meaningful future direction. 
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Appendix B 
Sequence of VirB9-1 construct: 
Cloned DNA sequence: 
GGAGGCGGCGGCAGTAAGGCTTTCATGGTTTGTGCTGTAGCGCTGTTGTGCAGCTCGG
CTGCTTTTGGTAAGCAGGAGCCGCGCTCTATAGCCGCTGATGACCACATAAAGATTAT
AAACTTCAACCCCCAGTCTATACACAGGTACACGGGGTTTTACGGGTACCAGTCTAGC
ATATTGTTTGAGTCTGGTGAGGTTATAGACACGGTCTCCATGGGGGATTCAACCGGGTG
GCAGTTGGTGCCGAAGGGGAATAGGCTGTTCATAAAGCCCGTTGGGGATAATGCAGAT
ACCAACGTCACTATAATCACGAACAGGCGCGTGTATTACTTTGAGCTGCACGCTGAGG
AGGCTAGTGGCCTTGATGACCCTAGATTAGCGTATGAGGTCAGGTTCGTGTATCCCGCT
GCGAGTAGTGTTGATGCGGCATCGTCATCCGATTTGGGTGGCGGAGTGTCTTTTCCCAC
ATACCAGAATGACGTGCCTGACTTAAGTGATCCTGAGGTTGCCAAAAAGGGCCTGAAC
TTTGACTATTCCGTGTCCCATACTGCTGGTTCTGCGAATATCGTCCCTATCAGGGTGTTT
GATGACCGCAAGTTCACATACATGCAGTTTTCCAACGTTAACGGAGACCTTCCATCCAT
TTTCAATGTCGACGCTGAGGGGTATGAGTCTCTCGTGAACTTTAGGATCGTGGGTGATT
ATGTGGTGGTGGAGCGCGTCTCTCCGGCTTTTACGCTACGGTATGGTTCTAGTACTGCC
TGCGTGTTTAACGAGAAGCTGTACCGCACATCCTCTACATCCAGAAGGGGACGTTGA 
Translated protein sequence: 
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDG
DVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDF
LSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFK
KRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDGGGGSENLYFQGGGGSKAFM
VCAVALLCSSAAFGKQEPRSIAADDHIKIINFNPQSIHRYTGFYGYQSSILFESGEVIDTVSM
GDSTGWQLVPKGNRLFIKPVGDNADTNVTIITNRRVYYFELHAEEASGLDDPRLAYEVRFV
YPAASSVDAASSSDLGGGVSFPTYQNDVPDLSDPEVAKKGLNFDYSVSHTAGSANIVPIRV
FDDRKFTYMQFSNVNGDLPSIFNVDAEGYESLVNFRIVGDYVVVERVSPAFTLRYGSSTAC
VFNEKLYRTSSTSRRGR* 
Sequence of VirB9-2 construct: 
Cloned DNA sequence: 
GGTGGTGGTGGTAGCGAAAACTTGTACTTCCAAGGAGGCGGCGGCAGTAAAAACTTGC
TTGCGTGCTCGGCTCTACTGACCGTTGTTTTTACAGGAGGTGTGGCACAGTCTGCCGTA
AGCGGTGGTGCACCTGTGTCTGTAGACAGTAGGATCAAAACCTTTGTATACAGCCCGA
ACGAGATATTTACCGTTGTGTTTAACCACGGGTATCACTCGTTTATAGAGTTCTCCAAA
GGTGAGACCATAAAAGTGATGGCTATGGGAGACAGCGTTCACTGGAAGGTAAAGCCC
GTAGATAACAAACTGTTCATTATGCCACTGGAGAGGGAAGGCAAGACAAATATGCTGG
TAGAAACCAACAAAGGCAGGAGCTACGCTTTTGATCTTGTTTCAAAGTCTGCTGGCCCT
GATGCCGCGGGGTATAAAGAAGTGGCGGATGAGCTCGGCAGGGTGGACTCCCCCCTGT
TGGATATGGCCTACGTGGTGCGTTTTTACTACCCGGATAATAACAGGGAGTTCGATCTA
AAAGGGGCCGGACTGGCGGACTTGTCTGCTCCGAGCTTGGCAAAGAACCCCAACAGTG
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GCGAGGTTACTGTGCGCCCGAATGCAACTGGCAAGAATTATGTATACTCTGCAAGCAG
CGCTGATGCAACAATAGTCCCTGTGAAAACTTTTGATGATGGGGCCCTTACATATTTTC
AGTTCTATGACAATAACAAGGTGATCCCAAAAGTGTTTTCTGTGGGCAGACATGGCAA
AAAAGTGCCATGCAGGATGTTGCTACTTAAGGGCTATGTAATAATCGAAGGAGTCCAC
AAGCGGCTGTACCTTGACTACGGCAAGAGTGGCGTCGAAGTAGTGAATACGGTGCTTT
GA 
Translated protein sequence: 
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDG
DVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDF
LSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFK
KRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDGGGGSENLYFQGGGGSKNLL
ACSALLTVVFTGGVAQSAVSGGAPVSVDSRIKTFVYSPNEIFTVVFNHGYHSFIEFSKGETIK
VMAMGDSVHWKVKPVDNKLFIMPLEREGKTNMLVETNKGRSYAFDLVSKSAGPDAAGY
KEVADELGRVDSPLLDMAYVVRFYYPDNNREFDLKGAGLADLSAPSLAKNPNSGEVTVRP
NATGKNYVYSASSADATIVPVKTFDDGALTYFQFYDNNKVIPKVFSVGRHGKKVPCRMLL
LKGYVIIEGVHKRLYLDYGKSGVEVVNTVL* 
*Blue – Tobacco etch virus (TEV) protease recognition site 
*Red – G4S linker 
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Appendix C 
Materials characterization using nitrogen sorption analysis 
Nitrogen sorption analysis is widely utilized to characterize nanoporous materials with key 
parameters, including specific surface area and pore size (Carman, 1951, Carman and Raal, 1951). In 
this thesis, the nitrogen adsorption-desorption isotherms of all nanoparticles were measured at 77 K 
by using a Micromeritics Tristar II system. In every experiment, the samples were degassed at 453 K 
overnight on a vacuum line prior to the nitrogen sorption analysis.  
Calculation of total pore volume 
Gurvich’s rule was used to calculate the total pore volume of nanoparticles by measuring their total 
nitrogen adsorption capacity at the limiting plateau of an isotherm (Gurvish, 1915). The nitrogen can 
be assumed to have the molar volume of the liquid at the operational temperature to obtain the 
corresponding total pore volume. In this thesis, the total pore volume was calculated from the amount 
adsorbed at a maximum relative pressure (P/P0). The calculations were conducted by the MicroActive 
for TriStar II Plus Software installed with the Micromeritics Tristar II system using the following 
equation. 
𝑉𝑝 =
𝑊𝑎
𝜌
 
Where Vp is the total pore volume, Wa is the weight in gram of nitrogen that are adsorption at a 
maximum relative pressure (P/P0), ρ is the density of liquid nitrogen. 
Calculation of the Brunauere-Emmette-Teller (BET) specific surface area 
In this thesis, well-accepted BET method (Brunauer et al., 1938) was used to measure and calculate 
the specific surface area of the nanoparticles. The calculations were conducted by the MicroActive 
for TriStar II Plus Software installed with the Micromeritics Tristar II system using the following 
BET equations. 
𝑣 =  
𝑣𝑚𝑐𝑝
(𝑝0 − 𝑝){1 + (𝑐 − 1) (
𝑝
𝑝0
)}
 
Where vm is the volume of gas adsorbed when the entire adsorbent surface is covered with a complete 
unimolecular layer, c is an appropriate constant, p/p0 is the relative pressure. 
𝑣
𝐴𝑣0
=
𝑣
𝑣𝑚
=
∑ 𝑖𝑠𝑖∞𝑖=0
∑ 𝑠𝑖∞𝑖=0
 
Where A is the total surface area, v0 is the volume of gas adsorbed on one square centimeter of the 
adsorbent surface when it is covered with a complete unimolecular layer of adsorbed gas, s0, s1, s2, . 
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. . si, . . . represent the surface area that is covered by only 0, 1, 2, . . . i, . . . layers of adsorbed 
molecules. 
Calculation of the entrance size of the silica vesicles. 
The openings on the shells of silica vesicles (also called entrances) are considered as cylindrical pores, 
and Barrett-Joyner-Halanda (BJH) method was used to calculate the entrance size distributions from 
the desorption branch (Zhang et al., 2014). The calculations were conducted by the MicroActive for 
TriStar II Plus Software installed with the Micromeritics Tristar II system using the following BJH 
equation (Barrett et al., 1951). 
log (
𝑃
𝑃0
) =  
−𝜎𝑉
8.316 × 107 × 2.303𝑇𝑟𝑘
=
−4.14
𝑟𝑘
 
Where rk indicates radius of capillary in cm. (later converted to angstrom units for practical 
purposes), σ is the surface tension of liquid nitrogen, V is the liquid molar volume of nitrogen, T is 
the absolute temperature (°K.), 8.316 × 107 is the gas constant in ergs per degree. 
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